{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {},
   "outputs": [],
   "source": [
    "import glob\n",
    "import json\n",
    "from json import loads,dumps,load\n",
    "import random\n",
    "import pandas as pd\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "from yellowbrick.cluster import KElbowVisualizer\n",
    "import networkx\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_files(path,percent=10):\n",
    "    files=glob.glob(path+'/**/**/**/*.json')\n",
    "    print(len(files))\n",
    "    files_sample=random.sample(files,int((percent/100)*len(files)))\n",
    "    return files_sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 205,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "59311\n"
     ]
    }
   ],
   "source": [
    "files_sample=read_files('/home/nithivarn/TextAnalytics/Project-2/CORD-19-research-challenge/',percent=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "593"
      ]
     },
     "execution_count": 207,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(files_sample)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_json(file):\n",
    "    d = {}\n",
    "    dic = loads(open(file).read())\n",
    "    d[\"paper_id\"]=dic[\"paper_id\"]\n",
    "    d[\"body_text\"]=[]\n",
    "    for item in dic[\"body_text\"]:\n",
    "        d[\"body_text\"].append(item['text'])\n",
    "    d[\"body_text\"] = ''.join(d[\"body_text\"])\n",
    "    return d\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 212,
   "metadata": {},
   "outputs": [],
   "source": [
    "def json_2_df_2_tokenizer(files):\n",
    "    final_dict = {'paper_id':[],'body_text':[]}\n",
    "    for file in files:\n",
    "        d = read_json(file)\n",
    "        final_dict['paper_id'].append(d['paper_id'])\n",
    "        final_dict['body_text'].append(d['body_text'])\n",
    "    df = pd.DataFrame.from_dict(final_dict)\n",
    "    print(df)\n",
    "    #indexes with empty bodytext\n",
    "    indexes =df[df['body_text']==''].index\n",
    "    #drop them\n",
    "    df.drop(indexes,inplace=True)\n",
    "    #print(df)\n",
    "    normalize_function = np.vectorize(normalize_document)\n",
    "    normalized_corpus = normalize_function(list(df['body_text']))\n",
    "    print(normalized_corpus)\n",
    "    cv = CountVectorizer()\n",
    "    doc_matrix =cv.fit_transform(normalized_corpus)\n",
    "    return doc_matrix,df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 219,
   "metadata": {},
   "outputs": [],
   "source": [
    "#using the yellow brick ELbowkneeVisulaizer\n",
    "def determining_n_clusters(doc_matrix):\n",
    "    model = KMeans()\n",
    "    visualizer=KElbowVisualizer(model,k=(2,30))\n",
    "    visualizer.fit(doc_matrix)\n",
    "    visualizer.show()\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 223,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clustering_documents(n_clusters,doc_matrix,df):\n",
    "    km = KMeans(n_clusters=n_clusters,max_iter=1000,random_state=42)\n",
    "    km.fit(doc_matrix)\n",
    "    print(km.labels_)\n",
    "    df['KMeans_label']=list(km.labels_)\n",
    "    print(df.info())\n",
    "    clustered_docs = (df.sort_values(by=['KMeans_label']).groupby(['KMeans_label']))\n",
    "    df_clustered=clustered_docs.apply(lambda x:x)\n",
    "    print(df_clustered)\n",
    "    # converting all clustered rows into dictionary\n",
    "    dic_clusters_docs = {}\n",
    "    for i in range(n_clusters):\n",
    "        doc = []\n",
    "        print(i)\n",
    "        for d in df_clustered[df_clustered[\"KMeans_label\"] == i]['body_text']:\n",
    "            doc.append(d)\n",
    "        print(len(doc))\n",
    "        doc_string = ''.join(doc)\n",
    "        #print(doc_string)\n",
    "        dic_clusters_docs[i]=doc_string\n",
    "    return dic_clusters_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "def summarize_clusters(dic_clusters_docs):\n",
    "    list_of_summaries=[]\n",
    "    for (cluster_index,item) in dic_clusters_docs.items():\n",
    "        list_of_summaries.append((cluster_index,summarize(item)))\n",
    "    for cluster_index,summary in list_of_summaries:\n",
    "        if not os.path.exists(os.getcwd()+\"/\"+\"output\"):\n",
    "            os.mkdir(\"output\")\n",
    "        filename=\"SUMMARY-\"+cluster_index+\".MD\"\n",
    "        path = os.getcwd()+\"/output/\"+filename\n",
    "        with open(path,\"w\") as f:\n",
    "            f.write(''.join(summary))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>paper_id</th>\n",
       "      <th>body_text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>8869bd83a3d8b813093f62f897c5478a96e311bf</td>\n",
       "      <td>Report 48 see https://www.who. int/docs/defaul...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>d6a98a653f12caba3f539f01b0fd84b2ca4f1672</td>\n",
       "      <td>Over the past few years, a new view of T cell ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ffb877d67fd30e14677580c292ca9caf64659987</td>\n",
       "      <td>In June 2015 the Healthcare Infection Society ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>PMC7008051</td>\n",
       "      <td>Respiratory syncytial virus (RSV) is well know...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>PMC6609751</td>\n",
       "      <td>The adenovirus (HAdV) is a double-stranded DNA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>31fb22d877d6efa55e7c8261a59a1f0d35962829</td>\n",
       "      <td>rapid assessment of the impact of physical dis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0738152fba8d21b4ae77293a3e2bfd5019a537a7</td>\n",
       "      <td>1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>PMC4217096</td>\n",
       "      <td>Dear Editor,For decades, Ebola members (EBOV) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>6861259e73b53c482dea9ed97abad64f5c1c479a</td>\n",
       "      <td>M. genavense infections occur only rarely in p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>PMC3235500</td>\n",
       "      <td>Multiple sclerosis (MS) was initially identifi...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   paper_id  \\\n",
       "0  8869bd83a3d8b813093f62f897c5478a96e311bf   \n",
       "1  d6a98a653f12caba3f539f01b0fd84b2ca4f1672   \n",
       "2  ffb877d67fd30e14677580c292ca9caf64659987   \n",
       "3                                PMC7008051   \n",
       "4                                PMC6609751   \n",
       "5  31fb22d877d6efa55e7c8261a59a1f0d35962829   \n",
       "6  0738152fba8d21b4ae77293a3e2bfd5019a537a7   \n",
       "7                                PMC4217096   \n",
       "8  6861259e73b53c482dea9ed97abad64f5c1c479a   \n",
       "9                                PMC3235500   \n",
       "\n",
       "                                           body_text  \n",
       "0  Report 48 see https://www.who. int/docs/defaul...  \n",
       "1  Over the past few years, a new view of T cell ...  \n",
       "2  In June 2015 the Healthcare Infection Society ...  \n",
       "3  Respiratory syncytial virus (RSV) is well know...  \n",
       "4  The adenovirus (HAdV) is a double-stranded DNA...  \n",
       "5  rapid assessment of the impact of physical dis...  \n",
       "6  1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...  \n",
       "7  Dear Editor,For decades, Ebola members (EBOV) ...  \n",
       "8  M. genavense infections occur only rarely in p...  \n",
       "9  Multiple sclerosis (MS) was initially identifi...  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "indexes =df[df['body_text']==''].index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(indexes,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>paper_id</th>\n",
       "      <th>body_text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>8869bd83a3d8b813093f62f897c5478a96e311bf</td>\n",
       "      <td>Report 48 see https://www.who. int/docs/defaul...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>d6a98a653f12caba3f539f01b0fd84b2ca4f1672</td>\n",
       "      <td>Over the past few years, a new view of T cell ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ffb877d67fd30e14677580c292ca9caf64659987</td>\n",
       "      <td>In June 2015 the Healthcare Infection Society ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>PMC7008051</td>\n",
       "      <td>Respiratory syncytial virus (RSV) is well know...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>PMC6609751</td>\n",
       "      <td>The adenovirus (HAdV) is a double-stranded DNA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>31fb22d877d6efa55e7c8261a59a1f0d35962829</td>\n",
       "      <td>rapid assessment of the impact of physical dis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0738152fba8d21b4ae77293a3e2bfd5019a537a7</td>\n",
       "      <td>1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>PMC4217096</td>\n",
       "      <td>Dear Editor,For decades, Ebola members (EBOV) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>6861259e73b53c482dea9ed97abad64f5c1c479a</td>\n",
       "      <td>M. genavense infections occur only rarely in p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>PMC3235500</td>\n",
       "      <td>Multiple sclerosis (MS) was initially identifi...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   paper_id  \\\n",
       "0  8869bd83a3d8b813093f62f897c5478a96e311bf   \n",
       "1  d6a98a653f12caba3f539f01b0fd84b2ca4f1672   \n",
       "2  ffb877d67fd30e14677580c292ca9caf64659987   \n",
       "3                                PMC7008051   \n",
       "4                                PMC6609751   \n",
       "5  31fb22d877d6efa55e7c8261a59a1f0d35962829   \n",
       "6  0738152fba8d21b4ae77293a3e2bfd5019a537a7   \n",
       "7                                PMC4217096   \n",
       "8  6861259e73b53c482dea9ed97abad64f5c1c479a   \n",
       "9                                PMC3235500   \n",
       "\n",
       "                                           body_text  \n",
       "0  Report 48 see https://www.who. int/docs/defaul...  \n",
       "1  Over the past few years, a new view of T cell ...  \n",
       "2  In June 2015 the Healthcare Infection Society ...  \n",
       "3  Respiratory syncytial virus (RSV) is well know...  \n",
       "4  The adenovirus (HAdV) is a double-stranded DNA...  \n",
       "5  rapid assessment of the impact of physical dis...  \n",
       "6  1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...  \n",
       "7  Dear Editor,For decades, Ebola members (EBOV) ...  \n",
       "8  M. genavense infections occur only rarely in p...  \n",
       "9  Multiple sclerosis (MS) was initially identifi...  "
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "corpus = df['body_text'].values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "numpy.ndarray"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'In June 2015 the Healthcare Infection Society held a twoday Middle East Infection Prevention Summit with the aim of uniting colleagues across the globe in driving down infection rates and improving infection prevention and control practice. In many ways the Middle East is a microcosm for the challenges in infection prevention and control across the world. The economies range from underdeveloped countries such as Egypt, with a low per-capita gross domestic product, to the wealthy hydrocarbon-exporting, and increasingly diversified, economies of the Gulf Cooperation Council countries; of course these vast economic differences impact on the resources available for healthcare. Moreover, there are large ex-patriot populations in many Middle Eastern countries and international travel to and from the Middle East is frequent, meaning that infections emerging there can quickly have a global impact.Two of the themes of the conference that have particular international relevance are the huge challenges presented by multidrug-resistant Gram-negative bacteria in Middle Eastern hospitals, and local experience with Middle East respiratory syndrome coronavirus (MERS-CoV). Coverage of the latter was particularly opportune, given the outbreak of MERS-CoV in South Korea in May 2015 originating from a traveller returning from visiting several Middle Eastern countries.This special section of the journal includes three papers relating to the Summit. Drs Omrani and Shalhoub present a review of MERS-CoV, and Dr Jon Otter and Professor Nesrene Omar describe their British and Egyptian perspectives of the Summit. 1e3'"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "corpus[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import nltk\n",
    "stop_words = nltk.corpus.stopwords.words('english')\n",
    "other_stop_words = ['report','docs','document','fig','figure']\n",
    "stop_words+=other_stop_words\n",
    "def normalize_document(txt,lemmatize=True):\n",
    "    txt=re.sub(r'(?:(?:https?|ftp):\\/\\/)?[\\w/\\-?=%.]+\\.[\\w/\\-?=%.]+','',txt)\n",
    "    txt = re.sub(r'[^a-zA-Z0-9\\s]', '', txt,flags=re.I|re.A)\n",
    "    txt = re.sub(r'[0-9]','',txt)\n",
    "    txt = txt.lower()\n",
    "    txt = txt.strip()\n",
    "    txt = remove_stopwords(txt)\n",
    "    if lemmatize:\n",
    "            txt = lemmatize_text(txt)\n",
    "    else:\n",
    "        txt = txt\n",
    "    return txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk.stem import WordNetLemmatizer\n",
    "from nltk.corpus import wordnet as wn"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_stopwords(text):\n",
    "    stopword_list = nltk.corpus.stopwords.words('english')\n",
    "    other_stop_words = ['report','docs','document']\n",
    "    stopword_list+=other_stop_words\n",
    "    tokens = tokenize_text(text)\n",
    "    filtered_tokens = [token for token in tokens if token not in stopword_list]\n",
    "    filtered_text = ' '.join(filtered_tokens)\n",
    "    return filtered_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tokenize_text(text):\n",
    "    tokens = nltk.word_tokenize(text)\n",
    "    tokens = [token.strip() for token in tokens]\n",
    "    return tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {},
   "outputs": [],
   "source": [
    "def pos_tag_text(text):\n",
    "    text = nltk.word_tokenize(text)\n",
    "    tagged_text = nltk.pos_tag(text)\n",
    "    tagged_lower_text = [(word.lower(), penn_to_wn_tags(pos_tag))\n",
    "                         for word, pos_tag in\n",
    "                         tagged_text]\n",
    "    return tagged_lower_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {},
   "outputs": [],
   "source": [
    "def penn_to_wn_tags(pos_tag):\n",
    "        if pos_tag.startswith('J'):\n",
    "            return wn.ADJ\n",
    "        elif pos_tag.startswith('V'):\n",
    "            return wn.VERB\n",
    "        elif pos_tag.startswith('N'):\n",
    "            return wn.NOUN\n",
    "        elif pos_tag.startswith('R'):\n",
    "            return wn.ADV\n",
    "        else:\n",
    "            return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "metadata": {},
   "outputs": [],
   "source": [
    "def lemmatize_text(text):\n",
    "    pos_tagged_text = pos_tag_text(text)\n",
    "    wnl = WordNetLemmatizer()\n",
    "    lemmatized_tokens = [wnl.lemmatize(word, pos_tag) if pos_tag\n",
    "                         else word                    \n",
    "                         for word, pos_tag in pos_tagged_text]\n",
    "    lemmatized_text = ' '.join(lemmatized_tokens)\n",
    "    return lemmatized_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "metadata": {},
   "outputs": [],
   "source": [
    "def normalize_corpus(corpus, lemmatize=True, tokenize=False):\n",
    "    normalized_corpus = []    \n",
    "    for text in corpus:\n",
    "        text=re.sub(r'(?:(?:https?|ftp):\\/\\/)?[\\w/\\-?=%.]+\\.[\\w/\\-?=%.]+','',text)\n",
    "        text = text.lower()\n",
    "        text = remove_stopwords(text)\n",
    "        #print(type(text))\n",
    "        #print(text)\n",
    "        text = re.sub(r'[^a-zA-Z0-9\\s]', '', text,flags=re.I|re.A)\n",
    "        text = re.sub(r'[0-9]','',text)\n",
    "        if lemmatize:\n",
    "            text = lemmatize_text(text)\n",
    "        if tokenize:\n",
    "            text = tokenize_text(text)\n",
    "            normalized_corpus.append(text)\n",
    "        else:\n",
    "            normalized_corpus.append(text)\n",
    "    return normalized_corpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 161,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>paper_id</th>\n",
       "      <th>body_text</th>\n",
       "      <th>KMeans_label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>8869bd83a3d8b813093f62f897c5478a96e311bf</td>\n",
       "      <td>Report 48 see https://www.who. int/docs/defaul...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>d6a98a653f12caba3f539f01b0fd84b2ca4f1672</td>\n",
       "      <td>Over the past few years, a new view of T cell ...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ffb877d67fd30e14677580c292ca9caf64659987</td>\n",
       "      <td>In June 2015 the Healthcare Infection Society ...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>PMC7008051</td>\n",
       "      <td>Respiratory syncytial virus (RSV) is well know...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>PMC6609751</td>\n",
       "      <td>The adenovirus (HAdV) is a double-stranded DNA...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>31fb22d877d6efa55e7c8261a59a1f0d35962829</td>\n",
       "      <td>rapid assessment of the impact of physical dis...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0738152fba8d21b4ae77293a3e2bfd5019a537a7</td>\n",
       "      <td>1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>PMC4217096</td>\n",
       "      <td>Dear Editor,For decades, Ebola members (EBOV) ...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>6861259e73b53c482dea9ed97abad64f5c1c479a</td>\n",
       "      <td>M. genavense infections occur only rarely in p...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>PMC3235500</td>\n",
       "      <td>Multiple sclerosis (MS) was initially identifi...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   paper_id  \\\n",
       "0  8869bd83a3d8b813093f62f897c5478a96e311bf   \n",
       "1  d6a98a653f12caba3f539f01b0fd84b2ca4f1672   \n",
       "2  ffb877d67fd30e14677580c292ca9caf64659987   \n",
       "3                                PMC7008051   \n",
       "4                                PMC6609751   \n",
       "5  31fb22d877d6efa55e7c8261a59a1f0d35962829   \n",
       "6  0738152fba8d21b4ae77293a3e2bfd5019a537a7   \n",
       "7                                PMC4217096   \n",
       "8  6861259e73b53c482dea9ed97abad64f5c1c479a   \n",
       "9                                PMC3235500   \n",
       "\n",
       "                                           body_text  KMeans_label  \n",
       "0  Report 48 see https://www.who. int/docs/defaul...             0  \n",
       "1  Over the past few years, a new view of T cell ...             2  \n",
       "2  In June 2015 the Healthcare Infection Society ...             0  \n",
       "3  Respiratory syncytial virus (RSV) is well know...             0  \n",
       "4  The adenovirus (HAdV) is a double-stranded DNA...             3  \n",
       "5  rapid assessment of the impact of physical dis...             4  \n",
       "6  1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...             0  \n",
       "7  Dear Editor,For decades, Ebola members (EBOV) ...             0  \n",
       "8  M. genavense infections occur only rarely in p...             0  \n",
       "9  Multiple sclerosis (MS) was initially identifi...             1  "
      ]
     },
     "execution_count": 161,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 142,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "metadata": {},
   "outputs": [],
   "source": [
    "normalize_function = np.vectorize(normalize_document)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "metadata": {},
   "outputs": [],
   "source": [
    "normalized_corpus = normalize_function(list(df['body_text']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['see intdocsdefaultsource outbreak coronavirus disease covid cause severe acute respiratory syndrome coronavirus sarscov first report china december affect whole world march laboratoryconfirmed case deaths country sarscov rna first detect stool specimen first report covid case usa much attention pay study report gastrointestinal tract infection sarscov accord study include patient laboratoryconfirmed covid hospital china jan nausea vomit diarrhoea report patient autopsy study crucial help understand involvement covid digestive system however date one autopsy man age year covid show segmental dilatation stenosis small intestine whether find secondary covid preexist gastrointestinal comorbidity implication management patient preexist digestive disease indeed presence number comorbidities associate poorer clinical outcome patient covid study patient laboratoryconfirmed covid patient covid report least one comorbidity hypertension diabetes coronary heart disease common study patient hepatitis b infection severe case likely hepatitis b infection v nonsevere case abnormal liver function test include elevated aspartate aminotransferase alanine aminotransferase total bilirubin note liver abnormality patient covid might due viral infection liver cell could also due cause drug toxicity systemic inflammation data suggest liver injury prevalent severe case mild case covid however data underlie chronic liver condition nonalcoholic fatty liver disease alcoholrelated liver disease autoimmune hepatitis effect prognosis covid need transplantation might involve risk transmission viral infection donor recipient show previous sars outbreak therefore donor screen test crucial although many patient comorbidities report series none transplant recipient transplant clinician encourage follow guidance issue transplantation society well local health department guideline isolate quarantine test monitoring return traveller endemic cancer general susceptible infection due immunocompromised status cause malignancy anticancer treatment however whether patient gastrointestinal cancer likely infect sarscov healthy individual remain unknown recent nationwide analysis china covid case history cancer among case three history colorectal cancer one colonic tubular adenocarcinoma one rectal carcinoma one colorectal carcinoma patient covid cancer observe high risk severe event several strategy propose intentional postponing adjuvant chemotherapy elective surgery patientbypatient basis strong personal protection provision intensive surveillance treatment give use biologics immunosuppressive agent whether patient inflammatory bowel disease ibd susceptible sarscov infection raise great concern currently patient ibd report infected sarscov ibd elite union incorporates seven large ibd referral centre china patient ibd furthermore patient ibd sarscov infection report three large tertiary ibd centre wuhan tongji hospital union hospital zhongnan hospital time manuscript prepare march several strategy implement china minimise potential risk sarscov infection patient ibd since outbreak covid first chinese ibd society issue official guideline manage patient ibd early february guideline include practical recommendation use immunosuppressive agent biologics diet intentional post ponement elective surgery endoscopy well personal protection provision outline panel second china crohn colitis foundation organise group volunteer gastroenterologist specialise ibd offer online consultancy patient ibd since jan third online virtual ibd visit programme initiate ibd centre provide convenient costeffective care could potentially reduce risk sarscov infection avoid close contact infected patient public area increase concern patient ibd globally helpful online resource covid provide international nonprofit organisation crohns colitis foundation america crohn colitis uk guidance advice deliver urgently healthcare worker well patient comorbidity spectrum digestive condition impact treatment outcome covid remain largely unknown data need analyse covid cohort establish national health commission people republic china would help precisely ascertain risk sarscov infection patient digestive comorbidities ibd data experience guidance manage patient underlining comorbidities china could facilitate integrate care patient declare compete interest thank member chinese ibd elite union chinese society ibd chinese ibd quality care evaluation center committee ibdqcc collaboration rm jl contribute equally',\n",
       "       'past year new view cell recognition emerge tcrs previously think simple onoff switch highly specific single foreign peptide numerous study demonstrate different functional outcome result engagement tcr different peptide ligands depend whether peptide act agonist partial agonist antagonist tcr time show several peptide relatively little primary sequence homology act agonists tcr activation autoreactive cell pathogenderived peptide mimic selfpeptides term molecular mimicry emerge complexity tcr recognition important implication understand selftolerance pathogenesis human autoimmune disease review discuss structural requirement activation autoreactive cell microbial peptide development human autoimmune versus degeneracy cell receptor recognition mhc molecule bind peptide highly degenerate give mhc molecule bind peptide majority antigens set overlap antigenderived peptide test peptide elution study demonstrate hundred different peptide bound single mhc class ii molecule majority mhc class ii molecules every position peptide substitute one many different amino acid cell recognition however much specific cell clone crossreact majority control antigens test addition removal single methyl hydroxyl group primary tcr contact residue result complete loss tcell recognition cell clone change position tolerate certain extent however tcrs generated random rearrangement germline encode segment fetal development contrast antibody affinity maturation process improve fit tcr give mhc moleculepeptide complex ongoing immune response specificity adult tcr repertoire balance two possible extreme highly specific tcrs require particular amino acid many position mhc moleculebound peptide highly degenerate tcrs require certain sequence feature mhc moleculebound peptide therefore crossreact many different microbial peptide obvious disadvantage extremes highly specific tcrs may never engage immune response respective microbial peptide sequence may exist highly degenerate tcrs may crossreact many selfpeptides cause autoimmunity balance two extreme likely result thymic selection process firstly negative selection delete cell high affinity mhc molecule regardless peptide content likely highly crossreactive secondly failure undergo positive selection eliminate cell low affinity mhc data indicate cell clone differ degree specificity versus degeneracy peptide recognition human myelin basic protein mbpspecific cell clone degenerate peptide recognition find crossreact number microbial peptide whereas cell clone specific crossreacted one two microbial peptide martin k wucherpfennig unpublished data tcr peptidecontact residue could substitute least one structurally related amino acid cell clone degenerate peptide recognition clone specific require amino acid identity primary tcr peptidecontact residues martin k wucherpfennig unpublished data data suggest mature tcell repertoire represent spectrum cell clone term degree specificitydegeneracy peptide recognition figure accord model cell clone degenerate peptide recognition frequently engage immune response likely induce autoimmune response due crossreactivity microbial selfpeptide potential crossreactivityautoimmunity current opinion immunology schematic depict distribution peripheral cell regard degree specificitydegeneracy tcr degenerate cell engage peptidemhc molecule complex frequently high potential causing autoimmunity specific use isolate cell clone may determine part spectrum cell clone derive early cloning cell line generation cell line limit dilution condition may favor sample different part spectrum longterm selection polyclonal population limit concentration antigen likely favor outgrowth cell high degree specificity give mhc moleculepeptide crystal structure complex human tcr htlvi tax peptide hlaa solve structure provide important insight structural basis tcr specificity degeneracy htlvi tax specific tcr orient diagonally mhc moleculepeptide complex cdr cdr loop c tcr chain variable region contact peptide orientation tcr mhc moleculepeptide complex observe murine mhc class restrict tcr suggest bind mode general peptide bind surface tcr find remarkably flat exception central pocket occupy central residue singleletter amino acid code tax peptide pocket create cdr loop v vi small size contact surface tcr tax peptide z fact substantial contact make peptide residue indicate limit place specificity tcr substitute alanine ya peptide still form tcrpeptidehlaa complex crystallize acted partial agonist recognition peptide sequence strikingly different tcr observe several alloreactive cell clone two structural explanation phenomenon first two peptidemhc molecule complex peptide differ primary sequence may form similar tcraccessible surface term volume charge hydrophobicity allow tcr engage complex similar way second may certain degree flexibility conformation tcr cdr loop allow tcr specifically bind different mhc moleculepeptide surface crystal structure different tcrpeptidemhc molecule complex require answer question recognition hladrpresented mbp autoreactive cell clone ms patient study extensively illustrate several aspect specificitydegeneracy cell recognition analysis fine specificity mbpspecific cell clone use single amino acid analog peptide reveal high degree specificity toward major tcr contact residue combine certain degree degeneracy toward minor tcr contact example addition single hydroxyl group fy completely abrogate cell activation clone whereas change position ia little effect certain substitution even enhance hladr bind ta tcr recognition mutation differ cell clone represent call superagonists substitution compensate substitution suboptimal result multisubstituted peptide similar efficacy native antigen addition additive effect complementary substitution describe cell clone respond single amino acid substitute peptide fy kr doublesubstituted peptide fy kr hladr bindintcr recognition motif mbp use identify crossreactive peptide human pathogen via protein data base search seven viral single bacterial peptide find stimulate least one seven mbpspecific cell clone study see table microbial peptide quite distinct sequence mbp peptide primary tcr contact residues either f k conserve presentation microbial peptide infect cell examine epsteinbarr virus ebv dna polymerase peptide reactivation epsteinbarr virus ebv lytic cycle phorbol ester result activation mbpspecific cell clone crossreacted ebv peptide activation control clone recognize mbp peptide cell activation observe mhcmismatched b cell line block antidr antibody comparison fine specificity mbpspecific autoreactive cell clone also demonstrate obvious difference specificitydegeneracy peptide recognition specific clone amino acid identity require primary tcr contact residue whereas every tcr contact residue could substitute least one structurally related amino acid degenerate clone martin k wucherpfennig unpublished data illustrates specificitydegeneracy distribution pattern propose figure specific cell represent left part main curve degenerate one right small fraction cell extreme end example highly degenerate cell clone recently describe notably cell clone crossreacted diverse set microbial peptide sequence stimulate random peptide library indicate level degeneracy peptide recognition require cell crossreactivity microbial peptide martin k wucherpfennig unpublished dataanother interesting aspect mbp peptide fact also represent immunodominant antibody epitope mbp moreover core region peptide important antibody bind recognition hladr restrict cell clone important difference however antibody cell epitope firstly longer peptide require optimal cell stimulation antibody bind secondly sequence identity require every peptide position core antibody epitope whereas mhc molecule contact residue cell epitope could substitute amino acid due similarity antibody tcell epitope human papillomavirus peptide recognize mbpspecific antibody mbpspecific cell clone take together analysis mbpspecific cell clone ms patient demonstrate microbial peptide limit sequence homology effective activator autoreactive cell result make unlikely single microbial peptide responsible activation autoreactive cell human autoimmune disease crossreactive peptide mbp table example experimentally determine cell crossreactivity self microbial peptide human autoimmune antigen sequence alignment reference multiple sclerosis cd cell clone hladrbor hladq restrict crossreactive tcell epitope also identify autoantigens human autoimmune disease table yet know whether autoantigensmicrobial peptide important development autoimmune disease examples demonstrate crossreactive cell epitope study also examine issue crossreactivity merely perform sequence alignment candidate selfantigens microbial sequence absence functional data study suffer follow relate problem firstly frequently know whether region autoantigen study represent cell epitope secondly peptides visual sequence similarity may biological activity lack mhc molecule bind failure activate autoreactive cell thirdly peptides biologically active may overlook structural similarity selfpeptide may obvious observation make analysis mbpspecific cell clone indicate detailed characterization immunodominant epitope autoantigen require identification crossreactive microbial peptide development autoimmunity microbial antigen also study immunization microbial activation autoreactive call pepudes human pathogen hausmann wucherpfennig table example experimentally determine cell crossreactivity self microbial peptide experimental animal model reference organismpathogen antigen sequence alignment experimental autoimmune uveitis lewis rat immunize foreign peptidesexperimental ovarian autoimmune disease baf antigenspeptides sequence homology immunodominant tcell epitope table first study examine induction experimental autoimmune encephalomyelitis eae use hepatitis b virus polymerase peptide share identity six amino acid position encephalitogenic site rabbit mbp follow immunization rabbit peptide antibody crossreactivity certain degree cell crossreactivity mbp observe four eleven animal show histological sign eae analysis aminoterminal mbp peptide aclll immunodominant plj mouse demonstrate epitope could shorten seven amino acid peptide without loss encephalitogenicity test alanine analog identity four amino acid position find require tcell crossreactivity whereas five position necessary induction eae importance aminoterminal acetylation however absent viral bacterial peptide may make difficult identify microbial peptide induce two experimental modelsexperimental autoimmune uveitis experimental ovarian autoimmune diseasemicrobial peptide identify induce tissue specific autoimmunity experimental autoimmune uveitis lewis rat mediate cell specific retinal santigen review santigen specific autoimmunity could induce several microbial peptide share identity five six amino acid uveitogenic epitope santigen although high dos fold microbial peptide require experimental ovarian autoimmune disease immunization microbial peptide similar target antigen zona pellucida protein induce autoimmune oophoritis tissuespecific autoimmunity also induce immunization whole microbial antigen lewis rat highly sensitive development arthritis follow immunization heatkilled mycobactehum tuberculosis mineral oil complete freunds adjuvant cell response mycobacterial heat shock protein hsp appear play important role cell clone specific mycobacterial hsp peptide transfer disease naive irradiated recipient review mycobacterialspecific cell clone find crossreact proteoglycan find joint peptide sequence crossreactive selfepitope yet know whereas hspspecific cell clone transfer disease neither hsp peptide hsp antigen sufficient induce arthritis suggest mycobacterial component pathogenic necessary inducing cell epitope example discuss autoimmunity induce immunization peptide protein artificial question whether challenge infectious virus initiate autoimmune process activate autoreactive cell address use transgenic mouse selectively express viral antigen target organ review study animal model reveal multiple factor example expression cytokine costimulatory molecule critical importance disease development support notion initiation autoimmune disease multistepmuhifactorial wide search human autoimmune disease experimental animal model indicate multiple gene mhc nonmhc require development spontaneous autoimmunity susceptible individual activation autoreactive cell necessary sufficient development autoimmune disease table insufficient degree clonal expansion autoreactive cell may major limit factor autoreactive cell clone activate peptide different pathogen stepwise expansion autoreactive cell subsequent infection possible another limiting factor may functional phenotype induce infectious agent eae model small fraction mbpspecific cell clone pathogenic presence ofa thl phenotype alone insufficient induce eae brocke personal communication therefore autoreactive cell may pathogenic particular functional program induce infectious agent factor limit occurrence autoimmune disease access target organ addition expression level mhc class ii costimulatory molecule target organ illustrated observation mouse transgenic mbpaclllspecific tcr vivo activation autoreactive ceils even native mbp peptide sufficient induce eae unless entry cell cns facilitate pertussis toxin table requirement development chronic autoimmune disease follow activation autoreactive sufficient clonal expansion autoreactive cell induction functional phenotype cytokine profile make cell pathogenic entry activate autoreactive cell target organ sufficient expression level mhc molecule costimulatory molecule antigen present cell target organactivation autoreactive cell important induction human autoimmune diseases several study past two year demonstrate human cell clone recognize several peptide ligand quite distinct primary sequence cell clone degenerate recognition mhc moleculebound peptides likely crossreact selfantigen therefore induce autoimmunity differential contact disparate class ipeptide complexes basis epitope crossrecognition single cell receptor j immuno analysis fine specificity murine xenoreactive hlaaspecific cell clone reveals difference relative importance peptide side chain tcr recognition different mhc moleculepeptide complex implies single tcr able use differential contact sit recognition fine specificity highly degenerate myelin basic proteinspecific cell clone mbp specific analyze use random peptide library base motif several peptide human microbial origin identify activate autoreactive clone restrict tcell clone multiple sclerosis patient identity key contact residue bcell tcell epitope j cin invest fine specificity myelin basic protein mbpspecific antibody purify brain multiple sclerosis patient compare mbp specific cell clone residues critical antibody bind cell receptor recognition locate amino acid segment viral peptide identify bound purified autoantibody also stimulate mbp specific cell pj paquette j ciurli c antel jp ouellet f myelin basic protein human coronavirus e crossreactive cell multiple sclerosis ann neuro j wood larson l weiner lp hood l zauer dm transgenic mouse express myelin basic proteinspecific cell receptor develop spontaneous autoimmunity cell goldrath aw yon dassow p paez liggitt hd goverman j trigger autoimmune disease murine tcrtransgenic model multiple sclerosis j immuno increase incidence spontaneous experimental autoimmunoe encephalomyelitis tcr transgenic mouse nongerm free condition demonstrate impact microbial environment induction autoimmunity study transgenic mouse show follow cell activation vivo entry autoreactive mbpspecific cell central nervous system critical step initiation autoimmune disease',\n",
       "       'june healthcare infection society hold twoday middle east infection prevention summit aim unite colleague across globe drive infection rate improve infection prevention control practice many way middle east microcosm challenge infection prevention control across world economy range underdeveloped country egypt low percapita gross domestic product wealthy hydrocarbonexporting increasingly diversified economy gulf cooperation council country course vast economic difference impact resource available healthcare moreover large expatriot population many middle eastern country international travel middle east frequent meaning infection emerge quickly global theme conference particular international relevance huge challenge present multidrugresistant gramnegative bacteria middle eastern hospital local experience middle east respiratory syndrome coronavirus merscov coverage latter particularly opportune give outbreak merscov south korea may originate traveller return visit several middle eastern special section journal include three paper relate summit drs omrani shalhoub present review merscov dr jon otter professor nesrene omar describe british egyptian perspective summit e',\n",
       "       'respiratory syncytial virus rsv well know virus cause low respiratory tract infection lrti infant immunocompromised adult bronchopneumonia pattern common finding rsvinduced lrti rsvlrti however rsvlrti often show variable finding chest image although factor virulence rsv host immune status might affect chest compute tomography ct finding rsvlrti detailed mechanism remain perspective rsv outbreak due genetically identical rsv ideal set investigate chest image rsvlrti thus far however one show chest image rsvlrti outbreak set addition report investigate correlation clinical manifestation abnormal finding chest ct remain rare genetically identical rsv outbreak occur hematooncology ward university ryukyus hospital subset rsvinfected patient underwent chest xray ct outbreak herein analysis radiological finding clinical manifestation outbreak rsv infection diagnose reverse transcriptase polymerase chain reaction use respiratory specimen genetic proximity confirm phylogenetical analysis eight rsvinfected patient underwent chest xray ct outbreak clinical information chest xray finding retrospectively review patient medical record within one week chest ct medical record radiological image collect case retrospectively review identify information remove study review approved clinical research ethic committee university patient background characteristic clinical manifestation laboratory data finding chest image show table seven case receive various immunosuppressive treatment none airway diseases bronchial asthma five case newly appear abnormal finding chest ct however abnormal finding detect chest xray patient case upper respiratory symptom include rhinitis sore throat however low respiratory symptom wheeze sputum hypoxemia see patient newly appear finding chest ct bacterial culture respiratory specimen perform six case bacteria detect three case however patient diagnose bacterial pneumonia treat targeted antibiotic detect bacteria addition case receive antiviral therapy ct finding five patient show figs common finding among patient bronchial wall thickening see patient term finding parenchymal lesion pattern distribution vary inconsistent two case show groundglass opacity ggos along bronchus however distribution differ one localize ggo multilobar ggo one case show groundglass nodule treeinbud pattern remain case show diffuse ggos centrilobular septal thickening also know crazypaving pattern three case underwent two ct scan course disease abnormal finding chest ct disappear fig chest ct show variable finding rsv infection even outbreak set case chest xray fail detect abnormality rsvinfected hematological malignancy patient receive anticancer chemotherapy lower respiratory symptom may predict existence ct abnormality due author state conflict interest coi',\n",
       "       'adenovirus hadv doublestranded dna virus divide seven specie dna homology serotypes depend serotype hadv cause various infectious disease respiratory infection gastroenteritis epidemic conjunctivitis common infection due hadv pharyngitis mainly develop among child recover naturally however case progress severe respiratory infection pneumonia cause death know type cause severe respiratory infection among adult type type report cause outbreak adenovirus transmit via respiratory droplet fecal oral route contaminate environment rarely via swim pool water incubation period acute respiratory infection adenovirus day adenovirus infection outbreak swim pool healthcare facility military camp report oral vaccine introduce united state prevent extensive epidemic respiratory infection cause type military camp korea severe case adenovirus infection military camp case pneumonia consequent death cause type report adenovirus respiratory infection outbreak school education facility private residential facility korea study first outbreak acute respiratory infection cause adenovirus occur school may cluster acute respiratory infection due adenovirus swim department physical education school school j report korea center disease control prevention kcdc epidemiological investigation conduct identify transmission route infection control outbreak paper aim recommend infection control measure prevention adenovirus respiratory infection outbreak epidemiological analysis suspect case define person two follow acute respiratory infection symptom without laboratory confirmation fever sore throat cough rhinorrhea headache confirm case define person test positive adenovirus respiratory virus polymerase chain reaction pcr among suspected case case april day first identify case july day last identified case include case test positive virus adenovirus pcr test physical education school j integrated school specialize athletics education consist class class per grade total grade include middle high school total school population consist student teacher student member one athletic department every student accommodate campus dormitory student respiratory symptom identify member department use swim pool swim modern sport onsite investigation perform may retrospective cohort investigation study conduct instantaneously student teacher use swim pool since may prospective active surveillance study conduct student school personnel detect additional case active surveillance teacher class check student every morning symptom acute respiratory infection report result public health center questionnaire survey throat swab investigation conduct swim modern sport department additional case active surveillance thirty three case identify study case identify study enrol case present school activity student collected list name sort accord grade class athletic department dormitory room data sex age grade class athletic department information dormitory onset symptom history medical treatment information use swim pool contact person respiratory symptom collect interview suspected test conduct eight sentinel surveillance respiratory virus include adenovirus collect throat swab target population study suspect case study eight respiratory virus follow adenovirus human bocavirus parainfluenza virus respiratory syncytial virus rhinovirus human metapneumovirus human coronavirus influenza virus adenovirus pcr test conduct collect rectal swab addition throat swab suspect case improved school environment collect may adenovirus pcr test conduct sample collect swim pool water surface swim pool environment surface dormitory environment one liter swim pool water collect concentrated use concentration method innovaprep concentrate pipette pcr sequence analysis perform detected adenovirus use hadv hexon partial base compare attack rate base potential risk factor relative risk rrs calculated statistical significance evaluate fisher exact test multivariable logistic regression perform identify risk factor infection outbreak statistical significance identify confidence interval pvalue twotailed test epiinfotm cdc atlanta ga usa spss version window ibm armonk ny usa use statistical need ethical approval study waive base korean infectious disease control prevention act enforcement rule bioethics safety study total case identify confirmed case suspect case attack rate none asymptomatic case test positive adenovirus first suspect case occur april first grade high school student year old member modern sport department use swim pool continuously presence symptom second case occur april swim teacher hospitalize due acute pharyngotonsillitis day april time specimen collection may symptoms two case disappear first confirm case occur may may may increase trend incidence case may confirm case occur fig study total case identify confirmed case suspect case attack rate since onsite investigation may sporadic case occur june last case fig outbreak period identify case study student swim teacher case male st rd grade high school large number case swim modern sport department case respectively identify case study student ten case male nine case st grade student high school shoot department common symptom case headache fever rhinorrhea sputum sore throat eleven case accompany vomit diarrhea show eye congestion although none case show sign pneumonia case hospitalize due acute respiratory infection table study attack rate swimming department high others rr confidence interval ci table study member shoot department rr ci first grade student high school rr ci identify risk factor infection accord result multivariable logistic regression table adenovirus detect throat swab confirm case study duration symptom onset specimen collection day median day one confirm adenovirus detect throat swab collect day symptom onset detect rectal swab adenovirus detect throat swab confirm case study duration symptom onset specimen collection day median day two confirm case codetected influenza virus adenovirus influenza virus detect student among fever respiratory symptom student include result gene analysis specimen sequence analysis possible among identified adenovirus detect confirmed case sequence identical homology type confirm hadv swimming pool water filter use circular filtration system automatic chlorine injection system implement concentration free residual chlorine water ppm meeting requirement relate regulation adenovirus detect pool water surface locker room shower room frequent contact four student share dormitory room base athletic department adenovirus detect surface shower room door knobs shelf frequent contact student swim department continue train school without return home weekend prepare swim competition continue school activity even period respiratory symptom restriction school activity return home recommend prevent transmission student infection control measure day jun student return home school temporarily close day temporary closure school j last confirmed case occur june outbreak fig number school day day symptom onset decreased day day intervention statistically significant difference p use swim pool suspend disinfection conduct prevent transmission environment suspect case identify additional disinfection conduct dormitory room case temporary school closure period entire environment school clean regard infection control measure hand hygiene cough etiquette use personal equipment provide student total suspected case acute respiratory infection cause adenovirus identify physical education school test positive adenovirus gene analysis adenovirus show sequence identical homology type confirm hadv b outbreak hadv b acute respiratory infection report physical training facility hospital china military camp korea study first outbreak hadv b acute respiratory infection community except military b newly name virus know recombination type b b analysis hadv b acute respiratory infection occur state us show case fatality rate report hadv b cause severe pneumonia among member korean military physical education school j similarity military camp student accommodate dormitory sometimes stayed weekend attend training perform lots physical activity although none develop pneumonia hospitalize opinion overcrowd increased physical psychological stress one factor hadv b infection among adult therefore hadv b consider possible causal pathogen acute respiratory infection outbreak occur epidemic last day april jun epidemic curve show trend propagate transmission interval peak epidemic curve day similar incubation period acute respiratory infection cause adenovirus day epidemic initiated student modern sport department use swim pool spread swim department transmit student department use swim pool fig univariate analysis study identify attack rate significantly higher swim group table multivariable analysis study member shoot department first grade student high school identify independent risk factor table share dormitory room also assume contributed transmission infection identify independent risk factor therefore presumed propagation mostly occur performance activity hold athletic department propagation occur class transfer via contact droplet exposure contaminate environment investigation infection control measure apply two infection transmission rout prevent propagated transmission suspect case ask go home temporary school closure carry prevent environmental transmission disinfection conduct use high concentration chlorine clinical characteristic hadv b acute respiratory infection case could identify study common symptom among confirmed case adenovirus infection pcr test fever headache respectively sore throat symptom similar report previous study however headache high report china cough lower report korean military diarrhea appear confirmed case similar report korean military eye congestion appear confirmed case approximately confirm case hospitalize low rate report korean military study several limitation first selection bias could potentially occur initial investigation perform student teacher use swim pool student teacher use pool investigation perform show symptom respiratory infection prospective surveillance thus possibility thorough investigation conduct nonusers swim pool second possibility information bias epidemiological investigation start month outbreak order minimize bias facetoface interview conduct considerable amount time case hospital admission medical record investigate third possibility misclassification possibility infection pathogens among initial suspected case could source respiratory infection easy determine outbreak due relatively long incubation period complicate transmission route affect human environmental factor therefore identify cause transmission route necessary perform systematic investigation initiation investigation identify characteristic epidemic via indepth investigation initial conclusion confirm adenovirus respiratory infection case suspect case identify one physical education school korea result suggest infection initiate user swim pool transmit student school activity hold athletic department class continue performance school activity without restriction student respiratory symptom could cause outbreak therefore infection control measure early detection symptom respiratory infection restriction group activity necessary prevent respiratory infection outbreak communal living though hadv b recently report pathogenic organism respiratory infection outbreak severe case characteristic acute respiratory infection cause hadv b well explore korea study contribute identify clinical epidemiological characteristic hadv b basis research future',\n",
       "       'rapid assessment impact physical distancing measure routine epidemiological study many government adopt physical distancing measure mitigate impact covid pandemic however unclear extent measure reduce number contact therefore transmission search pubmed medrxiv march term coronavirus covid influenza school work closure holiday contact mix identify result one study conduct china covid pandemic report reduction daily contact outside home period lockdown found publish article empirically quantify impact measure ageand locationspecific mix survey adult behaviour uk period stringent physical distance lockdown compare result previously collect data find large reduction daily contact particularly outside home result mark reduction estimate reproduction number bootstrapped confidence interval ci method allow rapid assessment change reproduction number unaffected reporting human contact behaviour drive respiratory infection rate understanding change different stage covid pandemic allows us rapidly quantify impact physical distancing measure transmission case death covid record worldwide th march attempt mitigate covid pandemic many country adopt unprecedented physical distancing policy rd march confirm case uk government implement strict physical distancing measure instruct individual stay home avoid leave house except essential work take one form exercise day buy essential item food medicine follow closure sport event school restaurant bar gyms leisure hospitalityrelated business previous week increase social distancing among population take place several day announcement physical distancing intervention attempt reduce contact relevant infectious disease spread individual multiple survey instigate uptake different physical distancing measure current pandemic explicitly measure contact people make accurate prediction impact measure quantitative data relevant contact pattern require one previous surveyconducted two chinese city wuhan shanghai february quantified impact measure individual contact pattern covid pandemic paper describe survey contact pattern compliance physical distance measure present result sample adult uk evaluate whether measure might sufficient control epidemic estimate impact reproduction number average number secondary case generate per caseparticipation optin study voluntary analysis carry anonymised data study approve ethic committee london school hygiene tropical medicine reference number ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprintwe commission market research company ipsos conduct survey uk adult refer comix survey adult year recruit survey send email invitation exist member online panel representativeness general uk population ensure set quota age gender geographical location cohort individual request answer survey every two week total week track change selfreported behaviour first surveys send tuesday th march one day lockdown announce asked attitude towards covid effect physical distancing intervention whether household member experience recent symptom whether test covid whether contact know covid case whether affected physical distancing report person household advise quarantine isolate limit time workplace educational facility precede seven day due covid ii heed advice isolate quarantined stay away workplace educational facility survey define quarantine limiting contact stay home restrict allowance movement outside home potential exposure covid case define isolation completely separate uninfected contact include household member either home health facility assess impact advice policy change regard physical distancing ask participant indicate plan participate set event precede week event type report whether proceeded plan ii cancel decide go iii frequency event type previous seven question ask preventive behaviour hand wash wear mask use public transport previous seven addition ask participant record direct contact make day precede survey day survey direct contact define anyone meet person least word exchange anyone participant sort skintoskin ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprint every record contact participant document age gender contact relationship contact frequency usually contact person whether contact physical skintoskin set contact occur home work school undertaking leisure activity etc include whether contact occur inor outside enclosed building question social contact consistent uk arm polymod survey use baseline prepandemic comparison dataset detail survey methodology copy questionnaire use provide supplementary group study participant contact follow age band age gender location participant compare midyear estimate provide uk office national statistic ons assess representativeness study sample descriptively analyse answer relate symptom attitude exposure physical distancing measure individual preventative measure present number percentage mean standard deviation appropriate table calculate average number social contact per person per day overall stratify age category sex household size location contact type contact day compare mean total number daily contact age group polymod stratify contact calculate social contact matrix agespecific daily frequency direct social contact adjust age distribution study population reciprocity contact use socialmixr package r child year include survey participant imputed contact young age group childchild childadult contact use polymod uk data specifically child contact group miss use scale version polymod social contact matrix follow previous method develop klepac et al scale factor take ratio dominant eigenvalue polymod comix ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprint matrix age group present study stratify set furthermore reflect school closure collection survey remove schoolcontacts polymod data basic reproduction number r average number secondary infection arise typical single infection completely susceptible population estimate dominant eigenvalue next generation matrix exact form next generation matrix model dependent respiratory infection sarscov pathogen cause covid usually function agespecific number daily contact probability single contact lead transmission total duration r proportional dominant eigenvalue contact matrix assume contact pattern prior physical distancing similar observe polymod data duration infectiousness probability single contact lead transmission change study period assumption relative reduction r equivalent reduction dominant eigenvalue contact matrix multiply value r prior intervention ratio dominant eigenvalue polymod comix contact matrix able calculate r physical distancing intervention prior intervention assume r follow normal distribution mean standard deviation base metaanalysis literature present supplementary assess uncertainty repeat age imputation process take bootstrapped sample polymod comix matrix every bootstrap sample calculate ratio dominant eigenvalue sample polymod comix sample provide distribution relative change r contact pattern observe polymod comix subsequently scale initial distribution r distribution bootstrap sample estimate r physical distancing result bbc pandemic study suggest decrease nearly average number contact make teenager year compare polymod data assess sensitivity result potential reduction contact time take conservative reduction year old polymod study repeat approach estimate reduction ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint table compare midyear ons population estimate take individual year individual age year age participant report tested covid seven test positive two participant still wait result fortyone participant state contact know covid case term perceive risk thought likely would develop coronavirus agree strongly agree covid would serious disease acquire report data total household member include ask quarantine asked quarter household member live house someone least one symptom fever ache shortness breath cough roughly employ individual either ask limit time work work close andor visit work precede day table household member attend educational establishment institution close visit previous ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprint clear suggestion physical distance previous week impact planned activity survey participant participant cancel plan visit pub table contrastingly small percentage participant intend go supermarket unable due mean number physical nonphysical contact per person measure study iqr low measure polymod reduction mean contact polymod comix consistent across age gender household size table respective social contact matrix include physical nonphysical contact also reflect much low number mean contact across age stratum present figure majority contact occur home contrasting report polymod survey figure ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint measure introduce uk government appear high level uptake among participant result large reduction total number contact similar change observe across uk population would expect basic reproduction number ci physical distancing measure lead decline case come week however project decline incidence result immediate decline report case significant delays infection onset symptomatic disease hospitalisation well delay event report hence routine surveillance data unlikely show decline case time however directly measure individual contact pattern estimate correspond basic reproduction number able rapidly quantify impact physical distancing total number daily contact mean per person significantly reduce compare pattern previously estimate polymod study exclude child year old recently bbc pandemic study exclude yearolds observe reduction appear unlikely due chance give large difference average contact consistent recent study conduct wuhan china estimate reduction average number contact per day prior outbreak physical distancing intervention unaware directly comparable data uk finding certainly consistent report uk dramatic reduction social contact example half respondents one survey reporting house past hrs several limitation survey ask individual contact day may result recall bias moreover individual adhere physical distancing measure may likely respond survey potentially result selection bias overestimate impact measure able ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprint sample child childchild contact impute comparison previous able quantify additional effect intervention transmission reduction infectiousness increase handwash addition able calculate net reproductive number r account proportion population longer susceptible could reduce net reproductive number value lower estimate analysis assume direct contact appropriate proxy effective contact thus transmissibility equal across agegroups contact single infect child susceptible adult likely result transmission contact single infect adult susceptible adult assume reduction nonschool contact child similar observe adult furthermore assume contact pattern prior intervention consistent similar magnitude recent study find significantly low number contact report teenager compare polymod survey decrease mixing among year whilst reduce magnitude reduction r affect qualitative conclusion study plan continue uk next week future analysis able explore change contact patterns different intervention may provide early warning sign change contact pattern due intervention lift decrease adherence show behavioural monitoring give rapid insight transmission covid provide first evidence restriction adopt uk government lead decrease transmission ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprint ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint table show compliance different social distancing measure due covid n symptom show total number household member live household someone follow symptom fever ache shortness breath cough many individual report covid symptom column ask refers total number people report asked quarantine isolate column show total number people report quarantine isolation least one day seven day ccbynd international license make available authorfunder grant medrxiv license display preprint peerreviewed copyright holder preprint doi medrxiv preprint',\n",
       "       'giulia polverari md vincenzo arena md francesco ceci md phd ettore pelosi md phd annarita ianniello md elana poli md alberto sandri md case yearold male patient underwent medium lobe resection ptan nonsmall cell lung cancer nsclc april without administration adjuvant therapy routine ct scan perform february centimetric nodule leave superior lobe suspect malignancy report functional imaging ffdg petct request tumor board evaluate nodule metabolism ffdg petct schedule march th twentyseven day sarscov outbreak italy triage procedure require covid prevention body temperature result c patient present cough wheeze neither shortness breath patient declare suspected exposition infect people nonsmoker cardiovascular comorbidities nuclear medicine team interpret pet scan active inflammatory process consensus ct pattern highly suspicious ongoing covid pneumonia report literature consultation covid taskforce authority patient test realtime reverse transcription polymerase chain reaction rtpcr result positive subsequently quarantine however hospitalization intensive care unit necessary three day petct scan rapid disease progression severe respiratory distress present people affect covid italy lead covid related death patient pet scan still offer oncological patient guarantee continuation best clinical practice even scenario national restrictive directive thus number asymptomatic pathogen carrier nuclear medicine facility negligible covid radiological pattern rx ct become known usually describe peripheral predominant ggos lung consolidation involve mainly low lobe however discrepancy radiological pattern clinical symptom possible several study report clinicalradiological dissociation report ffdg petct patient covid currently available describe case symptomatic patient common covid manifestation include fever cough shortness breath myalgia fatigue best knowledge first case asymptomatic patient investigate ffdg petct case highlight rapid disease progression asymptomatic patient present fdg avid covid pneumonia far give definitive evidence asymptomatic patient present typical radiological ct pattern positive fdg uptake promptly test strictly monitor since sudden worsening patient clinical condition might procedure perform study involve human participant accordance ethical standard institutional andor national committee helsinki declaration later amendment comparable ethical consent obtain individual participant include author declare conflict interest',\n",
       "       'dear editorfor decade ebola member ebov filoviridae family highly pathogenic filamentous singlestranded rna virus responsible sporadic selflimiting cluster ebola virus disease evd central africa current outbreak evd west africa rise epidemic status consider world health organization public health emergency international concern level concern world health organization healthcare authority provider base high lethality ebovzaire human high communicability though body fluid high incidence infection primary healthcare worker total lack proven efficacious drug vaccine although variety potential ebov inhibitor drug development pipeline none sufficient human safety data complicates estimate efficacy current crisis situation west one experimental drug zmapp monoclonal antibody cocktail n show highly effective reversing advance evd nonhuman however rapid acquisition ebov sequence variation recently demonstrate genomic surveillance current evd epidemic suggests drug development dependent viral nonvariant protein sequence may letter briefly address evidencebased potential several tolllike receptor agonists latestage clinical development reduce morbidity mortality ebov infection associate markedly impaired coagulation innate immunity cascade increase production proinflammatory cytokine profound immune suppression result peripheral lymphocyte apoptosis lack adaptive contrast survivor infection ebov develop effective immune response production ebov neutralize antibody early event ebov infection influence patient ability develop effective immune response success ebov replication dependent viral inhibition initial innate immune response infection disarm innate immune response common mechanism employ highly pathogenic human virus include influenza coronavirus ebov one successful emerge highly pathogenic virus evasion innate immune interference viral protein vp essential component ebov replication matrix represent evidencebased target potential reduction morbidity mortality rna dsrna common component viral replication initiate systemic signal cascade normally activate interferon ifn regulatory factor lead production ifn type ifns ifns activate multiple ifn response pathway necessary inhibit viral replication include transitory expression enzyme adenylate synthetase protein kinase r require dsrna cofactor activity circumvent viral recognition human cell highly virulent virus include ebola evolve different strategy block biological activity associate induction ifn subsequent multiplicity antiviral response initiation adaptive immunity vp multifunctional major virulence protein indispensable ebov replication component viral polymerase factor also counteract host innate immune response block cellular production response type ifn transient gene activation key component innate immune response viral infection include activation tolllike receptor helicases melanoma differentiationassociated protein retinoic acidinducible gene viral however viral inhibition dsrna responsive element effectively disarm essential component innate immune response particular positively charge cterminal amino acid motif figure vp bind sequenceindependent dsrna result suppression multiple step ifn signal cascade otherwise would lead broad antiviral state strong activation innate adaptive arm immune thus vp provide attractive evidencebased target antiviral interruption ebov potentially ameliorate pathogenesis form dsrna studied inducer type ifns although original dsrna study efficacy human poly ipoly c find induce serious adverse event human limited pharmaceutical development several derivative survive rigor animal clinical test poly iclc hiltonol oncovir inc washington dc usa consist poly ipoly c noncovalent adduct polymeric chain polyllysine carboxymethylcellulose adduct increase drug halflife steric hindrance phosphodiester backbone rnase hydrolysis hiltonol study clinical trial cancer therapy adjuvant cancer poly ipoly cu rintatolimod ampligen hemispherx biopharma inc philadelphia pa usa design ifn inducer markedly reduce incidence adverse advent compare parent compound poly ipoly c devoid adduct hiltonol ampligen demonstrate antiviral activity wide variety dna rna viruses preclinical animal study rintatolimd efficacious epitopeexpanding adjuvant highly pathogenic avian influenza virus vaccine drug evaluate adjuvant variety cancer vaccine trial rintatolimod demonstrate activity two doubleblind placebocontrolled clinical trial chronic fatigue syndrome currently advance clinical trial treatment condition hiltonol andor rintatolimod experimental pharmaceutical attractive evidencebased candidate treatment evd expand basis recently approve world health organization use experimental pharmaceutical beyond phase food drug administrationsanctioned clinical trial help ensure availability product establish safety profile sufficient openlabel clinical test analysis efficacy use potential drug clinical trial also help ensure reliable supply clinicalgrade drug remove ethical dilemma patient selection',\n",
       "       'genavense infection occur rarely person aid patient present case always occur immunocompromised person date case disseminate infection report solidorgan kidney transplant recipient diagnosis make molecular identifi cation isolates blood marrow culture patient die complication genavense infection genavense fastidious organism infection cause diffi cult diagnose frequency probably underestimate may change increase use direct molecular biological treatment genavense infection establish experience genavense infection aid patient nontuberculous mycobacteria infection solidorgan transplant recipient suggest least antimicrobial drug use prolonged period possible immunosuppressive drug concurrently reduce outcome nontuberculous mycobacteria infection transplant patient highly variable satisfactory present patient treat quintuple antimicrobialdrug therapy reduce immunosuppressive case disseminate infection due genavense heart transplant recipient diagnose early universal rrna gene sequence amplifi cation directly intestinal biopsy specimen enable fast diagnosis appropriate management editor bat think one important reservoir virus nipah virus severe acute respiratory syndrome sars coronavirus ebola virus pathogen become known extensive survey bat follow outbreaks fi rst step investigate unidentifi ed pathogen bat help forecast potential threat emerge infectious disease try isolate characterize virus persistently infect bat process isolate novel adenovirus fruit bat dasymallus yayeyamae ryukyu fl ying fox fruit bat japan permission governor okinawa catch adult male bat specie use spleen kidney establish primary cell culture th passage primary adherent cell derive spleen cytopathic effect cpe appear without visible microbe indicate cell culture contain virus virus tentatively name ryukyu virus rv cause apparent cpe primary kidney cell derive ryukyu fl ying fox establish bat kidney bkt cell derive kidney horseshoe bat rhinolophus ferrumequinum transform expression plasmid dna encode large antigen replication origindefective simian virus identify virus rv apply rapid determination viral rna rdv system version however viral nucleic acid sequence detect rna sample rvinfected bkt cell detection viral dna develop system rapid determination viral dna sequence rdvd minor modifi cation rdv system rna virus result indicate fragment homologous gene encode precursor terminal protein ptp adenoviruses rdvd analysis show fragment bp ddbjemblgenbank accession ab homologous ptp gene another fragment bp ddbjembl genbank accession ab homologous gene encode precursor protein vi pvi adenoviruses result indicate rv must belong family confi rm rv isolate adenovirus use pcr sequence perform fi rst reaction outer primer pair polfouter polrouter nest pcr method target viral dna polymerase gene highly degenerate consensus primer describe recently fragment bp amplifi ed rv well human adenovirus data show sequence analysis amplifi ed product ddbjemblgenbank accession ab show rv homologous tree shrew adenovirus amino acid sequence identity porcine adenovirus canine adenovirus human adenoviruses virus genus mastadenovirus less homologous virus genus siadenovirus aviadenovirus atadenovirus addition phylogenic tree base amino acid sequence indicate rv belongs family adenoviridae genus mastadenovirus figure electron microscopy rvinfected bkt cell indicate rv accumulate nucleus size capsid nm data show restriction endonuclease analysis rv genome indicated genome kbp data show feature consistent rv number rna virus isolate bat isolation dna virus rare isolation novel adenovirus seem possible usage primary cell originate host dna virus might restrict host range rna virus require hostoriginated cell growth addition success dna virus isolation might result usage adult animal latently persistently infect dna virus adenovirus conclusion isolate novel virus fruit bat virus isolate healthy bat suggest virus may persistently infect fruit bat although pathogenicity human still unknown knowledge rv useful epidemiologic study infectious disease emerge bat persistently infect virus might isolate together primary pathogen plan establish cell line bat isolate virus persistently infect bat editor fluoroquinolones fqs active streptococcal specie levofl oxacin moxifl oxacin recommend numerous national health authority international organization treat acute exacerbation chronic bronchitis pneumonia adult however use antimicrobial drug treat communityacquired infection lead increase fqresistant strain bacteria streptococcus pneumoniae group b streptococci gb agalactiae lead cause invasive infection pneumonia septicemia meningitis neonate gbs also associate bacteremia endocarditis arthritis responsible death illness nonpregnant woman underlie disease elderly adult describe knowledge fi rst gb clinical isolate france resistant fq isolate patient treat levofl cnr strain isolate predominant bacterium culture cfuml purulent sputum sample yearold man leukocytes epithelial cell obtain day apart patient treated week levofl oxacin mgday acute exacerbation chronic bronchitis relevant respiratory bacterial pathogen present sample gbs cnr capsular serotype iv strain suspect reduced susceptibility fqs inhibition zone observe around disk contain norfl oxacin pefl oxacin disk reduce diameter observe around disk contain ciprofl oxacin levofl oxacin antibiograms perform accord recommendation clinical laboratory standard institute mueller hinton agar biorad marnes la coquette france supplement horse blood strain susceptible antimicrobial drug usually active gb penicillin erythromycin clindamycin tetracycline rifampicin vancomycin show lowlevel resistance aminoglycosides mics fqs table indicate gb cnr highly resistant pefl oxacin norfl oxacin mics mgl show increased mics ciprofl oxacin sparfl oxacin levofl oxacin moxifl oxacin reduction fq mics observe reserpine mgl indicate resistance fq cause active effl ux pump system three major mutation report fq resistance streptococci codon position gyra parc dna sequence analysis region show mutation parc ser tyr wildtype susceptible strain nem mutation detect gyra gene fq resistance streptococci acquire stepwise process extensively study pneumoniae firststep mutant confer lowlevel resistance generally result mutation either gyra parc also letter comment recent article well letter report case outbreaks original research welcome letter comment article contain word reference likely publish submit within week original article publication letter report case outbreaks original research contain word reference may one figure table divide section letter contain material previously publish include word count',\n",
       "       'multiple sclerosis m initially identify charcot disease often begin young adulthood intermittent episodes neurological dysfunction include visual impairment ataxia motor sensory deficit bowel bladder incontinence attributable recurrent inflammatory attack white matter brain spinal cord lead accumulation perivascularly distribute inflammatory cell within brain spinal cord white matter beeton et al first establish animal model m immunize monkeys central nervous system cns homogenate induce know experimental autoimmune encephalomyelitis eae since pilot animal study eae become accepted animal model m recent decade pathogenic hypothesis investigate novel therapeutic agent test model field cns inflammation demyelination therefore eae provide valuable tool investigation tcelldependent pathogenesis autoimmune inflammation cns orchestration autoimmune demyelinate inflammation cns m patient mice andor genetically modify mouse also fundamental value exploration complex pathogenesis m eae undoubtedly best animal model study autoimmune disease particularly demyelinate disease cns ms myelin basic proteinmbpspecific cell isolated peripheral lymphocyte human individual ms encephalitogenic cell recover circulate autoreactive cell either immunized nave animal show autoreactive tcell line recognize encephalitogenic part mbp vitro distinguish unprimed rat tcell population confirm autoreactive cell play central role pathology m eae also induce adoptively transfer expand population myelinreactive encephalitogenic cd helper th cell allow dissection immunopathogenic potency different encephalitogenic cd cell population mosmann coffman postulate th cell classify two distinct subset th th th cell produce large quantity interferon ifn driven interleukin il promotes cellular immunity direct intracellular pathogen alternatively th cell secrete il il il il essential destruction extracellular parasite mediation humoral immunity selfreactive th clone derive vitro capable adoptively transfer eae nave recipient increase level th cytokine particularly evident eaems relapse whereas increase th cytokine find remission m patient compare control level clinical hematological symptom exacerbate relapsingremitting m patient follow administration ifn also observe thtype disease whereas less apparent th disease th cell earlier think pathogenic cell whereas th cell think confer antiinflammatory potential constituting protective cell ms eae however clearcut immunodysregulation thth balance eae m may part hide complex interaction underlie eae m thdriven nature eaems disease challenge find ifn ifnreceptordeficient mouse well mice lack molecule involve th differentiation ilp il receptor ilr il protect eae instead susceptible disease unexpectedly mice deficient il ilp component th paradigm vulnerable eae similarly ilrdeficient mouse develop severe clinical manifestation eae whereas ilpdeficient mouse resistant eae discrepancy conflict data indicate imbalance thth milieu explain overall immunopathogenic mechanism underlie eae novel cytokine heavychain homologue il subfamily discover computational sequence p chain link p chain subunit il another subunit il heterodimers p chain form novel cytokine designate il therefore deletion ilp affect function il il cua colleague verify il il essential induction eae generate ilp knockout ko mouse compare ilp ko mouse furthermore ilproducing tcell subset driven expand il pathogenically induce eae adoptively transfer nave wildtype mouse ilproducing cell dramatically reduce cns ilpdeficient mouse base study researcher confidently suggest ilproducing cd cell distinct novel th subset exacerbate autoimmunity designate th cell th cell thcell subset distinct th th cell term differentiation expansion effector function discovery th cell clarifies cytokine profile m recently level il produce mbpstimulated peripheral blood cell obtain ms patient control show correlate active lesion ms patient observe magnetic resonance image mri like th subset th lineage activate specific cytokine milieu however il produce th cell de novo nave cell il receptor ilr express nave cell transform growth factor tgf upregulates ilr expression thereby confer responsiveness il confirm tgf critical cytokine commitment th expansion vitro vivo mouse tgf together il activate antigenresponsive nave cd cell develop th cell human nave cd cell expose il tgf il develop th cell production il play role maintain th cell altogether th cell require il tgf il il generation th cell produce ila ilf upregulated chronic lesion il also involved pathogenesis m thus th cell recently discover unique th lineage produce repertoire signature cytokine include ila ilf il il essential development autoimmune disease ms discovery transcription factor key regulator cytokine expression require launch lineagespecific transcriptional program greatly extend understand thcell lineage commitment show tbet stat program commitment th lineage th cytokine production whereas gatabinding protein gata stat drive th population expansion th cytokine production tbet stat necessary th differentiation transcription factor important differentiation autoimmune cell eae model tbet statdeficient mouse resistant eae however transcription factor mediate induction th cell instead unique inductive milieu th differentiation drive distinct transcription factor retinoic acid receptorrelated orphan receptort rort ror stat deletion cell also prevent autoimmune uveitis eae increase expression il forkhead box p foxp expression foxp program development function treg cell human il il also induce development th cell express ila ilf il il ifn chemokine ccl transcription factor ror illustrated figure adapt hirota et al recent microarray study lesion ms patient demonstrate increased expression il confirm th cell play important role development inflammation demyelination eventual damage cns il recently describe cytokine produce human almost exclusively activated memory cell induce production proinflammatory cytokine chemokines parenchymal cell macrophages patient ms great number ilmrnaexpressing mononuclear cell cerebrospinal fluid csf blood previously increase number expression il mrna mononuclear cell isolate csf observe patient ms high level il mrna observe csf blood high level blood detect clinical exacerbation data confirm pivotal role il ms peripherally express circulation cns antigen think express cervical lymph node trigger conversion autoaggressive myelinreactive cell pathogenic cell adhesion molecule integrins allow myelinreactive cell penetrate bloodbrain barrier bbb inflammatory condition way activate memory cell enter cns autoaggressive myelinreactive cell migrate cns recognize cognate target antigens movement antigenpresenting cell apcs cns essential lymphocyte reactivation within cns compartment initiation inflammatory cascade development eae subsequently inflammatory immune cell granulocytes macrophage attract cns parenchyma mediate tissue inflammation lead demyelination tissue damage brain formerly consider immunoprivileged organ perspective revise last two decade today understand damage cns activate immune cell situ cns particularly microglial cell deshpande et al demonstrate transient inactivation microglial cell via cellspecific deficiency cd expression indicate microglial cell crucial maintain autoimmune response cns major histocompatibility complex mhc also know human leukocyte antigen human class ii molecule display specialized apc dendritic cell dc b cell macrophages whereas mhc class molecule express cell inflammatory milieu cns microglial cell upregulate expression mhc costimulatory molecule initiate generation maintenance inflammatory milieu dc seem play critical role antigen presentation invade cell release cytokine chemokines thereby guide entry monocyte lymphocytes cell phenotype similar dc lesion th cell recruit macrophages release proinflammatory cytokine destructive molecule nitric oxide il il tumor necrosis factor tnf matrix metalloproteinases mmps cd cell also directly attack mhc class iexpressing cell oligodendrocytes neuron secretion destructive molecule tnf degradation myelin consequence cascade tnf receptor tnfr tnfr signal critical demyelination limitation tcell response immunemediated cns disease complicate process trigger recruitment innate immune cell generally consist cell macrophage microglia turn mediate demyelination axonal damage autopsy sample ms patient expression il evident perivascular lymphocyte astrocytes oligodendrocyte locate active area cns lesion ilr also identifiable acute chronic m plaque patient ms suggest enrichment th cd cell active ms lesion confirm important role il pathogenesis m th cell identify expression ilr memory tcell marker cdro situ marker investigate include chemokine receptor ccr rorc variant central transcription factor thcell development microarray analysis m lesion also demonstrate increased transcript gene encode inflammatory cytokine particularly il il ifn associate downstream pathway significant increase il mrna protein expression find lesion tissue compare nonlesion tissue activate macrophagesmicroglia show important source ilp active chronically active m lesion ilpexpressing mature dc preferentially locate perivascular cuff active lesion data expression ilp m lesion improve understanding pathogenesis m also evidence ms endothelial cell express high level ilr permeable il nonms endothelial cell perivascular dc also express high level granzyme b inflammatory lesion polarize nave cd cell th cell th cell transmigrate efficiently across bbb endothelial cell bbbecs lead destruction human neuron initiate cns inflammation thcell recruitment similarly expression ilr ilr bbbecs examine ms lesion il il show disrupt bbb tight junction vitro vivo il transsignaling may also play role autoimmune inflammation cns mainly regulate early expression adhesion molecules possibly via cellular network bbb ifergan et al demonstrate subset cd monocyte migrate across inflamed human bbb differentiate cdcd dc influence bbbsecreted tgf granulocytemacrophage colonystimulating factor gmcsf dc produce ilp tgf il promote proliferation expansion distinct population th th cell abundance dc situ strongly associate microvascular bbbecs within acute ms lesion significant number th cell perivascular infiltrate astrocyte play significant physiological role cns homeostasis act bridge cns immune system astrocytes also contribute complex interaction cns inflammation il function synergistic manner il induce il expression astrocytes astrocyte upregulate expression il ifn gene proteins cell consistent astrocyte capacity express il subunit p common ilil subunit p il subunit p two cell type cocultured das sarma et al demonstrate increased ilra expression cns mouse eae constitutive expression functional ilra mouse cns tissue also identify expression ilra astrocytes microglia vitro study secretion chemokines mcp mcp mip cxcl upregulated cell suggest upregulation chemokines glial cell result ila signal constitutively express ilra et al demonstrate suppressor cytokine signal socs participates il function cns negative feedback regulator use mouse model socs small interfering rna sirna knockdown socs deletion mouse loss socs function show enhanced il il signal astrocyte via activation nfb mapk pathway indicate astrocyte act target th cell il cns similarly kang et al construct specific deletion mutant act critical component require il signal mouse eae examine cns inflammation endothelial cell macrophage microglia neuroectoderm neuron astrocytes oligodendrocyte actdeficient mouse th cell show normal infiltration cns fail recruit lymphocytes neutrophil macrophage therefore astrocytes critical ilactmediated leukocyte recruitment eae interestingly merkler et al demonstrate macrophage respond th milieu neutrophil respond th cytokine marmoset monkey model eae also show dense accumulation b lymphocytes mhciiexpressing macrophagesmicroglia early activate macrophage site perivascular parenchymal lesion neocortex subcortical white matter indicate inflammatory response especially macrophage microglia activation may regulate differently gray matter area primate brain summary dcs peripheral tissue microglia cns responsible cytokine polarization expansion th cell complex interaction th cell different dc microglia astrocytes peripheral dc include neutrophil macrophage contribute immunopathogenesis eae ko mouse impair th cell protect eae il increase susceptibility progression relapse onset ms imply role il development eae m eae abolish virusexpressing il virusexpressing il chronic relapse eae therefore cytokine environment convert diseasepromoting ilproducing condition diseaselimiting ilproducing condition local expression il herpes simplex virus vector deliver brain moreover increase expression il glial cell associate reduced severity eae suggest upregulation th cytokine inhibits propagation inflammation eaems encephalitogenic th cell cdcdfoxp cell wellknown regulatory cell tregs retain potential inhibit autoimmune response protect inflammatory injury tgf key cytokine generation tregs tregs primarily involve regulation th cell also regulate function thth cell distinction draw generation pathogenic th cell induce autoimmunity generation tregs inhibit autoimmune tissue injury although eae consider classical th disease propose predominantly th driven recently singh et al demonstrate overexpression il cell exacerbate eae moreover genetic antibody study indicate absence ila ilf reduce incidence severity eae collective finding il ifn study indicate role may depend nature immune response il occur brain may overcome inhibitory effect ifn generally prevent inflammation site pure th cell myelin oligodendrocyte glycoproteinmog immunize mice polarize tgf deplete ifn production adoptively transfer mouse induce eae suggest reciprocal interaction among threlated cytokine enrol activate involvement associate immune cell interestingly th cell combine th cell fully induce eae disease liu et al also demonstrate loss stat th cell result intrinsic developmental defect render stat mouse resistant cns inflammatory disease stat require production il th cell generation double positive cell express il ifn cell traffic cns tissue suggest stat may therapeutic target modulate cns autoimmune disease th cell facilitate entrance th cell cns eae encephalitogenic th cell line induces recruitment host th cell cns initiation eae report stromnes et al show significant difference regulation inflammation brain spinal cord depend different thth ratio demonstrate specific tcell population target different myelin epitope characterize different thth ratio eae therefore th cell potential reciprocally regulate th cell type fourhelix bundle cytokine belongs il family function growth hormonelike cytokine antigenresponsive differentiation phase th cell enter amplification stage il play pivotal role expansion differentiation th lineage provide autocrine paracrine stimulus th cell clonal expansion il also promote ilr expression differentiate th cell play important role stabilization th lineage presence il although effect observe il administer eae progression administration il boost natural killer nk cell function induction eae include secretion ifn therefore il affect nk cell various effect initiation progression eae alternatively il ilil family member negative regulator th cell differentiation prevent inflammatory demyelination eae model il drive expansion differentiation ilproducing tr cell induce expression three key molecule transcription factor cmaf cytokine il icos moreover ildriven cmaf expression transactivates production il act autocrine growth factor expansion andor maintenance ilinduced tr cell icos also promote ildriven tr cell elements essential loss cmaf il signal icos reduces frequency ilinduced differentiation tr cell figure exacerbation eae demonstrate ildeficient mouse interestingly iltreated mouse markedly reduce cns inflammatory infiltration indicate downregulation th phenomenon recently novel effector tcell subset th cell identify ability tcell subset induce eae currently investigate jger et al generate mogspecific th th th th cell vitro directly characterize encephalitogenic potency adoptive transfer find mogspecific th th th cell th cell induce eae interestingly tcell subset induced disease distinct pathological manner suggest different effector th subset induce eae differently imply pathological heterogeneity m lesion might partly attributable various characteristic myelinreactive effector cell author also suggest m might disease caused multiple distinct myelinreactive effector cell disease induce th cell animal exhibit symptoms atypical eae include ataxia severe imbalance weight loss associate high mortality animal mixture atypical typical eae symptom cell recover cns appear transfer th cell produce ifn identity cell population seem drift vivo transfer nowak et al recently demonstrate like cell culture presence tgf th cell produce il th cell generate vitro il tgf ex vivopurified th cell produce il data show il neutralization ilr deficiency attenuate disease correlate reduction th cell ilproducing macrophage cns author also confirm role il development progression eae implicate il thderived cytokine contribute inflammatory disease together th cell tr cell tregs exert repressive effect th cell th cell stimulatory effect th cell suppress eae m however th cell play dual role understand pathophysiology neurodegenerative process ms lead development novel therapeutic strategy since early diseasemodifying drug introduce selective management m include ifn glatiramer acetate ga become standard treatment relapsingremitting ms recommendation previously make multiple sclerosis therapy consensus group mstcg use diseasemodifying drug therapy remain valid hermmer hartung publish apparent review development rational therapy ms therefore discuss four domain novel immunomediated therapeutic use ms current first domain include immunosuppressive agent mitoxantrone laquinimod abr cladribine mylinax teriflunomide probably via suppression tnf il production second domain include immunomodulatory agent cytokine inhibitor ifn agent deplete specific immune cell subset alemtuzumab human monoclonal antibody mab target cd express b cell produce longterm tcell depletion rituximab target cd deplete human b cell agent selectively block coreceptors costimulators daclizumab anticd mab inhibits activate cell induces regulatory immune cell third domain involves development migrationmodifying therapy agent affect adhesion molecule natalizumab mab block late antigen vla sphingosine phosphate receptor spr agonists fingolimod fty fourth domain include neuroprotective agent associate immunomodulation include broadspectrum immunomodulators statins ppar agonist pioglitazone gemfibrozil sex hormone estriol e fumarate minocycline erythropoietin epo effective treatment eae m ifn clinically introduce treat patient ms base ability shift thmediated response thmediated response however microarray study indicate number gene patient ms upregulated cytokine associate differentiation cell th lymphocytes rather th lymphocyte suggest shift may therapeutic mechanism ifn m ifn therapy also reduce il mrna level ifn inhibits human th cell differentiation th axis could another target ifn therapy ifnmediated il production innate immune cell show play critical role immunoregulatory role ifn eae inhibit th cell eae mouse ms patient besides galligan et al evidence ifn mouse exhibit earlier disease onset rapid progression eae compare ifn mouse eae ifn mouse eae increase number cdb leukocytes infiltrate affected brain increase percentage th cell cns augmentation autoreactive cellssuggesting ifn act suppress production autoimmuneinducing th cell development disease well modulate proinflammatory addition therapeutic effect ifn probably attributable induction regulatory cytokine il furthermore axtell et al design delicate study clarify role ifn mseae likewise demonstrate ifn effective reduce eae symptom transfer th cell transfer exacerbated disease th cell transfer effective treatment ifn thinduced eae correlate augmented il production differently thinduced eae amount il unaffected treatment ifn likewise high ilf level serum people rrms associate fail ifn therapy characteristic ifn might contribute explore logical biomarkers predictive assessment response popular therapy m although b cell may dual role pathogenesis ms contribute induction autoimmune response also mediate resolution cns inflammatory infiltrate however ramgolam et al demonstrate supernatant transfer ifnbtreated b cell inhibit th cell differentiation suppress gene expression rorc ila secretion ila likewise ifnb also induce b cell il secretion may mediate regulatory potent thus ifnb exerts therapeutic effect least part target b cell function contribute autoimmune pathogenesis rr m may uncover extra mechanism bcell contribution autoimmune effect provide novel target future selective treatment m glatiramer acetate ga copaxone copolymer exert clinical response m patient via modulation ifn il reduce expression ifn ensure stable expression il anticdcdstimulated peripheral blood mononuclear cell pbmcs moreover ga enhances suppressive effect tregs eae m study human dcs show ga modulates production inflammatory mediator without affect dc maturation immunostimulatory potential dc expose ga secrete low level thpolarizing factor ilp response lipopolysaccharide trigger cd ligand human dc expose ga also induce ilsecreting effector th cell increase expression il result show apcs include dcs essential gamediated shift thcell phenotype indicate dc important target immunomodulatory effect ms show threefold fourfold increase expression subunit integrin vla normally express activate lymphocyte monocyte cell type csf circulation elovaara et al confirm methylprednisolone reduce adhesion molecule blood csf patient ms imply target leukocyte trafficking may possible therapeutic strategy m therefore natalizumab humanize mab direct vla adhesion complex introduce treatment m reduces risk sustain progression disability rate clinical relapse patient relapse ms however clinical trial two natalizumabtreated m patient develop progressive multifocal leukoencephalopathy pml result voluntary removal drug market february retrospective safety evaluation subsequently conduct natalizumab consequently return market monotherapy july treatment relapse m however case pml report subsequently natalizumabtreated m patient april evidently risk develop pml m patient natalizumab tysabri almost time high patient take drug two year prior history immunosuppressant use test positive antibody jc virus compare patient none three risk factor instead currently convince evidence natalizumabassociated pml restrict combination therapy diseasemodifying immunosuppressive agent nevertheless natalizumab use must restrict indicated cytotoxic drug immunomodulatory property use treat progressive form ms mitoxantrone increase ex vivo production th cytokine il il significant change ifn tnf il il expression pbmcs cd cell indicate immunomodulation afford mitoxantrone treatment m act enhancement thtype cytokine currently headtohead race approval initially develop two spotlight oral immunomodulatory agentsfingolimod cladribine figure fingolimod ftygilenya novartis spr modulator spotlight complete phase iii trial approve us food drug administration first oral firstline treatment relapse ms spr mainly express immune cell neuronal cell endothelial cell smooth muscle cell key role spr angiogenesis neurogenesis regulation immune cell traffic endothelial barrier function vascular tone demonstrate genetic deletion spr murine model immunomodulatory effect fingolimod act two pathway one pathway inhibit function spr facilitate ccchemokine receptor ccr mediate retention lymphocytes lymph node include nave cell central memory cell effective memory cell significantly reduce infiltration inflammatory cell cns reduces number autoreactive th cell recirculating via lymph blood cns second pathway prohibit neuroinflammation via modulation spr express oligodendrocyte neuron astrocyte microglia another oral immunomodulatory drug cladribine chlorodeoxyadenosine synthetic chlorinate deoxyadenosine analog activate intracellular phosphorylation specific cell type result preferential sustain reduction peripheral b lymphocytes mimic immunedeficient status hereditary adenosine deaminase deficiency orally administer cladribine show significantly efficacy patient rrms relative placebo oral cladribine reduces relapse impact disability progression mri outcome marker patient rrms nevertheless exactly weight benefit novel immunomodultory agent potential risk necessary must monitor continually advance identify unique therapeutic target ms instigate numerous phase ii phase iii clinical trial example trial various mabs include directed cd alemtuzumab cd daclizumab cd rituximab trial diseasemodifying therapy teriflunomide laquinimod fumarate example alemtuzumab humanize mab target surface molecule cd tcell population cellular component immune system thymocytes b cell monocytes offner report estrogen derivative exert neuroimmunoprotective effect eae e upregulates expression foxp ctla contribute activity tregs suggest therapeutic application estrogen m papenfuss et al also demonstrate estriol e pregnancyspecific estrogen therapeutic efficacy m eae confirm e protects mice eae induce dc increase expression inhibitory costimulatory marker pdl pdl bh deviate towards th phenotype peroxisome proliferatoractivated receptor ppars member nuclear hormone receptor superfamily include receptor steroid retinoids thyroid hormone involve immune response natarajan et al demonstrate ppar agonist inhibit eae block il production il signal th cell differentiation kanakasabai et al demonstrate ppar agonist ameliorate eae block ifn il production th th cell inhibition eae ppar agonist also associate reduction il il increase il il expression cns lymphoid organ indicate ppar agonist modulate th th response eae suggest use treatment m autoimmune diseases minocycline oral semisynthetic tetracycline antibiotic penetrate cns interest pleiotropic biological function neuroprotective effect include demyelinate disease ms nikodemova et al show minocycline attenuate eae rat reduce tcell infiltration spinal cord downregulating lfa cell without modify production dominant cytokine zabad et al demonstrate cohort study impact oral minocycline clinical mri outcome serum immune molecule month openlabel minocycline treatment relapse occur month level p subunit il elevate month treatment might counteract proinflammatory effect ilr downregulation mmp activity reduce minocycline treatment brine et al demonstrate epo mediate neuroprotection experimental ischemic brain injury agnello et al show epo exerts antiinflammatory effect ameliorate eae yuan et al also demonstrate epo retains immunomodulatory capacity periphery inflame spinal cord promote massive expansion treg cell inhibit th polarization abrogate proliferation antigenpresenting dc observe significantly reduce level th th cell cns significantly increase proportion splenic tregs epotreated mogeae mouse also demonstrate mogspecific tcell proliferation suppress epotreated group immunomodulatory mechanism immunomediated therapeutic agent fully understood current understanding immunomodulatory effect clinically proven clinically tried agent potential candidate agent decoy receptor dcr selectively review immunomodulation eae m demjen et al show neutralization cdl fasl promote axonal regeneration functional improvement injure animal model suggest therapeutic strategy may constitute potent future treatment human spinal injury dcr recognize member tnfr superfamily predominantly express tumor cell allow evade immune attack dcr soluble receptor bind member tnf family competitively inhibit bind tnf tnfrs fasl light tnflike molecule tla confirm ligand dcr dcr bind fasl inhibits faslinduced apoptosis also recently show dcr counteracts effect th cell interfere faslfas interaction demonstrate dcr ameliorates eae directly counteract inflammation downregulating th cell situ imply dcr downregulates th response inhibits inflammation cns situ eae block ligandreceptor interaction fasfasl drlight andor drtla therefore introduce dcr another immunomodulatory molecule potential candidate consideration clinical treatment summary figure immunomodulatory agent neuroprotective therapy ms great value clinical agent test clinical trial preclinical study development novel therapeutic strategy ms ms common disable cns disease young adult characterize recurrent relapse andor progression attributable multifocal inflammation demyelination axonal pathology within brain andor spinal cord effector th cell play wellrecognized role initiation autoimmune tissue inflammation autoreactive effector cd cell establish association pathogenesis disorder however model think driven th cell mice lack hallmark th cytokine ifn protect eae tend display enhance susceptibility disease identification th cell shed light apparent discrepancy like th cell polarize th cell capacity cause inflammation autoimmune disease deficiency threlated cytokine il threlated cytokine il induces resistance eae imply th cell chief contributor eaems whereas th cell consistently transfer eae disease komiyama et al demonstrate eae significantly suppress il mouse manifest delayed onset reduce maximum severity ameliorate histological change early recovery however outcomes varied differentiation andor function th cell block clinical trial human autoimmune disease notable success psoriasis crohns disease negative result relapsingremitting ms strategy inhibit th response even less support preclinical study animal model data raise question whether m mediate solely th cell solely th cell whether mediate pathway whether perhaps mediate neither pathway grow evidence autoreactive cell particularly th th cell participate pathophysiology m although exact role th th cell development m lesion well understood appear effector tcell population cause cns inflammation demyelinate lesion ms eae increase understanding immunopathogenic role th th th cell tregs mseae facilitate development novel immunomodulatory therapeutic approach ms treatment m always hamper untoward adverse effect cause immunosuppression agent natalizumab currently approve diseasemodifying treatment achieve effect primarily block proinflammatory response nonspecific manner limit clinical efficacy call differentiate specific therapeutic approach confidently say ifn ga mitoxantrone fairly clinically effective m patient addition estrogens minocycline also show benefit treatment m establish protective effect dcr epo eae evidence require use clinically treatment ms immunomodulatory therapeutic agent currently clinical trial include fingolimod fty alemtuzumab rituximab addon therapy extensive clinical application potential novel immunomodulatory therapeutic agent close scrutiny near future'],\n",
       "      dtype='<U31115')"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "normalized_corpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.feature_extraction.text import CountVectorizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(normalized_corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "cv = CountVectorizer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc_matrix = cv.fit_transform(normalized_corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<10x3426 sparse matrix of type '<class 'numpy.int64'>'\n",
       "\twith 5134 stored elements in Compressed Sparse Row format>"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc_matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(10, 3426)"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc_matrix.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.cluster import KMeans"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Silhoutte analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(10, 3426)"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc_matrix.toarray().shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "scipy.sparse.csr.csr_matrix"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(doc_matrix)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.metrics import silhouette_samples, silhouette_score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "from yellowbrick.cluster import SilhouetteVisualizer"
   ]
  },
  {
   "cell_type": "raw",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "for n in range(2,doc_matrix.shape[0]):\n",
    "    model = KMeans(n_clusters=n,random_state=42)\n",
    "    visualizer = SilhouetteVisualizer(model,colors='yellowbrick')\n",
    "    visualizer.fit(doc_matrix)\n",
    "    visualizer.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x7f1b2054d908>"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from yellowbrick.cluster import KElbowVisualizer\n",
    "model = KMeans()\n",
    "visualizer=KElbowVisualizer(model,k=(2,10))\n",
    "visualizer.fit(doc_matrix)\n",
    "visualizer.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.decomposition import PCA\n",
    "\n",
    "pca = PCA(n_components=0.95, random_state=42)\n",
    "matrix_reduced= pca.fit_transform(doc_matrix.toarray())\n",
    "matrix_reduced.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([0, 0, 0, 0, 0, 0, 0, 0, 0, 1], dtype=int32)"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(9, 6154)"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(9, 6154)"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "num_clusters =5 "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "km = KMeans(n_clusters=num_clusters,max_iter=1000,random_state=42)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "KMeans(algorithm='auto', copy_x=True, init='k-means++', max_iter=1000,\n",
       "    n_clusters=5, n_init=10, n_jobs=None, precompute_distances='auto',\n",
       "    random_state=42, tol=0.0001, verbose=0)"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "km.fit(doc_matrix)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([0, 2, 0, 0, 3, 4, 0, 0, 0, 1], dtype=int32)"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "km.labels_\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(km.labels_)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import Counter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Counter({0: 6, 2: 1, 3: 1, 4: 1, 1: 1})"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Counter(km.labels_)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "Int64Index: 10 entries, 0 to 9\n",
      "Data columns (total 2 columns):\n",
      "paper_id     10 non-null object\n",
      "body_text    10 non-null object\n",
      "dtypes: object(2)\n",
      "memory usage: 240.0+ bytes\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['KMeans_label']=list(km.labels_)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "Int64Index: 10 entries, 0 to 9\n",
      "Data columns (total 3 columns):\n",
      "paper_id        10 non-null object\n",
      "body_text       10 non-null object\n",
      "KMeans_label    10 non-null int64\n",
      "dtypes: int64(1), object(2)\n",
      "memory usage: 320.0+ bytes\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "raw",
   "metadata": {},
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [],
   "source": [
    "clustered_docs = (df.sort_values(by=['KMeans_label']).groupby(['KMeans_label']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_clustered=clustered_docs.apply(lambda x:x)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>paper_id</th>\n",
       "      <th>body_text</th>\n",
       "      <th>KMeans_label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>8869bd83a3d8b813093f62f897c5478a96e311bf</td>\n",
       "      <td>Report 48 see https://www.who. int/docs/defaul...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ffb877d67fd30e14677580c292ca9caf64659987</td>\n",
       "      <td>In June 2015 the Healthcare Infection Society ...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>PMC7008051</td>\n",
       "      <td>Respiratory syncytial virus (RSV) is well know...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0738152fba8d21b4ae77293a3e2bfd5019a537a7</td>\n",
       "      <td>1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>PMC4217096</td>\n",
       "      <td>Dear Editor,For decades, Ebola members (EBOV) ...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>6861259e73b53c482dea9ed97abad64f5c1c479a</td>\n",
       "      <td>M. genavense infections occur only rarely in p...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>PMC3235500</td>\n",
       "      <td>Multiple sclerosis (MS) was initially identifi...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>d6a98a653f12caba3f539f01b0fd84b2ca4f1672</td>\n",
       "      <td>Over the past few years, a new view of T cell ...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>PMC6609751</td>\n",
       "      <td>The adenovirus (HAdV) is a double-stranded DNA...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>31fb22d877d6efa55e7c8261a59a1f0d35962829</td>\n",
       "      <td>rapid assessment of the impact of physical dis...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   paper_id  \\\n",
       "0  8869bd83a3d8b813093f62f897c5478a96e311bf   \n",
       "2  ffb877d67fd30e14677580c292ca9caf64659987   \n",
       "3                                PMC7008051   \n",
       "6  0738152fba8d21b4ae77293a3e2bfd5019a537a7   \n",
       "7                                PMC4217096   \n",
       "8  6861259e73b53c482dea9ed97abad64f5c1c479a   \n",
       "9                                PMC3235500   \n",
       "1  d6a98a653f12caba3f539f01b0fd84b2ca4f1672   \n",
       "4                                PMC6609751   \n",
       "5  31fb22d877d6efa55e7c8261a59a1f0d35962829   \n",
       "\n",
       "                                           body_text  KMeans_label  \n",
       "0  Report 48 see https://www.who. int/docs/defaul...             0  \n",
       "2  In June 2015 the Healthcare Infection Society ...             0  \n",
       "3  Respiratory syncytial virus (RSV) is well know...             0  \n",
       "6  1 18Giulia Polverari, MD 1 , Vincenzo Arena, M...             0  \n",
       "7  Dear Editor,For decades, Ebola members (EBOV) ...             0  \n",
       "8  M. genavense infections occur only rarely in p...             0  \n",
       "9  Multiple sclerosis (MS) was initially identifi...             1  \n",
       "1  Over the past few years, a new view of T cell ...             2  \n",
       "4  The adenovirus (HAdV) is a double-stranded DNA...             3  \n",
       "5  rapid assessment of the impact of physical dis...             4  "
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_clustered"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "pandas.core.frame.DataFrame"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(df_clustered[df_clustered[\"KMeans_label\"] == 2][['paper_id','body_text']])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_new =df_clustered[df_clustered[\"KMeans_label\"] == 2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>paper_id</th>\n",
       "      <th>body_text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>d6a98a653f12caba3f539f01b0fd84b2ca4f1672</td>\n",
       "      <td>Over the past few years, a new view of T cell ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   paper_id  \\\n",
       "1  d6a98a653f12caba3f539f01b0fd84b2ca4f1672   \n",
       "\n",
       "                                           body_text  \n",
       "1  Over the past few years, a new view of T cell ...  "
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_new[['paper_id','body_text']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "l=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [],
   "source": [
    "for d in df_clustered[df_clustered[\"KMeans_label\"] == 0]['body_text']:\n",
    "    l.append(d)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Over the past few years, a new view of T cell recognition has emerged. TCRs were previously thought of as simple \\'on/off\\' switches that were highly specific for a single \\'foreign\\' peptide. Numerous studies have now demonstrated different functional outcomes resulting from the engagement of the same TCR by different peptide ligands depending on whether a peptide acts as an agonist, partial agonist or antagonist of a TCR [1]. At the same time, it has been shown that several peptides that have relatively little primary sequence homology to each other can all act as agonists of the same TCR [2, 3] . The activation of autoreactive T cells by such pathogen-derived peptides that mimic self-peptides has been termed \\'molecular mimicry\\' [4, 5] . The emerging complexity of TCR recognition has important implications for understanding both self-tolerance and the pathogenesis of human autoimmune diseases. This review will discuss the structural requirements for the activation of autoreactive T cells by microbial peptides in the development of human autoimmune diseases.Specificity versus the degeneracy of T cell receptor recognition MHC molecule binding of peptides is highly degenerate; a given MHC molecule will bind peptides from the majority of antigens when a set of overlapping antigen-derived peptides is tested. Peptide elution studies have demonstrated that hundreds of different peptides are bound by a single MHC class II molecule [6, 7] . For the majority of MHC class II molecules, every position in the peptide can be substituted by one of a few or many different amino acids. T cell recognition, however, is much more specific as a T cell clone will not cross-react with the majority of \\'control\\' antigens tested. Addition or removal of a single methyl or hydroxyl group at a primary TCR contact residue can result in the complete loss of T-cell recognition for some T cell clones. Changes at other positions are tolerated to a certain extent, however [8] .TCRs are generated by random rearrangements of germline encoded segments during fetal development. In contrast to antibodies, there is no affinity maturation process that improves the fit of a TCR for a given MHC molecule-peptide complex during an ongoing immune response. The specificity of the adult TCR repertoire is a balance between two possible extremes: highly specific TCRs that require particular amino acids at many positions of the MHC molecule-bound peptide and highly degenerate TCRs that only require certain sequence features in the MHC molecule-bound peptide and therefore cross-react with many different microbial peptides. The obvious disadvantages of these extremes are that the highly specific TCRs may never be engaged in an immune response (i.e. the respective microbial peptide sequence may not exist) and that the highly degenerate TCRs may cross-react with many self-peptides and cause autoimmunity. The balance between these two extremes is likely to be the result of the thymic selection process: firstly, negative selection will delete the T cells that have a high affinity for the MHC molecule (regardless of its peptide content) and that are likely to be highly cross-reactive, and secondly, a failure to undergo positive selection will eliminate the T cells that have a too low an affinity for MHC molecules.Experimental data indicate that T cell clones differ in the degree of specificity versus degeneracy of peptide recognition. Human myelin basic protein (MBP)-specific T cell clones with degenerate peptide recognition were found to cross-react with a number of microbial peptides whereas T cell clones that were more specific cross-reacted only with one or two microbial peptides (M Martin and K Wucherpfennig, unpublished data). Each TCR peptide-contact residue could be substituted by at least one structurally related amino acid for T cell clones with degenerate peptide recognition; clones that were more specific required amino acid identity at the primary TCR peptide-contact residues (M Martin and K Wucherpfennig, unpublished data). These data suggest that the mature T-cell repertoire represents a spectrum of T cell clones in terms of the degree of specificity/degeneracy of peptide recognition (Figure 1 ). According to this model, T cell clones with degenerate peptide recognition are more frequently engaged in an immune response and are more likely to induce an autoimmune response due to cross-reactivity between a microbial and a self-peptide. Potential for cross-reactivity/autoimmunity Current Opinion in Immunology Schematic depicting the distribution of peripheral T cells regarding the degree of specificity/degeneracy of their TCR. Degenerate T cells will be engaged by peptide-MHC molecule complexes more frequently and have a higher potential for causing autoimmunity than more specific TCRs.Methods used to isolate T cell clones may determine from which part of the spectrum T cell clones are derived. Early cloning of T cell lines or the generation of T cell lines under limiting dilution conditions may favor sampling from different parts of the spectrum. Long-term selection of polyclonal populations under limiting concentrations of antigen is likely to favor the outgrowth of T cells that have the highest degree of specificity for a given MHC molecule-peptide complex.The crystal structure of the complex of a human TCR, an HTLV-I tax peptide and HLA-A2 has been solved [9\"]; this structure provides important insights into the structural basis of TCR specificity and degeneracy. The HTLV-I tax specific TCR was oriented diagonally over the MHC molecule-peptide complex, with the CDR1 and CDR3 loops from both the c~ and 13 TCR chain variable regions contacting the peptide. The same orientation of the TCR on the MHC molecule-peptide complex was observed for a murine MHC class I restricted TCR [10\\'], suggesting that this binding mode is general. The peptide binding surface of the TCR was found to be remarkably flat, with the exception of a central pocket that occupied the central residue (Y5: in single-letter amino acid code) of the tax peptide. This pocket was created by the CDR3 loops of both V~ and VI]. The small size of the contact surface between the TCR and the tax peptide (326,~,z) and the fact that substantial contacts were made only to the peptide residues Y5 and Y8 indicates that there are limits placed on the specificity of a TCR. When Y5 was substituted by alanine (Y5A) the peptide still formed TCR-peptide-HLA-A2 complexes that crystallized and acted as a partial agonist [9\"].Recognition of peptide sequences that are strikingly different by the same TCR has been observed for several alloreactive T cell clones [11,12\",13] There are two structural explanations for this phenomenon. First, two peptide-MHC molecule complexes in which the peptides differ in their primary sequence may form similar TCR-accessible surfaces in terms of volume, charge, and hydrophobicity, allowing the TCR to engage those complexes in a similar way. Second, there may be a certain degree of flexibility in the conformation of the TCR CDR loops, allowing a TCR to specifically bind to different MHC molecule-peptide surfaces [16]. The crystal structures of such different TCR-peptide-MHC molecule complexes are required to answer this question. The recognition of HLA-DR2-presented MBP(85-99) by autoreactive T cell clones from MS patients has been studied extensively and illustrates several aspects of specificity/degeneracy in T cell recognition. Analysis of the fine specificity of MBP(85-99)-specific T cell clones, by using single amino acid analog peptides, revealed a high degree of specificity toward some (\\'major\\') TCR contact residues combined with a certain degree of degeneracy toward other (\\'minor\\') TCR contacts. For example, the addition of a single hydroxyl group (F91Y) completely abrogated T cell activation by some clones, whereas changes at other positions (e.g. I95A) had little effect [25, 26] . Certain substitutions even enhance HLA-DR2 binding (T97A) or TCR recognition (these mutations differ between T cell clones), representing so called \\'superagonists\\'. Such substitutions can compensate for other substitutions that are suboptimal, resulting in multisubstituted peptides that have a similar efficacy as the native antigen [25, 27] . In addition to such \\'additive\\' effects, \\'complementary\\' substitutions have been described in which a T cell clone does not respond to a single amino acid substituted peptide (F91Y or K93R) but only to the double-substituted peptide (F91Y K93R) [28\"].The HLA-DR2 bindin~TCR recognition motif of MBP(85-99) was used to identify cross-reactive peptides from human pathogens via a protein data base search. Seven viral and a single bacterial peptide were found that stimulated at least one out of the seven MBP-specific T cells clones studied ( [3] ; see Table 1 ). The microbial peptides were quite distinct in their sequence from the MBP peptide and each other as only the primary TCR contact residues (either F91 or K93) were conserved. Presentation of microbial peptides by infected cells was examined for the Epstein-Barr virus (EBV) DNA polymerase peptide. Reactivation of the Epstein-Barr virus (EBV) lytic cycle by phorbol esters resulted in the activation of an MBP-specific T cell clone that cross-reacted with the EBV peptide, but not in the activation of a control clone that only recognized the MBP peptide. T cell activation was not observed with an MHC-mismatched B cell line and was blocked by an anti-DR antibody [3] .Comparison of the fine specificity of the MBP-specific autoreactive T cell clones also demonstrated obvious differences in the specificity/degeneracy of peptide recognition. For the more specific clones amino acid identity was required at the primary TCR contact residues, whereas every TCR contact residue could be substituted by at least one structurally related amino acid for the more degenerate clones ([25,26]; M Martin, K Wucherpfennig, unpublished data). This illustrates the specificity/degeneracy distribution pattern proposed in Figure 1 , in which the more specific T cells are represented in the left part of the main curve and the more degenerate ones on the right, with a small fraction of T cells at the extreme ends. An example of a highly degenerate T cell clone has recently been described [29] . Notably, the T cell clones that cross-reacted with a diverse set of microbial peptide sequences were not stimulated by these random peptide libraries indicating that such a level of degeneracy in peptide recognition is not required for T cell cross-reactivity with microbial peptides (M Martin, K Wucherpfennig, unpublished data).Another interesting aspect of the MBP(85-99) peptide is the fact that it also represents the immunodominant antibody epitope of MBP [34] . Moreover, the same core region of the peptide was important for both antibody binding and recognition by HLA-DR2 restricted T cell clones. Important differences, however, in the antibody and T cell epitopes were: firstly, a longer peptide was required for optimal T cell stimulation than for antibody binding, and secondly, sequence identity was required at every peptide position in the core of the antibody epitope whereas the MHC molecule contact residues in the T cell epitope could be substituted by other amino acids. Due to the similarity between the antibody and T-cell epitopes, a human papillomavirus peptide was recognized both by MBP-specific antibodies and by a MBP(85-99)-specific T cell clone [35] .Taken together, the analysis of MBP-specific T cell clones from MS patients demonstrates that microbial peptides with limited sequence homology are effective activators of autoreactive T cells. These results make it unlikely that a single microbial peptide is responsible for the activation of autoreactive T cells in human autoimmune diseases. Other cross-reactive peptides of the MBP(85-99) Table 1 Examples of experimentally determined T cell cross-reactivity between self and microbial peptides in human autoimmune diseases.Organism/pathogen Antigen Sequence alignment* and reference Multiple sclerosis [3] CD4 + T cell clones HLA-DR2b-or HLA-DQ1 restricted Cross-reactive T-cell epitopes have also been identified for autoantigens in other human autoimmune diseases (Table 1) . While it is not yet known whether these autoantigens/microbial peptides are important in the development of these autoimmune diseases, these examples demonstrate that cross-reactive T cell epitopes can be identified.Many studies have also examined the issue of cross-reactivity by merely performing sequence alignments between candidate self-antigens and microbial sequences. In the absence of functional data, these studies suffer from the following related problems: firstly, it is frequently not known whether the region of the autoantigen that was studied represents a T cell epitope; secondly, peptides that have visual sequence similarity may have no biological activity (e.g. lack of MHC molecule binding, failure to activate autoreactive T cells); and thirdly, peptides that are biologically active may be overlooked because the struc-tural similarity to the self-peptide may not be obvious. The observations made in the analysis of MBP-specific T cell clones indicate that a detailed characterization of the immunodominant epitope of an autoantigen is required for the identification of cross-reactive microbial peptides. The development of autoimmunity by microbial antigens has also been studied by immunization with microbial Activation of autoreactive T calls by pepUdes from human pathogens Hausmann and Wucherpfennig 835 Table 2 Examples of experimentally determined T cell cross-reactivity between self and microbial peptides in experimental animal models.Experimental model and reference Organism/pathogen Antigen Sequence alignment* Experimental autoimmune uveitis [39] Lewis rats immunized with foreign peptidesExperimental ovarian autoimmune disease [40] B6AF antigens/peptides that have sequence homology with immunodominant T-cell epitopes ( Table 2 ). The first of these studies [36] examined the indu\\'ction of experimental autoimmune encephalomyelitis (EAE) using a hepatitis B virus polymerase peptide that shared identity at six amino acid positions with the encephalitogenic site of rabbit MBP. Following immunization of rabbits with this peptide, antibody cross-reactivity and a certain degree of T cell cross-reactivity to MBP was observed. Four out of eleven animals showed histological signs of EAE [36] . Analysis of the amino-terminal MBP peptide (Acl-ll), which is immunodominant in B10.PL and PL/J mice, demonstrated that this epitope could be shortened to a seven amino acid peptide without the loss of encephalitogenicity. When tested with alanine analogs, identity at four amino acid positions was found to be required for T-cell cross-reactivity whereas five position were necessary for the induction of EAE [37, 38] . The importance of the amino-terminal acetylation, however, which is absent in viral and bacterial peptides, may make it difficult to identify microbial peptides that induce EAE.In two experimental models--experimental autoimmune uveitis and experimental ovarian autoimmune disease-microbial peptides have been identified that induce tissue specific autoimmunity. Experimental autoimmune uveitis in Lewis rats is mediated by T cells specific for the retinal S-antigen (reviewed in [39] ). S-antigen specific autoimmunity could be induced by several microbial peptides which shared identity with five or six amino acids of the uveitogenic epitope of the S-antigen, although higher doses (10-to 40-fold) of the microbial peptides were required. In experimental ovarian autoimmune disease, immunization with microbial peptides similar to the target antigen zona pellucida 3 protein induced an autoimmune oophoritis [44] .Tissue-specific autoimmunity has also been induced by immunization with whole microbial antigens. Lewis rats are highly sensitive to the development of arthritis following immunization with heat-killed MycobacteHum tuberculosis in mineral oil (complete Freund\\'s adjuvant). A T cell response against the Mycobacterial heat shock protein (hsp) 65 appears to play an important role, as a T cell clone specific for the mycobacterial hsp65(180-188) peptide can transfer disease to naive, irradiated recipients (reviewed in [45] ). The mycobacterial-specific T cell clone was found to cross-react with a proteoglycan found in joints; the peptide sequence of the cross-reactive self-epitope is not yet known. Whereas an hsp65(180-188)-specific T cell clone can transfer disease, neither the hsp peptide nor the hsp65 antigen are sufficient to induce arthritis, suggesting that other mycobacterial components that are pathogenic are necessary for inducing T cells to this epitope [46, 47] .In the examples discussed above autoimmunity was induced by immunization with a peptide or a protein, which is artificial. The question of whether challenge with an infectious virus can initiate an autoimmune process by activating autoreactive cells was addressed by using transgenic mice that selectively express a viral antigen in the target organ (reviewed in [44] Further studies in these animal models [48] [49] [50] [51] reveal that multiple other factors, for example expression of cytokines and costimulatory molecules, are of critical importance for disease development, which supports the notion that initiation of an autoimmune disease is a multistep/muhifactorial process.Genome wide searches in human autoimmune diseases and in experimental animal models indicate that multiple genes (both MHC and non-MHC) are required for the development of spontaneous autoimmunity [17] [18] [19] 52] . In susceptible individuals, the activation of autoreactive T cells is necessary but not sufficient for the development of an autoimmune disease (Table 3 ). An insufficient degree of clonal expansion of autoreactive T cells may be a major limiting factor. As some autoreactive T cell clones are activated by peptides from different pathogens a stepwise expansion of autoreactive T cells by subsequent infections is possible. Another limiting factor may be the functional phenotype induced by the infectious agent. In the EAE model, only a small fraction of MBP-specific T cell clones is pathogenic (<10%) and the presence ofa Thl phenotype alone is insufficient to induce EAE (S Brocke, personal communication). Therefore, autoreactive T cells may only be pathogenic if a particular functional program is induced by the infectious agent. Other factors that limit the occurrence of an autoimmune disease are access to the target organ, in addition to the expression levels of MHC class II and costimulatory molecules in the target organ. This is illustrated by the observation that in mice transgenic for an MBP(Acl-ll)-specific TCR, the in vivo activation of the autoreactive T ceils, even with the native MBP peptide, is not sufficient to induce EAE unless the entry of those cells into the CNS is facilitated by pertussis toxin [34]. Table 3 Requirements for the development of chronic autoimmune disease following activation of autoreactive T cells.1. Sufficient clonal expansion of autoreactive T cells 2. Induction of a functional phenotype (i.e. cytokine profile) that makes T cells pathogenic 3. Entry of activated autoreactive T cells into the target organ 4. Sufficient expression levels of MHC molecules and costimulatory molecules on antigen presenting cells in the target organActivation of autoreactive T cells is important in the induction of human autoimmune diseases. Several studies over the past two years have demonstrated that human T cell clones can recognize several peptide ligands that are quite distinct in their primary sequence. T cell clones that are more degenerate in the recognition of MHC molecule-bound peptides are more likely to cross-react with a self-antigen and to therefore induce autoimmunity. Differential contact of disparate class I/peptide complexes as the basis for epitope cross-recognition by a single T cell receptor. J Immuno11997, 158:3651-3658. The analysis of the fine specificity of a murine xenoreactive HLA-A2-specific T cell clone reveals differences in the relative importance of peptide side chains for TCR recognition in different MHC molecule-peptide complexes. This implies that a single TCR is able to use differential contact sites for recognition. The fine specificity of a highly degenerate myelin basic protein-specific T cell clone -MBP(88-98) specific -is analyzed using random peptide libraries. Based on that motif several peptides of human and microbial origin were identified that can activate this autoreactive clone. restricted T-cell clones from multiple sclerosis patients: identity of key contact residues in the B-cell and T-cell epitopes. J C/in Invest 1997, 100:1114-1122. The fine specificity of myelin basic protein (MBP)-specific antibodies that were purified from brains multiple sclerosis patients was compared to MBP specific T cell clones. Residues that were critical for both antibody binding and T cell receptor recognition were located in a 10 amino acid segment. A viral peptide was identified that was bound by purified autoantibodies and that also stimulated a MBP specific T cell clone.Talbot PJ, Paquette J-S, Ciurli C, Antel JP, Ouellet F: Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann Neuro11996, 39:233-240.Goverman J, Woods A, Larson L, Weiner LP, Hood L, ZaUer DM: Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993, 72:551-560.Brabb T, Goldrath AW, yon Dassow P, Paez A, Liggitt HD,  Goverman J: Triggers of autoimmune disease in a murine TCR-transgenic model for multiple sclerosis. J Immuno/1997, 159:497-507. The increased incidence of spontaneous experimental autoimmunoe encephalomyelitis in TCR transgenic mice under non-germ free conditions demonstrates the impact of the microbial environment on the induction of autoimmunity. Further studies on these transgenic mice show that following T cell activation in vivo the entry of the autoreactive MBP-specific T cells into the central nervous system is a critical step for the initiation of the autoimmune disease. ',\n",
       " \"Report 48 see https://www.who. int/docs/default-source/ coronaviruse/situationreports/20200308-sitrep-48covid-19.pdf?sfvrsn=16f7ccef_4The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China, in December, 2019, now affects the whole world. As of March 8, 2020, more than 105 000 laboratoryconfirmed cases and more than 3500 deaths in over 100 countries had been reported.Since SARS-CoV-2 RNA was first detected in a stool specimen of the first reported COVID-19 case in the USA, 1 much attention has been paid to the study and reporting of gastrointestinal tract infection of SARS-CoV-2. According to a study 2 including 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in China as of Jan 29, 2020, nausea or vomiting, or both, and diarrhoea were reported in 55 (56%) and 42 (38%) patients. Autopsy studies are crucial to help understand the involvement of COVID-19 in the digestive system; however, to date, there has been only one autopsy report 3 for a man aged 85 years with COVID-19, which showed segmental dilatation and stenosis in the small intestine. Whether this finding is secondary to COVID-19 or a preexisting gastrointestinal comorbidity is unknown.COVID-19 has implications for the management of patients with pre-existing digestive diseases. Indeed, the presence and number of comorbidities is associated with poorer clinical outcome in patients with COVID-19. In the study 2 of 1099 patients with laboratoryconfirmed COVID-19, 261 (237%) patients with COVID-19 reported having at least one comorbidity, with hypertension, diabetes, and coronary heart disease being the most common. In this study, 2 23 (21%) patients had hepatitis B infection. Severe cases were more likely to have hepatitis B infection (24% vs 06%) than non-severe cases. Abnormal liver function tests, including elevated aspartate aminotransferase, alanine aminotransferase, and total bilirubin were noted. 2 Liver abnormalities in patients with COVID-19 might be due to viral infection in liver cells but could also be due to other causes such as drug toxicity and systemic inflammation. 4 Data suggest that liver injury is more prevalent in severe cases than in mild cases of COVID-19. 4 However, data about other underlying chronic liver conditions such as non-alcoholic fatty liver disease, alcohol-related liver disease, and autoimmune hepatitis, and their effect on prognosis of COVID-19 needs to be further evaluated.Liver transplantation might involve a risk of transmission of viral infection from donor to recipient, as shown in the previous SARS outbreak, and therefore donor screening and testing is crucial. 5 Although many patients had comorbidities in the reported series, 2 none had been a transplant recipient. Transplant clinicians are encouraged to follow guidance issued by The Transplantation Society, 6 as well as local health department guidelines for isolating, quarantining, testing, and monitoring returned travellers from endemic areas.Patients with cancer in general are more susceptible to infection due to their immunocompromised status caused by the malignancy and anticancer treatments. However, whether patients with gastrointestinal cancers are more likely to be infected with SARS-CoV-2 than healthy individuals remains unknown. In a recent nationwide analysis from China, 7 18 (1%) of 1590 COVID-19 cases had a history of cancer. Among these 18 cases, three had a history of colorectal cancer (one colonic tubular adenocarcinoma, one rectal carcinoma, and one colorectal carcinoma). 7 Patients with COVID-19 and cancer were observed to have a higher risk of severe events; several strategies have been proposed, such as intentional postponing of adjuvant chemotherapy or elective surgery on a patient-bypatient basis, stronger personal protection provisions, and more intensive surveillance or treatment. 7 Given the use of biologics and immunosuppressive agents, whether patients with inflammatory bowel disease (IBD) are more susceptible to SARS-CoV-2 infection has raised great concern. Currently no patients with IBD have been reported to be infected with SARS-CoV-2 in the IBD Elite Union, which incorporates the seven largest IBD referral centres in China with more than 20 000 patients with IBD. 8 Furthermore, no patients with IBD with SARS-CoV-2 infection have been reported from the three largest tertiary IBD centres in Wuhan (Tongji Hospital, Union Hospital, and Zhongnan Hospital) at the time that this manuscript was prepared (March 8, 2020) .Several strategies have been implemented in China to minimise the potential risk of SARS-CoV-2 infection in patients with IBD since the outbreak of COVID-19. First, the Chinese IBD Society issued official guidelines for managing patients with IBD in early February 2020. 9 The guidelines include practical recommendations on the use of immunosuppressive agents and biologics, diet, and intentional post ponement of elective surgery and endoscopy, as well as personal protection provisions; these are outlined in the panel. Second, the China Crohn's & Colitis Foundation has organised a group of volunteer gastroenterologists that specialise in IBD to offer online consultancy to patients with IBD since Jan 29, 2020. Third, an online virtual IBD visit programme has been initiated in some IBD centres, which provides convenient and cost-effective care, and could potentially reduce the risk of SARS-CoV-2 infection by avoiding close contact with infected patients in public areas. With the increasing concern from patients with IBD globally, helpful online resources about COVID-19 have been provided by international non-profit organisations such as Crohn's Colitis of Foundation America and Crohn's & Colitis UK. 10, 11 Such guidance and advice should be delivered urgently to health-care workers as well as patients with IBD.The comorbidity spectrum of digestive conditions and its impact on treatment and outcome of COVID-19 remains largely unknown. Further data need to be analysed from the COVID-19 cohort established by the National Health Commission of the People's Republic of China, which would help to more precisely ascertain the risk of SARS-CoV-2 infection in patients with digestive comorbidities such as IBD. These data and experience with guidance on how to manage patients with underlining comorbidities in China could facilitate integrated care for patients globally.We declare no competing interests. We thank the members of Chinese IBD Elite Union, Chinese Society of IBD and Chinese IBD Quality Care Evaluation Center Committee (IBDQCC) for their collaboration. RM and JL contributed equally. \",\n",
       " 'In June 2015 the Healthcare Infection Society held a twoday Middle East Infection Prevention Summit with the aim of uniting colleagues across the globe in driving down infection rates and improving infection prevention and control practice. In many ways the Middle East is a microcosm for the challenges in infection prevention and control across the world. The economies range from underdeveloped countries such as Egypt, with a low per-capita gross domestic product, to the wealthy hydrocarbon-exporting, and increasingly diversified, economies of the Gulf Cooperation Council countries; of course these vast economic differences impact on the resources available for healthcare. Moreover, there are large ex-patriot populations in many Middle Eastern countries and international travel to and from the Middle East is frequent, meaning that infections emerging there can quickly have a global impact.Two of the themes of the conference that have particular international relevance are the huge challenges presented by multidrug-resistant Gram-negative bacteria in Middle Eastern hospitals, and local experience with Middle East respiratory syndrome coronavirus (MERS-CoV). Coverage of the latter was particularly opportune, given the outbreak of MERS-CoV in South Korea in May 2015 originating from a traveller returning from visiting several Middle Eastern countries.This special section of the journal includes three papers relating to the Summit. Drs Omrani and Shalhoub present a review of MERS-CoV, and Dr Jon Otter and Professor Nesrene Omar describe their British and Egyptian perspectives of the Summit. 1e3',\n",
       " \"Respiratory syncytial virus (RSV) is well known as a virus causing lower respiratory tract infection (LRTI) in infants and immunocompromised adults (1-3). Bronchopneumonia patterns are common findings of RSV-induced LRTI (RSV-LRTI); however, RSV-LRTI often shows variable findings on chest imaging (4-11). Although some factors, such as the virulence of RSV and host immune status, might affect the chest computed tomography (CT) findings of RSV-LRTI (12, 13), the detailed mechanisms remain unknown.From this perspective, an RSV outbreak due to genetically identical RSV is an ideal setting for investigating the chest images of RSV-LRTI. Thus far, however, there has only been one report showing the chest images of RSV-LRTI in the outbreak setting (11). In addition, reports investigating the correlation between the clinical manifestations and abnormal findings on chest CT remain rare (14).In 2014, a genetically identical RSV outbreak occurred in the hemato-oncology ward of the University of the Ryukyus Hospital (15), and a subset of RSV-infected patients underwent both chest X-ray and CT during the outbreak. We herein report our analysis of the radiological findings and the clinical manifestations in the outbreak.During the 2014 outbreak, RSV infection was diagnosed by reverse transcriptase polymerase chain reaction using respiratory specimens, and genetic proximity was confirmed by a phylogenetical analysis (15). Eight RSV-infected patients underwent both chest X-ray and CT during the outbreak. The clinical information and chest X-ray findings were retrospectively reviewed from patient medical records within one week of the chest CT scan.The medical records and radiological images of the collected cases were retrospectively reviewed, with identifying information removed. This study was reviewed and approved by the Clinical Research Ethics Committee of University of the Ryukyus.The patients' background characteristics, clinical manifestations, laboratory data, and findings from chest imaging are shown in Table. Seven cases (88%) received various immunosuppressive treatment, and none had airway diseases, such as bronchial asthma. Five cases (63%) had newly appearing abnormal findings on chest CT; however, no abnormal findings were detected by chest X-ray in 3 of those 5 patients (60%). Most cases had upper respiratory symptoms, including rhinitis and sore throat. However, lower respiratory symptoms, such as wheeze, sputum, and hypoxemia, were only seen in patients with newly appearing findings on chest CT. Bacterial culture for respiratory specimens was performed in six cases, and bacteria were detected in three cases; however, no patient was diagnosed with bacterial pneumonia or treated with targeted antibiotics against these detected bacteria. In addition, no cases received antiviral therapy against RSV.Chest CT findings for the five patients are shown in Figs. 1-5. The most common finding among these patients was bronchial wall thickenings; seen in 4 of 5 patients (80%). In terms of the findings in the parenchymal lesion, the patterns and distributions were varied and inconsistent. Two cases showed ground-glass opacities (GGOs) along the bronchi; however, the distribution differed, as one was a localized GGO and the other a multilobar GGO. One case showed ground-glass nodules with a tree-in-bud pattern. The remaining case showed diffuse GGOs with centrilobular septal thickening, also known as the crazy-paving pattern. Three cases underwent two or more CT scans during the course of their disease, and the abnormal findings on chest CT disappeared (Fig. 1, 2, 5).Chest CT showed variable findings for RSV infection, even during an outbreak setting. In most cases, chest X-ray failed to detect abnormalities. In RSV-infected hematological malignancy patients receiving anticancer chemotherapy, lower respiratory symptoms may predict the existence of CT abnormalities due to RSV-LRTI.The authors state that they have no Conflict of Interest (COI).\",\n",
       " '1 18Giulia Polverari, MD 1 , Vincenzo Arena, MD 1 , Francesco Ceci, MD, PhD 2 , Ettore Pelosi, MD, PhD 1 , Annarita Ianniello, MD 1 , Elana Poli, MD 3 , Alberto Sandri, MD 4 This is a case of 73-year-old male patient who underwent medium lobe resection for pT2aN0 non-small cells lung cancer (NSCLC) in April 2016, without administration of adjuvant therapies. During routine CT scan performed in February 2020 a centimetric nodule in left superior lobe suspected for malignancy was reported. Functional imaging with 18 F-FDG PET/CT was requested by tumor board to evaluate nodule metabolism. 18 F-FDG PET/CT was scheduled for March 18 th 2020, twenty-seven days after SARS-CoV-2 outbreak in Italy. During triage procedures required for COVID-19 prevention, body temperature resulted < 37.5 C and the patient did not present nor cough or wheezing, neither shortness of breath. Patient declared no suspected expositions to infected people and he was a non-smoker with no cardiovascular comorbidities. The nuclear medicine team interpreted the PET scan as active inflammatory processes with consensus, with a CT pattern highly suspicious for on-going COVID-19 pneumonia, as reported in literature (1, 2) . After consultation with COVID-19 task-force authorities, the patient has been tested with real-time reverse transcription polymerase chain reaction (RT-PCR), resulted positive, and he was subsequently quarantined. However, hospitalization in intensive care unit was necessary three days after PET/CT scan for rapid disease progression and severe respiratory distress syndrome.At present, more than 80.000 people are affected by COVID-19 in Italy leading to COVID-19 related death more than 7000 of patients. PET scans are still offered to oncological patients to guarantee the continuation of best clinical practice, even in the scenario of national 3 restrictive directives. Thus, the number of asymptomatic pathogen carrier in Nuclear Medicine facilities is not negligible. COVID-19 radiological pattern (Rx and CT) has become known, usually described as peripheral predominant GGOs or lung consolidation involving mainly the lower lobes (3) . However, discrepancy between radiological patterns and clinical symptoms is possible and several studies have reported this clinical-radiological dissociation (4, 5) . The few reports of 18 F-FDG PET/CT in patients with COVID-19 currently available, describe in all cases symptomatic patients with common COVID-19 manifestation including fever, cough, shortness of breath, myalgia and fatigue (1, 2) . To the best of our knowledge this is the first case report in asymptomatic patient, investigated with 18 F-FDG PET/CT. This case highlights the rapid disease progression in asymptomatic patient presenting FDG avid COVID-19 pneumonia. While far from giving definitive evidence, asymptomatic patients presenting typical radiological CT patterns and positive FDG uptake should be promptly tested and strictly monitored, since sudden worsening of patient clinical condition, might be possible.All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from all individual participants included in the study.The authors declare that they have no conflict of interest.',\n",
       " \"Dear Editor,For decades, Ebola members (EBOV) of the Filoviridae family of highly pathogenic, filamentous single-stranded RNA viruses have been responsible for sporadic self-limiting clusters of Ebola virus disease (EVD) in Central Africa. The current outbreak of EVD in West Africa has risen to epidemic status and is considered by the World Health Organization to be a public health emergency of international concern. This level of concern by the World Health Organization and other health-care authorities and providers is based on the high lethality of EBOV-Zaire in humans (up to 90%), its high communicability though body fluids, the high incidence of infection in primary health-care workers and the total lack of proven efficacious drugs or vaccines. Although there are a variety of potential EBOV inhibitors in the drug development pipeline, none have sufficient human safety data, which complicates estimates of their efficacy in the current crisis situation in West Africa.1 One such experimental drug is the Zmapp monoclonal antibody cocktail (n=3), which was shown to be highly effective in reversing advanced EVD in non-human primates.2 However, the rapid acquisition of EBOV sequence variation recently demonstrated during genomic surveillance of the current EVD epidemic suggests that drug development dependent on viral non-variant protein sequences may be problematic.3 In this Letter, we briefly address the evidence-based potential of several Toll-like receptor 3 agonists in late-stage clinical development for reducing the morbidity and mortality of EVD.Death from EBOV infection is associated with markedly impaired coagulation and innate immunity cascades, increased production of pro-inflammatory cytokines, profound immune suppression resulting in peripheral T lymphocyte apoptosis and a lack of adaptive immunity.4 By contrast, survivors of infection by EBOV develop an effective immune response with the production of EBOV neutralizing antibodies. Early events in EBOV infection influence the patient's ability to develop an effective immune response. The success of EBOV replication is dependent on viral inhibition of initial innate immune responses to infection. Disarming innate immune responses is a common mechanism employed by highly pathogenic human viruses, including those of the influenza and coronavirus families.5 EBOV is one of the more successful of the emerging highly pathogenic viruses in evasion of innate immune interference. Viral protein (VP35), an essential component of the EBOV replication matrix, represents an evidence-based target for the potential reduction of the morbidity and mortality of EVD.Double-stranded RNA (dsRNA) is a common component of viral replication, which initiates systemic signaling cascades that normally activate interferon (IFN) regulatory factors leading to the production of IFN-/ (type I IFNs). The IFNs activate multiple IFN response pathways necessary to inhibit viral replication, including transitory expression of enzymes such as 25 adenylate synthetase and protein kinase R, which require dsRNA as a cofactor for activity. To circumvent viral recognition by human cells, highly virulent viruses (including Ebola) have evolved different strategies to block the biological activities associated with the induction of IFN-/ and the subsequent multiplicity of anti-viral responses and the initiation of adaptive immunity. VP35 is a multifunctional major virulence protein that is indispensable for EBOV replication as a component of the viral polymerase complex.4 This factor also counteracts the host innate immune response by blocking the cellular production of and responses to type I IFN transient gene activation. Key components of the innate immune response to viral infection include activation of Toll-like receptor 3 and the helicases melanoma differentiation-associated protein 5 and retinoic acid-inducible gene1 by viral dsRNA.5 However, viral inhibition of these dsRNA responsive elements effectively disarms essential components of the innate immune response. In particular, a positively charged C-terminal amino acid motif (Figure 1) of VP35 binds to sequence-independent dsRNA, resulting in the suppression of multiple steps in the IFN signaling cascade, which otherwise would lead to a broad antiviral state with strong activation of both the innate and adaptive arms of the immune response.8 Thus, VP35 provides an attractive evidence-based target for antiviral interruption of EBOV, potentially ameliorating the pathogenesis of EVD.Various forms of dsRNA have been studied as inducers of type I IFNs. Although the original dsRNA studied for efficacy in humans, Poly I:Poly C, was found to induce serious adverse events in humans that limited pharmaceutical development, several derivatives have survived the rigors of animal and clinical testing. Poly ICLC (Hiltonol) (Oncovir, Inc., Washington, DC, USA) consists of Poly I:Poly C with non-covalent adduct polymeric chains of poly-L-lysine and carboxymethylcellulose. These adducts increase the drug half-life by steric hindrance of the phosphodiester backbone from RNAse hydrolysis. Hiltonol has been studied in clinical trials as a cancer therapy and as an adjuvant for cancer vaccines.9 Poly I:Poly C12U (rintatolimod, Ampligen) (Hemispherx Biopharma, Inc., Philadelphia, PA, USA) was designed as an IFN inducer with a markedly reduced incidence of adverse advents compared to the parent compound Poly I:Poly C8 and is devoid of adducts. Both Hiltonol and Ampligen have demonstrated antiviral activity against a wide variety of DNA and RNA viruses in preclinical testing.In animal studies, rintatolimd was efficacious as an epitope-expanding adjuvant for highly pathogenic avian influenza virus vaccines,10 and this drug is now being evaluated as an adjuvant in a variety of cancer vaccine trials. Rintatolimod has demonstrated activity in two double-blind, placebo-controlled clinical trials of chronic fatigue syndrome8 and is currently in an advanced clinical trial as a treatment for this condition. Hiltonol and/or rintatolimod experimental pharmaceuticals are attractive evidence-based candidates for the treatment of EVD on the expanded basis recently approved by the World Health Organization. The use of experimental pharmaceuticals beyond phase I in Food and Drug Administration-sanctioned clinical trials helps ensure the availability of products with established safety profiles sufficient for open-label clinical testing and analysis of efficacy. The use of potential drugs in clinical trials also helps ensure a reliable supply of clinical-grade drugs, which removes the ethical dilemma of patient selection for treatment.1\",\n",
       " \"M. genavense infections occur only rarely in persons other than AIDS patients (as in the present case), but they always occur in immunocompromised persons (7,8). To date, only 1 case of disseminated infection has been reported in a solid-organ (kidney) transplant recipient; the diagnosis was made by molecular identifi cation in isolates from blood and marrow cultures. That patient died of complications from M. genavense infection (9). Because M. genavense is a fastidious organism, the infections it causes are diffi cult to diagnose and their frequency is probably underestimated, which may change with increased use of direct molecular biological methods.Optimal treatment of M. genavense infections has not been established (10). Experience with M. genavense infections in AIDS patients and with other nontuberculous mycobacteria infections in solid-organ transplant recipients suggests that at least 2 antimicrobial drugs should be used for a prolonged period; when possible, immunosuppressive drugs should be concurrently reduced (1,3,6,10). Outcome of nontuberculous mycobacteria infections in transplant patients is highly variable (1,5) but was satisfactory in the present patient, who was treated with quintuple antimicrobialdrug therapy and reduced immunosuppressive therapy.This case of a disseminated infection due to M. genavense in a heart transplant recipient was diagnosed early. Universal 16S rRNA gene sequencing after amplifi cation directly from intestinal biopsy specimens enabled fast diagnosis and appropriate management. To the Editor: Bats are thought to be one of the most important reservoirs for viruses such as Nipah virus, severe acute respiratory syndrome (SARS) coronavirus, and Ebola virus (1). These pathogens became known after extensive surveys of bats following outbreaks. As a fi rst step in investigating unidentifi ed pathogens in bats and to help forecast the potential threat of emerging infectious diseases, we tried to isolate and characterize viruses that persistently infect bats. In the process, we isolated a novel adenovirus from a fruit bat in Japan.Pteropus dasymallus yayeyamae, or Ryukyu fl ying fox, is a fruit bat of Japan. With the permission of the governor of Okinawa, we caught 1 adult male bat of this species and used its spleen and kidneys to establish primary cell cultures. On the 4th passage of the primary adherent cells derived from the spleen, a cytopathic effect (CPE) appeared without any visible microbe, indicating that the cell culture contained a virus. The virus, tentatively named Ryukyu virus 1 (RV1), caused apparent CPE on primary kidney cells derived from a Ryukyu fl ying fox and on our established bat kidney T1 (BKT1) cells, which were derived from the kidney of a horseshoe bat (Rhinolophus ferrumequinum) and transformed with expression plasmid DNA encoding the large T antigen of replication origin-defective simian virus 40.To identify the virus, RV1, we applied the rapid determination of viral RNA (RDV) system version 1.0 (2). However, no viral nucleic acid sequence was detected from an RNA sample in the RV1-infected BKT1 cells. For detection of viral DNA, we developed a system for rapid determination of viral DNA sequences (RDV-D) by minor modifi cation to the RDV system for RNA viruses (2) (3) (4) . The results indicated that 2 of the fragments were homologous to the gene encoding the precursor of terminal protein (pTP) of adenoviruses. Further RDV-D analysis showed that 6 fragments (139 bp, DDBJ/EMBL/GenBank accession no. AB302970) were homologous to the pTP gene and that another 6 fragments (316bp, DDBJ/EMBL/ GenBank accession no. AB302971) were homologous to the gene encoding the precursor of protein VI (pVI) of adenoviruses. These results indicated that RV1 must belong to the family Adenoviridae.To further confi rm that RV1 isolate was an adenovirus, we used PCR and sequencing. We performed the fi rst reaction with the outer primer pair (polFouter and polRouter) of a nested PCR method, targeting the viral DNA polymerase gene with highly degenerate consensus primers that have been described recently (5) . A fragment of 550 bp was amplifi ed from RV1 as well as from human adenoviruses-1, -3, -4, and -7 (data not shown). Sequence analysis of the amplifi ed product (DDBJ/EMBL/GenBank accession no. AB303301) showed that RV1 was homologous to tree shrew adenovirus 1 (70.0% amino acid sequence identity), porcine adenovirus 5 (69.2%), canine adenovirus 1 (68.9%), human adenoviruses-3, -16, -21 and -50 (68.9%), and other viruses (>64.8%) in genus Mastadenovirus, but less homologous (46.7%-57.8%) to viruses in other genuses, Siadenovi-rus, Aviadenovirus, and Atadenovirus. In addition, a phylogenic tree based on amino acid sequences indicated that RV1 belongs to family Adenoviridae, genus Mastadenovirus (Figure) .Electron microscopy of RV1-infected BKT1 cells indicated that RV1 accumulated in the nucleus and that the size of capsids was 60-70 nm (data not shown). Restriction endonuclease analysis of the RV1 genome indicated that the genome was 20-30 kbp (data not shown). These features are consistent with RV1 being an adenovirus.Until now, a number of RNA viruses have been isolated from bats, but isolation of DNA virus is rare (1) . The isolation of the novel adenovirus seems to be possible because of usage of the primary cells originated from the host; DNA viruses might have more restricted host range than RNA viruses and require host-originated cells for the growth. In addition, our success in DNA virus isolation might have resulted from usage of the adult animal latently and persistently infected with DNA viruses such as adenovirus and herpesvirus.In conclusion, we isolated a novel virus from a fruit bat. This virus was isolated from a healthy bat, which suggests that the virus may persistently infect fruit bats. Although its pathogenicity for humans is still unknown, knowledge of RV1 will be useful in epidemiologic studies of infectious diseases emerging from bats because persistently infecting viruses might be isolated together with primary pathogens. We are planning to establish cell lines from bats and isolate more viruses from persistently infected bats. To the Editor: Fluoroquinolones (FQs) that are active against streptococcal species (e.g., levofl oxacin and moxifl oxacin) have been recommended by numerous national health authorities and international organizations for treating acute exacerbations of chronic bronchitis and pneumonia in adults (1). However, use of these antimicrobial drugs for treating community-acquired infections has led to an increase in FQ-resistant strains in bacteria such as Streptococcus pneumoniae. Group B streptococci (GBS, e.g., S. agalactiae) are the leading cause of invasive infections (pneumonia, septicemia, and meningitis) in neonates. GBS are also associated with bacteremia, endocarditis, and arthritis, and are responsible for deaths and illness in nonpregnant women with underlying diseases and in elderly adults (2) . We describe, to our knowledge, the fi rst GBS clinical isolate in France resistant to FQ; the isolate was from a patient treated with levofl oxacin.GBS CNR0717 strain was isolated as the predominant bacterium in a culture (>10 7 CFU/mL) from 2 purulent sputum samples from an 80year-old man (leukocytes >25, epithelial cells <10) obtained 8 days apart. This patient was treated for 2 weeks with levofl oxacin, 750 mg/day, for acute exacerbation of chronic bronchitis. No other relevant respiratory bacterial pathogens were present in these samples. GBS CNR0717, a capsular serotype IV strain, was suspected to have reduced susceptibility to FQs because no inhibition zone was observed around disks containing norfl oxacin and pefl oxacin disks, and reduced diameters were observed around disks containing ciprofl oxacin and levofl oxacin. Antibiograms were performed according to recommendations of the Clinical and Laboratory Standards Institute (3) on Mueller Hinton agar (Bio-Rad, Marnes la Coquette, France) supplemented with 5% horse blood. This strain was susceptible to all other antimicrobial drugs usually active against GBS (penicillin, erythromycin, clindamycin, tetracycline, rifampicin, vancomycin) and showed low-level resistance against aminoglycosides. MICs for 6 FQs ( Table) indicate that GBS CNR0717 was highly resistant to pefl oxacin and norfl oxacin, with MICs >64 mg/L, and showed increased MICs for ciprofl oxacin, sparfl oxacin, levofl oxacin, and moxifl oxacin. No reduction of FQ MICs was observed with reserpine (10 mg/L), which indicated that resistance to FQ was not caused by an active effl ux pump system. Three major mutations have been reported for FQ resistance in streptococci at codon positions 81 in gyrA and 79 or 83 in parC (4) . DNA sequence analysis of these regions showed a mutation in parC (Ser 79  Tyr) but not in the wild-type susceptible strain (NEM316). No mutation was detected in the gyrA gene. FQ resistance in streptococci is acquired through a stepwise process and has been extensively studied in S. pneumoniae. First-step mutants conferring low-level resistance generally result from mutations in either gyrA or parC. There is also Letters commenting on recent articles as well as letters reporting cases, outbreaks, or original research are welcome. Letters commenting on articles should contain no more than 300 words and 5 references; they are more likely to be published if submitted within 4 weeks of the original article's publication. Letters reporting cases, outbreaks, or original research should contain no more than 800 words and 10 references. They may have one Figure or Table and should not be divided into sections. All letters should contain material not previously published and include a word count.\"]"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "6\n",
      "1\n",
      "1\n",
      "2\n",
      "1\n",
      "3\n",
      "1\n",
      "4\n",
      "1\n"
     ]
    }
   ],
   "source": [
    "dic_clusters_docs = {}\n",
    "for i in range(num_clusters):\n",
    "    doc = []\n",
    "    print(i)\n",
    "    for d in df_clustered[df_clustered[\"KMeans_label\"] == i]['body_text']:\n",
    "        doc.append(d)\n",
    "    print(len(doc))\n",
    "    doc_string = ''.join(doc)\n",
    "    #print(doc_string)\n",
    "    dic_clusters_docs[i]=doc_string\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Multiple sclerosis (MS) was initially identified in 1868 by Charcot. This disease often begins in young adulthood with intermittent episodes of neurological dysfunction, including visual impairment, ataxia, motor and sensory deficits, and bowel and bladder incontinence. These are attributable to recurrent inflammatory attacks on the white matter of the brain and spinal cord, which lead to the accumulation of perivascularly distributed inflammatory cells within the brain and spinal cord white matter [1].Beeton et al. first established an animal model of MS in the 1930s, when they immunized monkeys with a central nervous system (CNS) homogenate to induce what is now known as experimental autoimmune encephalomyelitis (EAE) [2]. Since this pilot animal study, EAE has become the most accepted animal model of MS. In recent decades, pathogenic hypotheses have been investigated and novel therapeutic agents tested in this model in the fields of CNS inflammation and demyelination. Therefore, EAE provides a valuable tool for the investigation of the T-cell-dependent pathogenesis of autoimmune inflammation in the CNS and the orchestration of the autoimmune demyelinating inflammation in the CNS of MS patients. Mice and/or genetically modified mice have also been of fundamental value in the exploration of the complex pathogenesis of MS [3, 4]. EAE is undoubtedly the best animal model in which to study autoimmune diseases and particularly the demyelinating diseases of the CNS, such as MS [5].Myelin basic protein-(MBP)-specific T cells isolated from the peripheral lymphocytes of human individuals with MS and encephalitogenic T cells recovered from circulating autoreactive T cells of either immunized or nave animals have shown that autoreactive T-cell lines that recognize the encephalitogenic part of MBP in vitro can be distinguished from an unprimed rat T-cell population. This confirms that autoreactive T cells play a central role in the pathology of MS [68]. EAE can also be induced by adoptively transferring an expanded population of myelin-reactive encephalitogenic CD4+ (T helper [Th]) cells, which allows the further dissection of the immunopathogenic potency of different encephalitogenic CD4+ cell populations [9].In the 1990s, Mosmann and Coffman postulated that Th cells can be classified into two distinct subsets, Th1 and Th2. Th1 cells produce large quantities of interferon  (IFN), driven by interleukin 12 (IL12), which promotes cellular immunity directed against intracellular pathogens. Alternatively, Th2 cells, which secrete IL4, IL5, IL13, and IL25, are essential in the destruction of extracellular parasites and the mediation of humoral immunity [10, 11]. Self-reactive Th1 clones derived in vitro are capable of adoptively transferring EAE to nave recipients [12]. Increased levels of Th1 cytokines are particularly evident during EAE/MS relapse, whereas increased Th2 cytokines are found during remission in MS patients when compared with control levels [13]. Clinical and hematological symptoms are exacerbated in relapsing/remitting MS patients following the administration of IFN, and this is also observed in other Th1-type diseases, whereas it is less apparent in Th2 diseases [14, 15]. Th1 cells were earlier thought to be pathogenic T cells, whereas Th2 cells were thought to confer an anti-inflammatory potential, constituting protective T cells in both MS and EAE [1619].However, this clear-cut immunodysregulation of the Th1/Th2 balance in EAE and MS may be part of a hidden complex of interactions underlying EAE and MS [20]. The Th1-driven nature of the EAE/MS disease was challenged by the finding that IFN- and IFN-receptor-deficient mice, as well as mice that lack other molecules involved in Th1 differentiation, such as IL12p35, IL12 receptor 2 (IL12R2), and IL18, were not protected from EAE, but instead were more susceptible to the disease [2125]. Unexpectedly, mice deficient in IL12 (IL12p35), a component of the Th1 paradigm, are vulnerable to EAE. Similarly, IL12R2-deficient mice develop more severe clinical manifestations of EAE, whereas IL12p40-deficient mice are resistant to EAE [23, 24, 26]. These discrepancies and conflicting data indicate that an imbalance in the Th1/Th2 milieu cannot explain the overall immunopathogenic mechanisms underlying EAE and MS.p19, a novel cytokine heavy-chain homologue of the IL6 subfamily, was discovered as a computational sequence [27]. When the p19 chain is linked to the p40 chain, a subunit of IL12 (another subunit of the IL12 heterodimers is the p35 chain), it forms a novel cytokine designated IL23. Therefore, the deletion of IL12p40 will affect the functions of both IL12 and IL23. Cua and colleagues verified that Il23 but not Il12 is essential for the induction of EAE by generating Il23p19 knockout (KO) mice and comparing them with IL12p35 KO mice [28]. Furthermore, an IL17-producing T-cell subset, driven and expanded by IL23, can pathogenically induce EAE when adoptively transferred into nave wild-type mice [29, 30]. These IL17-producing T cells were dramatically reduced in the CNS of IL23p19-deficient mice. Based on these studies, researchers confidently suggested that IL17-producing CD4+ T cells are a distinct and novel Th subset that exacerbates autoimmunity, and designated them Th17 cells [31, 32]. Th17 cells are a Th-cell subset distinct from Th1 and Th2 cells in terms of their differentiation, expansion, and effector functions [33, 34]. The discovery of Th17 cells further clarifies the cytokine profile of MS [35]. Recently, the levels of IL17 produced by MBP-stimulated peripheral blood cells obtained from MS patients or controls were shown to correlate with the active lesions in MS patients observed with magnetic resonance imaging (MRI) [36].Like other Th subsets, the Th17 lineage is activated by a specific cytokine milieu. However, IL23 cannot produce Th 17 cells de novo from nave T cells, and the IL23 receptor (IL23R) is not expressed on nave T cells [37]. Transforming growth factor  (TGF) upregulates IL23R expression, thereby conferring responsiveness to IL23, which confirms that TGF is a critical cytokine in the commitment to Th17 expansion in vitro and in vivo [38]. In mice, TGF together with IL6 can activate antigen-responsive nave CD4+ T cells to develop into Th17 cells [39]. In humans, nave CD4+ cells exposed to IL6, TGF, and IL21 can develop into Th17 cells, and the production of IL23 plays a role in maintaining these Th17 cells [40, 41]. Altogether, Th17 cells require IL23, TGF, IL6, and IL1 for their generation. Th17 cells produce IL17A and IL17F, which are upregulated in chronic lesions [42], and IL22, which is also involved in the pathogenesis of MS. Thus, Th17 cells are a recently discovered, unique Th lineage that produces a repertoire of signature cytokines, including IL17A, IL17F, IL21, and IL22, that are essential for the development of autoimmune diseases such as MS [43].The discovery of transcription factors that are key regulators of the cytokine expression required to launch lineage-specific transcriptional programs has greatly extended our understanding of Th-cell lineage commitment [44]. It has been shown that T-bet and STAT4 program the commitment of the Th1 lineage and Th1 cytokine production [45], whereas GATA-binding protein 3 (GATA3) and STAT6 drive Th2 population expansion and Th2 cytokine production [46, 47]. The T-bet and STAT4 (necessary for Th1 differentiation) transcription factors are important in the differentiation of autoimmune T cells in the EAE model [48], and T-bet- and STAT4-deficient mice are resistant to EAE. However, these transcription factors do not mediate the induction of Th17 cells. Instead, in a unique inductive milieu, Th17 differentiation is driven by distinct transcription factors: retinoic acid receptor-related orphan receptor-t (Rort) and Ror [33, 34]. Stat3 deletion in T cells also prevents autoimmune uveitis and EAE and increases the expression of IL10 and forkhead box P3 (FoxP3) [49], and the expression of FoxP3 programs the development and functions of Treg cells [50]. In humans, IL23 and IL1 also induce the development of Th17 cells expressing IL17A, IL17F, IL22, IL26, IFN, the chemokine CCL20, and the transcription factor ROR [5153], as illustrated in Figure 1 (adapted from Hirota et al. [54]). Recent microarray studies of lesions in MS patients demonstrated an increased expression of IL17, confirming that Th17 cells play an important role in the development of inflammation and demyelination and in the eventual damage of the CNS. IL17 is a recently described cytokine produced in humans almost exclusively by activated memory T cells and can induce the production of proinflammatory cytokines and chemokines from parenchymal cells and macrophages. Patients with MS have greater numbers of IL17-mRNA-expressing mononuclear cells in the cerebrospinal fluid (CSF) than in the blood. Previously, no increase in the numbers and expression of IL17 mRNA by mononuclear cells isolated from the CSF was observed in patients with MS, but higher levels of IL17 mRNA were observed in the CSF than in the blood, with the highest levels in the blood detected during clinical exacerbations [56]. These data confirm the pivotal role of IL17 in MS both peripherally and centrally.Myelin is expressed in the circulation, and other CNS antigens are thought to be expressed in the cervical lymph nodes, which can trigger the conversion of autoaggressive myelin-reactive T cells to pathogenic T cells. Adhesion molecules, the integrins, allow these myelin-reactive T cells to penetrate the blood-brain barrier (BBB) under inflammatory conditions, and in this way, activated and memory T cells can enter the CNS [57]. Autoaggressive myelin-reactive T cells migrate into the CNS, where they recognize their cognate target antigens, and the movement of antigen-presenting cells (APCs) into the CNS is essential for lymphocyte reactivation within the CNS compartment and the initiation of the inflammatory cascade in the development of EAE [58]. Subsequently, inflammatory and immune cells, such as granulocytes and macrophages, are attracted into the CNS parenchyma, where they mediate tissue inflammation, leading to demyelination and tissue damage [59].The brain was formerly considered an immunoprivileged organ, but this perspective has been revised in the last two decades [60]. Today, we understand that any damage to the CNS can activate immune cells in situ in the CNS, particularly microglial cells. Deshpande et al. demonstrated the transient inactivation of microglial cells via a cell-specific deficiency of CD40 expression, indicating that microglial cells are crucial for maintaining the autoimmune responses in the CNS [61]. The major histocompatibility complex (MHC, also known as human leukocyte antigens in humans) class II molecules are only displayed on specialized APCs (e.g., dendritic cells [DCs], B cells, and macrophages), whereas MHC class I molecules are expressed by all cells in the inflammatory milieu of the CNS [62]. Microglial cells upregulate the expression of MHC and costimulatory molecules to initiate the generation and maintenance of the inflammatory milieu. DCs seem to play a critical role in antigen presentation to invading T cells and in the release of cytokines and chemokines, thereby guiding the entry of monocytes, lymphocytes, and cells with a phenotype similar to that of DCs into the lesion [63].Th cells recruit macrophages, which release proinflammatory cytokines and destructive molecules (such as nitric oxide [NO], IL1, IL6, tumor necrosis factor  [TNF], and matrix metalloproteinases (MMPs]), and CD8+ T cells also directly attack MHC class I-expressing cells, such as oligodendrocytes and neurons [64, 65]. The secretion of destructive molecules, such as NO and TNF, and the degradation of myelin are consequences of this cascade. TNF receptor 1 (TNFR1) but not TNFR2 signaling is critical for demyelination and the limitation of T-cell responses during immune-mediated CNS disease [66]. This complicated process triggers the recruitment of innate immune cells, generally consisting of T cells, macrophages, and microglia, which in turn mediate demyelination, axonal damage, and lesions.In autopsy samples from MS patients, the expression of IL17 is evident in perivascular lymphocytes and in astrocytes and oligodendrocytes located in the active areas of CNS lesions. IL17R is also identifiable in acute and chronic MS plaques of patients with MS, suggesting the enrichment of Th17 and CD8+ T cells in active MS lesions, and confirming an important role for IL17 in the pathogenesis of MS [67]. Th17 cells are identified by their expression of IL23R and the memory T-cell marker CD45RO in situ. Other markers that have been investigated including the chemokine receptor, CCR6, and RORC variant 2, which is a central transcription factor for Th17-cell development [42, 68]. Microarray analysis of MS lesions has also demonstrated increased transcripts of genes encoding inflammatory cytokines, particularly IL6, IL17, and IFN and associated downstream pathways [56]. A significant increase in IL23 mRNA and protein expression is found in lesion tissues compared with nonlesion tissues. Activated macrophages/microglia have been shown to be important sources of IL23p19 in active and chronically active MS lesions. IL23p19-expressing mature DCs are preferentially located in the perivascular cuffs of active lesions. This data on the expression of IL23p19 in MS lesions improves our understanding of the pathogenesis of MS [69].There is also evidence that MS endothelial cells express high levels of IL17R and are more permeable to IL17 than are non-MS endothelial cells. Perivascular DCs also express high levels of granzyme B in inflammatory lesions, polarizing nave CD4+ T cells into Th17 cells. These Th17 cells transmigrate efficiently across BBB endothelial cells (BBB-ECs), leading to the destruction of human neurons and initiating CNS inflammation through Th-cell recruitment [70]. Similarly, the expression of IL17R and IL22R on BBB-ECs has been examined in MS lesions, and IL17 and IL22 have been shown to disrupt BBB tight junctions in vitro and in vivo. IL6 transsignaling may also play a role in the autoimmune inflammation of the CNS, mainly by regulating the early expression of adhesion molecules, possibly via cellular networks at the BBB [71]. Ifergan et al. demonstrated that a subset of CD14+ monocytes migrate across the inflamed human BBB and differentiate into CD83+CD209+ DCs under the influence of BBB-secreted TGF and granulocyte-macrophage colony-stimulating factor (GM-CSF). These DCs can produce IL12p70, TGF, and IL6 and promote the proliferation and expansion of distinct populations of Th1 and Th17 cells. The abundance of such DCs in situ is strongly associated with microvascular BBB-ECs within acute MS lesions and with a significant number of Th17 cells in the perivascular infiltrate [72].Astrocytes play significant physiological roles in CNS homeostasis and act as a bridge between the CNS and the immune system. Astrocytes also contribute to the complex interactions during CNS inflammation. IL17 functions in a synergistic manner with IL6 to induce IL6 expression in astrocytes. Astrocytes upregulate the expression of IL17 and IFN genes and proteins in T cells, which is consistent with the astrocytes' capacity to express IL23 subunit p19 and the common IL12/IL23 subunit p40, but not IL12 subunit p35 when these two cell types are cocultured [73]. Das Sarma et al. demonstrated increased IL17RA expression in the CNS of mice with EAE and the constitutive expression of functional IL17RA in mouse CNS tissues. They also identified the expression of IL17RA in both astrocytes and microglia in vitro. In that study, the secretion of the chemokines Mcp1, Mcp5, Mip2, and CxcL1 was upregulated in these cells, suggesting that the upregulation of chemokines by glial cells is the result of IL17A signaling through constitutively expressed IL17RA [74].Ma et al. demonstrated that the suppressor of cytokine signaling 3 (Socs3) participates in IL17 functions in the CNS as a negative feedback regulator, using mouse models of Socs3 small interfering RNA (siRNA) knockdown and Socs3 deletion. These mice with loss of Socs3 function showed enhanced IL17 and IL6 signaling in astrocytes via the activation of the NF-B and Mapk pathways, indicating that astrocytes can act as a target of Th17 cells and IL17 in the CNS [75]. Similarly, Kang et al. constructed specific deletion mutants of Act1, a critical component required for IL17 signaling, in mice with EAE to examine CNS inflammation in endothelial cells, macrophages, microglia, and the neuroectoderm (neurons, astrocytes, and oligodendrocytes). In these Act1-deficient mice, Th17 cells showed normal infiltration into the CNS but failed to recruit lymphocytes, neutrophils, and macrophages. Therefore, astrocytes are critical in IL17Act1-mediated leukocyte recruitment during EAE [76].Interestingly, Merkler et al. demonstrated that macrophages respond to the Th1 milieu and neutrophils respond to Th17 cytokines in a marmoset monkey model of EAE. They also showed dense accumulations of T and B lymphocytes, MHC-II-expressing macrophages/microglia, and early activated macrophages at the sites of perivascular and parenchymal lesions in the neocortex and subcortical white matter, indicating that the inflammatory response, especially macrophage and microglia activation, may be regulated differently in the gray matter areas of the primate brain [77].In summary, DCs in the peripheral tissues and microglia in the CNS are responsible for cytokine polarization and the expansion of Th17 cells. The complex interactions of Th17 cells with different DCs, such as microglia, astrocytes, and peripheral DCs (including neutrophils and macrophages), all contribute to the immunopathogenesis of EAE and MS.IL1R KO mice have impaired Th17 cells and are protected from EAE [78], and IL1 increases the susceptibility to and progression of relapse onset in MS [79], implying a role for IL1 in the development of EAE and MS. EAE was abolished by a virus-expressing IL4 but not by a virus-expressing IL10 in chronic relapsing EAE. Therefore, the cytokine environment was converted from a disease-promoting IL23-producing condition to a disease-limiting IL4-producing condition by the local expression of IL4 from a Herpes simplex virus vector delivered to the brain [80]. Moreover, the increased expression of IL4 in glial cells was associated with the reduced severity of EAE [81], suggesting that the upregulation of Th2 cytokines inhibits the propagation of the inflammation of EAE/MS by encephalitogenic Th17 cells. CD4+CD25+Foxp3+ T cells, well-known regulatory T cells (Tregs), retain the potential to inhibit the autoimmune response, and protect against inflammatory injury. TGF is a key cytokine in the generation of Tregs. Tregs are not only primarily involved in the regulation of Th17 cells but can also regulate the functions of Th1/Th2 cells [82]. A distinction has been drawn between the generation of pathogenic Th17 cells that induce autoimmunity and the generation of Tregs that inhibit autoimmune tissue injury [39].Although EAE was once considered a classical Th1 disease, it has been proposed that it is predominantly Th17 driven. Recently, Singh et al. demonstrated that the overexpression of IL17 in T cells did not exacerbate EAE. Moreover, genetic and antibody studies have indicated that the absence of IL17A or IL17F does not reduce the incidence or severity of EAE. The collective findings of IL17 and IFN studies indicate that their roles may depend on the nature of the immune response and that the IL17 that occurs in the brain may overcome the inhibitory effect of IFN, which generally prevents inflammation at that site [83]. When pure Th17 cells from myelin oligodendrocyte glycoprotein-(MOG-) immunized mice, polarized with TGF to deplete any IFN production, are adoptively transferred to mice, they do not induce EAE, suggesting that the reciprocal interactions among Th17-related cytokines enrol and activate the involvement of associated immune cells. Interestingly, when Th17 cells are combined with Th1 cells, they can fully induce EAE disease [84]. Liu et al. also demonstrated that the loss of STAT3 by Th cells results in an intrinsic developmental defect that renders STAT3/ mice resistant to CNS inflammatory diseases. STAT3 is required for the production of IL17 by Th17 cells, the generation of double positive T cells expressing IL17 and IFN, and T cell trafficking into CNS tissues. This suggests that STAT3 may be a therapeutic target for modulating CNS autoimmune diseases, and that Th1 cells can facilitate the entrance of Th17 cells into the CNS during EAE [85].An encephalitogenic Th1 cell line that induces the recruitment of host Th17 cells to the CNS during the initiation of EAE has been reported [49]. Stromnes et al. showed significant differences in the regulation of inflammation in the brain and spinal cord, depending on different Th17/Th1 ratios, by demonstrating that specific T-cell populations targeting different myelin epitopes are characterized by different Th17/Th1 ratios in EAE [86]. Therefore, Th1 cells have the potential to reciprocally regulate Th17 cells during EAE.IL21 is a type I four--helix bundle cytokine that belongs to the IL2 family and functions as a growth hormone-like cytokine. After the antigen-responsive differentiation phase, Th17 cells enter the amplification stage, and IL21 plays a pivotal role in the expansion and differentiation of the Th17 lineage, providing an autocrine and paracrine stimulus for Th17 cells [41, 87]. During clonal expansion, IL21 also promotes IL23R expression in differentiated Th17 cells, which plays an important role in the stabilization of the Th17 lineage in the presence of IL23 [88]. Although no effects were observed when Il21 was administered after EAE progression, the administration of IL21 boosted natural killer (NK) cell functions before the induction of EAE, including the secretion of Ifn. Therefore, IL21, by affecting NK cells, has various effects during the initiation and progression of EAE [89].Alternatively, IL27, an IL12/IL23 family member, is a negative regulator of Th17 cell differentiation and can prevent inflammatory demyelination in the EAE model [44]. IL27 drives the expansion and differentiation of IL10-producing Tr1 cells by inducing the expression of three key molecules: the transcription factor c-MAF, the cytokine IL21, and ICOS. Moreover, IL27-driven c-MAF expression transactivates the production of IL21, which acts as an autocrine growth factor for the expansion and/or maintenance of IL27-induced Tr1 cells. ICOS also promotes IL27-driven Tr1 cells. Each of these elements is essential, because the loss of c-MAF, IL21 signaling, or ICOS reduces the frequency of IL27-induced differentiation of Tr1 cells (Figure 1) [90]. Exacerbation of EAE was demonstrated in IL27-deficient mice, and interestingly, Il27-treated mice had markedly reduced CNS inflammatory infiltration, indicating the downregulation of Th17 phenomena [91].Recently, a novel effector T-cell subset, Th9 cells, has been identified, and the ability of this T-cell subset to induce EAE is currently being investigated. Jger et al. generated Mog-specific Th17, Th1, Th2, and Th9 cells in vitro to directly characterize their encephalitogenic potency after their adoptive transfer. They found that Mog-specific Th1, Th17, and Th9 cells, but not Th2 cells, induce EAE. Interestingly, each T-cell subset induced disease in a distinct pathological manner, suggesting that the different effector Th subsets that induce EAE do so differently and implying that the pathological heterogeneity in MS lesions might be partly attributable to various characteristics of myelin-reactive effector T cells [92]. The authors also suggested that MS might be a disease caused by multiple distinct myelin-reactive effector cells. The disease induced by Th17 cells in some animals exhibited symptoms atypical of EAE, including ataxia, severe imbalance, and weight loss associated with high mortality. Some animals had a mixture of atypical and typical EAE symptoms. When cells were recovered from the CNS, it appeared that the transferred Th9 cells produced IFN. The identities of the other cell populations did not seem to drift after their in vivo transfer [93].Nowak et al. recently demonstrated that like other T cells cultured in the presence of TGF, Th17 cells produce IL9. Th17 cells generated in vitro with IL6 and TGF and ex vivo-purified Th17 cells both produced IL9. Data show that IL9 neutralization and IL9R deficiency attenuate the disease, and this correlated with reductions in Th17 cells and IL6-producing macrophages in the CNS. These authors also confirmed the role of IL9 in the development and progression of EAE and implicated Il9 as a Th17-derived cytokine that contributes to inflammatory disease [94].Together, Th2 cells, Tr1 cells, and Tregs exert repressive effects on Th17 cells, and Th9 cells have a stimulatory effect on Th17 cells, suppressing EAE and MS. However, Th1 cells play dual roles in EAE.Our understanding of the pathophysiology and neurodegenerative processes of MS has led to the development of novel therapeutic strategies. Since the early 1990s, disease-modifying drugs have been introduced for the selective management of MS, including IFN and glatiramer acetate (GA), which have become the standard treatment for relapsing/remitting MS [95]. Most recommendations previously made by the Multiple Sclerosis Therapy Consensus Group (MSTCG) on the use of disease-modifying drug therapies remain valid [96, 97]. Hermmer and Hartung have published an apparent review of the development of rational therapies in MS [98]. Therefore, we will discuss four domains of novel immunomediated therapeutics used for MS and their current status.The first domain includes immunosuppressive agents, such as mitoxantrone, laquinimod (ABR-215062), cladribine (Mylinax ), and teriflunomide (probably via the suppression of TNF and IL2 production). The second domain includes immunomodulatory agents: (1) cytokine inhibitors such as IFN; (2) agents that deplete specific immune cell subsets, such as alemtuzumab (a human monoclonal antibody [mAb] that targets CD52 expressed by T and B cells, producing long-term T-cell depletion) [99, 100] and rituximab (which targets CD20 to deplete human B cells) [99, 101]; (3) agents that selectively block coreceptors and costimulators, such as daclizumab (an anti-CD25 mAb that inhibits activated T cells and induces regulatory immune cells) [102]. The third domain involves the development of migration-modifying therapies: (1) agents that affect adhesion molecules, such as natalizumab (an mAb that blocks very late antigen 4 [VLA-4]) and (2) sphingosine 1-phosphate receptor (S1PR) agonists: fingolimod (FTY720). The fourth domain includes neuroprotective agents associated with immunomodulation, including broad-spectrum immunomodulators such as statins, PPAR agonists (e.g., pioglitazone, gemfibrozil), the sex hormone estriol (E3), fumarate, minocycline, and erythropoietin (EPO), all of which have been effective in the treatment of both EAE, and MS. IFN has been clinically introduced to treat patients with MS based on its ability to shift a Th1-mediated response to a Th2-mediated response [92]. However, microarray studies have indicated that a number of genes in patients with MS are upregulated by the cytokines associated with the differentiation of cells into Th1 lymphocytes rather than into Th2 lymphocytes, suggesting that this shift may not be the only therapeutic mechanism of IFN in MS [103]. IFN therapy also reduces IL23 mRNA levels [104]. IFN inhibits human Th17 cell differentiation, so the Th17 axis could be another target of IFN therapy [105]. IFN-mediated IL27 production by innate immune cells has been shown to play a critical role in the immunoregulatory role of IFN in EAE by inhibiting Th17 cells in EAE mice and MS patients [91, 106, 107]. Besides, Galligan et al. evidence further that IFN(/) mice exhibited an earlier disease onset and a more rapid progression of EAE compared to IFN(+/+) mice of EAE and IFN(/) mice of EAE had increased numbers of CD11b(+) leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the CNS with augmentation of autoreactive T cells,suggesting that IFN- acts to suppress the production of autoimmune-inducing Th17 cells during the development of disease as well as modulating proinflammatory [108]. In addition, the therapeutic effect of IFN is probably attributable to the induction of the regulatory cytokine IL10 [104]. Furthermore, Axtell et al. design a delicate study to further clarify the role of IFN in MS/EAE [109]. Likewise, They demonstrate that IFN was effective in reducing EAE symptoms transferred by Th1 cells transfer but exacerbated disease by Th17 cells transfer and effective treatment of IFN in Th1-induced EAE correlated with augmented IL10 production; differently, in Th17-induced EAE, the amount of IL10 was unaffected by treatment of IFN. Likewise, a high IL17F level in the serum of people with RRMS is associated with fail of IFN therapy. This characteristic of IFN might contribute to explore some logical biomarkers for predictive assessment of the response to a popular therapy for MS [109, 110]. Although, B cells may have a dual role in the pathogenesis of MS that they contribute to the induction of the autoimmune response but also mediate the resolution of the CNS inflammatory infiltrate [111, 112]. However, Ramgolam et al. demonstrate further that supernatants transferred from IFN-1b-treated B cells inhibited Th17 cell differentiation, as they suppressed gene expression of the RORC and IL-17A and secretion of IL-17A. Likewise, IFN-1b also induces B cells' IL-10 secretion which may mediate their regulatory potent [113]. Thus, IFN-1b exerts its therapeutic effects at least in part by targeting B cells' functions that contribute to the autoimmune pathogenesis of RR MS, which may uncover extra mechanisms of the B-cell contribution to the autoimmune effects and provide novel targets for future selective treatment of MS [113].Glatiramer acetate (GA; Copaxone; copolymer 1) exerts a clinical response in MS patients via its modulation of IFN and IL4 by reducing the expression of IFN and ensuring the stable expression of IL4 in anti-CD3/CD28-stimulated peripheral blood mononuclear cells (PBMCs) [114]. Moreover, GA enhances the suppressive effects of Tregs in both EAE and MS [115, 116]. Studies of human DCs have shown that GA modulates the production of inflammatory mediators without affecting DC maturation or immunostimulatory potential. DCs exposed to GA secrete low levels of the Th1-polarizing factor IL12p70 in response to lipopolysaccharide and triggering of the CD40 ligand [117]. Human DCs exposed to GA also induce IL4-secreting effector Th2 cells and increase their expression of IL10 [118]. These results show that APCs, including DCs, are essential for the GA-mediated shift in Th-cell phenotypes and indicate that DCs are an important target of the immunomodulatory effects of GA.Patients with MS show a threefold to fourfold increase in the expression of the 4 subunit of the integrin VLA-4, which is normally expressed on activated lymphocytes, monocytes, and other cell types in the CSF and circulation [119]. Elovaara et al. confirmed that methylprednisolone reduces the adhesion molecules in the blood and CSF in patients with MS [120], implying that targeting leukocyte trafficking may be a possible therapeutic strategy for MS [121]. Therefore, natalizumab, a humanized mAb directed against the VLA-4 adhesion complex, has been introduced into the treatment of MS and reduces the risk of sustained progression of disability and the rate of clinical relapse in patients with relapsing MS [122]. However, during clinical trials, two natalizumab-treated MS patients developed progressive multifocal leukoencephalopathy (PML), which resulted in the voluntary removal of the drug from the market in February 2005 [123, 124]. A retrospective safety evaluation was subsequently conducted, and natalizumab was consequently returned to the market as a monotherapy in July 2006 for the treatment of relapsing MS; however, there were 111 cases of PML reported subsequently in natalizumab-treated MS patients as of April 2011 [125]. More evidently, the risk of developing PML for a MS patient on natalizumab (Tysabri) is almost 100 times higher if the patient (1) has been taking the drug for more than two years, (2) has a prior history of immunosuppressant use, and (3) tests positive for antibodies to the JC virus [126], compared to a patient with none of these three risk factors [127]. Instead, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents [128]. Nevertheless, natalizumab use must be restricted to the indicated patients.Mitoxantrone, a cytotoxic drug with immunomodulatory properties, is used to treat progressive forms of MS [129]. Mitoxantrone increases the ex vivo production of the Th2 cytokines IL4 and IL5, but with no significant changes in IFN, TNF, IL10, or IL17 expression by PBMCs or CD4+ T cells, indicating that the immunomodulation afforded by mitoxantrone treatment in MS acts through the enhancement of Th2-type cytokines [130].Currently, a head-to-head race for approval had initially developed between two under spotlight oral immunomodulatory agentsfingolimod and cladribine (Figure 2) [131]. Fingolimod (FTY720/Gilenya, Novartis), an S1PR modulator [132], is under the spotlight because it has completed phase III trials [133] and has been approved by the US Food and Drug Administration as the first oral, first-line treatment for relapsing MS [134, 135]. S1PR is mainly expressed by immune cells, neuronal cells, endothelial cells, and smooth muscle cells [136139]. The key roles of S1PR in angiogenesis, neurogenesis, and the regulation of immune cell trafficking, endothelial barrier function, and vascular tone were demonstrated with the genetic deletion of S1pr in a murine model [140142]. The immunomodulatory effect of fingolimod acts in two pathways. In one pathway, it inhibits the function of S1PR, which facilitates the CC-chemokine receptor 7-(CCR7-) mediated retention of lymphocytes in the lymph nodes, including nave T cells and central memory T cells, but not effective memory T cells. This significantly reduces the infiltration of inflammatory cells into the CNS [143, 144] and reduces the numbers of autoreactive Th17 cells that are recirculating via the lymph and blood to the CNS [145147]. The second pathway prohibits neuroinflammation via the modulation of the S1PR1 expressed on oligodendrocytes, neurons, astrocytes, and microglia [76, 148, 149]. Another oral immunomodulatory drug Cladribine (2-chlorodeoxyadenosine) is a synthetic chlorinated deoxyadenosine analog [150] that is activated by intracellular phosphorylation in specific cell types, resulting in preferential and sustained reduction of peripheral T and B lymphocytes, mimicking the immune-deficient status of hereditary adenosine deaminase deficiency [151]. Orally administered cladribine shows significantly efficacy in patients with RR-MS [152]. Relative to placebo, oral cladribine reduces relapses by 5558% and has an impact on disability progression and all MRI outcome markers in patients with RR-MS [152154]. Nevertheless, to exactly weight the benefits of both novel immunomodultory agents against the potential risks is necessary and must be monitored continually. These advances in identifying unique therapeutic targets for MS have instigated numerous phase II and phase III clinical trials, for example, trials of various mAbs, including those directed against CD52 (alemtuzumab), CD25 (daclizumab), and CD20 (rituximab), and trials of disease-modifying therapies, such as teriflunomide, laquinimod, and fumarate [135, 155]. For example, alemtuzumab, a humanized mAb, targets the surface molecule CD52 on all T-cell populations and other cellular components of the immune system, such as thymocytes, B cells, and monocytes [156].Offner reported that estrogen and its derivatives exert neuroimmunoprotective effects against EAE and that E2 upregulates the expression of Foxp3 and Ctla4, which contribute to the activity of Tregs, suggesting the therapeutic application of estrogen to MS [157]. Papenfuss et al. also demonstrated that estriol (E3), a pregnancy-specific estrogen, has therapeutic efficacy in MS and EAE and they confirmed that E3 protects mice against EAE by inducing DCs to increase their expression of inhibitory costimulatory markers (PD-L1, PD-L2, B7-H3) and deviate towards a Th2 phenotype [158].Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily, which includes receptors for steroids, retinoids, and thyroid hormones, all of which are involved in the immune response [159]. Natarajan et al. demonstrated that PPAR agonists inhibit EAE by blocking IL12 production, IL12 signaling, and Th1 cell differentiation [160]. Kanakasabai et al. further demonstrated that the PPAR agonists ameliorate EAE by blocking IFN and IL17 production by Th1 and Th17 cells. The inhibition of EAE by PPAR agonists is also associated with reductions in IL12 and IL23 and increases in IL4 and IL10 expression in the CNS and lymphoid organs. This indicates that PPAR agonists modulate the Th1 and Th17 responses in EAE, and suggests their use in the treatment of MS and other autoimmune diseases [161].Minocycline, an oral semisynthetic tetracycline antibiotic, can penetrate the CNS and has interesting pleiotropic biological functions and neuroprotective effects, including in demyelinating diseases such as MS [55]. Nikodemova et al. have shown that minocycline attenuates EAE in rats by reducing T-cell infiltration into the spinal cord and downregulating LFA-1 on T cells, but without modifying the production of dominant cytokines [162]. Zabad et al. demonstrated in a cohort study the impact of oral minocycline on clinical and MRI outcomes and serum immune molecules during the 24 months of open-label minocycline treatment. No relapses occurred between months 6 and 24, and the levels of the p40 subunit of IL12 were elevated during the 18 months of treatment, which might have counteracted the proinflammatory effects of IL12R. The downregulation of MMP9 activity was reduced by minocycline treatment [163].Brines et al. have demonstrated that EPO mediates neuroprotection against experimental ischemic brain injury [164]. Agnello et al. have shown that EPO exerts an anti-inflammatory effect that ameliorates EAE [165]. Yuan et al. also demonstrated that EPO retains its immunomodulatory capacity in both the periphery and the inflamed spinal cord by promoting a massive expansion of Treg cells, inhibiting Th17 polarization and abrogating the proliferation of antigen-presenting DCs [166]. We observed significantly reduced levels of both Th1 and Th17 cells in the CNS and a significantly increased proportion of splenic Tregs in EPO-treated Mog-EAE mice. We also demonstrated that MOG-specific T-cell proliferation was suppressed in the EPO-treated group [167].The immunomodulatory mechanisms of immunomediated therapeutic agents are not fully understood. Here, we report our current understanding of the immunomodulatory effects of clinically proven and clinically tried agents, and of potential candidate agents, such as decoy receptor 3 (DcR3). We have selectively reviewed their immunomodulation in EAE and MS. Demjen et al. showed that the neutralization of CD95L (FasL) promoted axonal regeneration and functional improvement in an injured animal model, suggesting that this therapeutic strategy may constitute a potent future treatment for human spinal injury [168]. DcR3 is a recognized member of the TNFR superfamily and is predominantly expressed in tumor cells, allowing them to evade immune attack [169]. DcR3 is a soluble receptor that binds to members of the TNF family and can competitively inhibit the binding of TNF to TNFRs [170]. FasL, LIGHT, and TNF-like molecule 1A (TL1A) are all confirmed ligands of DcR3 [171, 172]. When DcR3 binds to FasL, it inhibits FasL-induced apoptosis [169]. It has also recently been shown that DcR3 counteracts the effects of Th17 cells by interfering with FasL-Fas interactions [173]. We have demonstrated that DcR3 ameliorates EAE by directly counteracting inflammation and downregulating Th17 cells in situ [174], implying that DcR3 downregulates the Th17 response and inhibits the inflammation of the CNS in situ during EAE by blocking ligand-receptor interactions, such as Fas-FasL, DR2LIGHT, and/or DR3TL1A. Therefore, we introduce DcR3, another immunomodulatory molecule, as a potential candidate for consideration in the clinical treatment of MS.In summary (Figure 2), these immunomodulatory agents and neuroprotective therapies for MS have great value as clinical agents, to be tested in clinical trials or preclinical studies, and in the development of novel therapeutic strategies for MS [55].MS is the most common disabling CNS disease in young adults. It is characterized by recurrent relapses and/or progression, which are attributable to multifocal inflammation, demyelination, and axonal pathology within the brain and/or spinal cord [175]. The effector Th cells play a well-recognized role in the initiation of autoimmune tissue inflammation, and these autoreactive effector CD4+ T cells have an established association with the pathogenesis of this disorder [17]. However, in models thought to be driven by Th1 cells, mice lacking the hallmark Th1 cytokine IFN were not protected from EAE but tended to display enhanced susceptibility to this disease [26]. The identification of Th17 cells has shed light on this apparent discrepancy. Like Th1 cells, polarized Th17 cells have the capacity to cause inflammation and autoimmune disease. A deficiency of the Th17-related cytokine IL23, but not of the Th1-related cytokine IL12, induces resistance to EAE, implying that Th17 cells are the chief contributors to EAE/MS [28], whereas Th1 cells can consistently transfer EAE disease [16, 17]. Komiyama et al. demonstrated that EAE was significantly suppressed in Il17/ mice, manifested as delayed onset, reduced maximum severity, ameliorated histological changes, and early recovery [176]. However, the outcomes have varied when the differentiation and/or functions of Th17 cells have been blocked in clinical trials of human autoimmune diseases, with notable success only in psoriasis and Crohn's disease, but negative results in relapsing/remitting MS. The strategy of inhibiting the Th17 response has had even less support in preclinical studies in animal models [177].These data raise the questions of whether MS is mediated solely by Th1 cells or solely by Th17 cells, whether it is mediated by both pathways, or whether perhaps it is mediated by neither pathway [175]. There is growing evidence that autoreactive T cells (particularly Th1 and Th17 cells) participate in the pathophysiology of MS. Although the exact roles of Th1 and Th17 cells in the development of MS lesions are not well understood, it appears that both these effector T-cell populations can cause CNS inflammation and demyelinating lesions in MS and EAE [50, 178].Our increasing understanding of the immunopathogenic roles of Th1, Th2, and Th17 cells and Tregs in MS/EAE should facilitate the development of novel immunomodulatory therapeutic approaches to MS [179, 180]. The treatment of MS has always been hampered by the untoward adverse effects caused by immunosuppression with agents such as natalizumab [128]. Currently approved disease-modifying treatments achieve their effects primarily by blocking the proinflammatory response in a nonspecific manner. Their limited clinical efficacy calls for a more differentiated and specific therapeutic approach. We can confidently say that IFN, GA, and mitoxantrone are fairly clinically effective for MS patients. The addition of estrogen(s) or minocycline has also shown benefits in the treatment of MS. We have established the protective effects of DcR3 and EPO against EAE [174, 181], but further evidence is required before they can be used clinically for the treatment of MS. More immunomodulatory therapeutic agents are currently in clinical trials, including fingolimod (FTY720), alemtuzumab, and rituximab add-on therapies [182]. The extensive clinical application of these potential novel immunomodulatory therapeutic agents will be under close scrutiny in the near future.\n"
     ]
    }
   ],
   "source": [
    "print(dic_clusters_docs[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_document(document):\n",
    "    document = re.sub('\\n', ' ', document)\n",
    "    if isinstance(document, str):\n",
    "        document = document\n",
    "    elif isinstance(document, unicode):\n",
    "        return unicodedata.normalize('NFKD', document).encode('ascii','ignore')\n",
    "    else:\n",
    "        raise ValueError('Document is not string or unicode!')\n",
    "    document = document.strip()\n",
    "    sentences = nltk.sent_tokenize(document)\n",
    "    sentences = [sentence.strip() for sentence in sentences]\n",
    "    #print(sentences)\n",
    "    return sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "invalid syntax (<ipython-input-81-8c930608761d>, line 1)",
     "output_type": "error",
     "traceback": [
      "\u001b[0;36m  File \u001b[0;32m\"<ipython-input-81-8c930608761d>\"\u001b[0;36m, line \u001b[0;32m1\u001b[0m\n\u001b[0;31m    I am ignoring contractions.\u001b[0m\n\u001b[0m       ^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m invalid syntax\n"
     ]
    }
   ],
   "source": [
    "I am ignoring contractions."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "pip3 is /usr/bin/pip3\r\n"
     ]
    }
   ],
   "source": [
    "!type pip3\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "from nltk.corpus import wordnet as wn"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tokenize_text(text):\n",
    "    tokens = nltk.word_tokenize(text)\n",
    "    tokens = [token.strip() for token in tokens]\n",
    "    return tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_stopwords(text):\n",
    "    stopword_list = nltk.corpus.stopwords.words('english')\n",
    "    tokens = tokenize_text(text)\n",
    "    filtered_tokens = [token for token in tokens if token not in stopword_list]\n",
    "    filtered_text = ' '.join(filtered_tokens)\n",
    "    return filtered_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "def pos_tag_text(text):\n",
    "    text = nltk.word_tokenize(text)\n",
    "    tagged_text = nltk.pos_tag(text)\n",
    "    tagged_lower_text = [(word.lower(), penn_to_wn_tags(pos_tag))\n",
    "                         for word, pos_tag in\n",
    "                         tagged_text]\n",
    "    return tagged_lower_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "def penn_to_wn_tags(pos_tag):\n",
    "        if pos_tag.startswith('J'):\n",
    "            return wn.ADJ\n",
    "        elif pos_tag.startswith('V'):\n",
    "            return wn.VERB\n",
    "        elif pos_tag.startswith('N'):\n",
    "            return wn.NOUN\n",
    "        elif pos_tag.startswith('R'):\n",
    "            return wn.ADV\n",
    "        else:\n",
    "            return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "def lemmatize_text(text):\n",
    "    pos_tagged_text = pos_tag_text(text)\n",
    "    wnl = WordNetLemmatizer()\n",
    "    lemmatized_tokens = [wnl.lemmatize(word, pos_tag) if pos_tag\n",
    "                         else word                    \n",
    "                         for word, pos_tag in pos_tagged_text]\n",
    "    lemmatized_text = ' '.join(lemmatized_tokens)\n",
    "    return lemmatized_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "def normalize_corpus(corpus, lemmatize=True, tokenize=False):\n",
    "    normalized_corpus = []    \n",
    "    for text in corpus:\n",
    "        text = text.lower()\n",
    "        text = remove_stopwords(text)\n",
    "        #print(type(text))\n",
    "        #print(text)\n",
    "        text = re.sub(r'[^a-zA-Z0-9\\s]', '', text,flags=re.I|re.A)\n",
    "        text = re.sub(r'[0-9]','',text)\n",
    "        if lemmatize:\n",
    "            text = lemmatize_text(text)\n",
    "        if tokenize:\n",
    "            text = tokenize_text(text)\n",
    "            normalized_corpus.append(text)\n",
    "        else:\n",
    "            normalized_corpus.append(text)\n",
    "    return normalized_corpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [],
   "source": [
    "import networkx\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [],
   "source": [
    "def summarize(doc,n_top=10):\n",
    "    sentences = parse_document(doc)\n",
    "    print(len(sentences))\n",
    "    norm_sentences = normalize_corpus(sentences)\n",
    "    vectorizer = TfidfVectorizer(min_df=0)\n",
    "    dt_matrix = vectorizer.fit_transform(norm_sentences)\n",
    "    similarity_matrix = (dt_matrix*dt_matrix.T)\n",
    "    similarity_graph = networkx.from_scipy_sparse_matrix(similarity_matrix)\n",
    "    networkx.draw_networkx(similarity_graph)\n",
    "    scores = networkx.pagerank(similarity_graph)\n",
    "    sentences_rank = sorted(((score,index) for index,score in scores.items()),reverse=True)\n",
    "    #print(sentences_rank)\n",
    "    top_indices =[sentences_rank[index][1] for index in range(n_top)]\n",
    "    print(top_indices)\n",
    "    summary=[sentences[index] for index in top_indices]\n",
    "    #print(summary)\n",
    "    return summary\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [],
   "source": [
    "l=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [],
   "source": [
    "l.append((1,2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(1, 2)]"
      ]
     },
     "execution_count": 135,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "155\n",
      "[51, 49, 75, 22, 7, 105, 8, 2, 43, 60]\n",
      "['However, lower respiratory symptoms, such as wheeze, sputum, and hypoxemia, were only seen in patients with newly appearing findings on chest CT. Bacterial culture for respiratory specimens was performed in six cases, and bacteria were detected in three cases; however, no patient was diagnosed with bacterial pneumonia or treated with targeted antibiotics against these detected bacteria.', 'Five cases (63%) had newly appearing abnormal findings on chest CT; however, no abnormal findings were detected by chest X-ray in 3 of those 5 patients (60%).', 'The few reports of 18 F-FDG PET/CT in patients with COVID-19 currently available, describe in all cases symptomatic patients with common COVID-19 manifestation including fever, cough, shortness of breath, myalgia and fatigue (1, 2) .', '8 Furthermore, no patients with IBD with SARS-CoV-2 infection have been reported from the three largest tertiary IBD centres in Wuhan (Tongji Hospital, Union Hospital, and Zhongnan Hospital) at the time that this manuscript was prepared (March 8, 2020) .Several strategies have been implemented in China to minimise the potential risk of SARS-CoV-2 infection in patients with IBD since the outbreak of COVID-19.', 'In the study 2 of 1099 patients with laboratoryconfirmed COVID-19, 261 (237%) patients with COVID-19 reported having at least one comorbidity, with hypertension, diabetes, and coronary heart disease being the most common.', 'Outcome of nontuberculous mycobacteria infections in transplant patients is highly variable (1,5) but was satisfactory in the present patient, who was treated with quintuple antimicrobialdrug therapy and reduced immunosuppressive therapy.This case of a disseminated infection due to M. genavense in a heart transplant recipient was diagnosed early.', 'In this study, 2 23 (21%) patients had hepatitis B infection.', 'As of March 8, 2020, more than 105 000 laboratoryconfirmed cases and more than 3500 deaths in over 100 countries had been reported.Since SARS-CoV-2 RNA was first detected in a stool specimen of the first reported COVID-19 case in the USA, 1 much attention has been paid to the study and reporting of gastrointestinal tract infection of SARS-CoV-2.', 'In addition, reports investigating the correlation between the clinical manifestations and abnormal findings on chest CT remain rare (14).In 2014, a genetically identical RSV outbreak occurred in the hemato-oncology ward of the University of the Ryukyus Hospital (15), and a subset of RSV-infected patients underwent both chest X-ray and CT during the outbreak.', '1, 2, 5).Chest CT showed variable findings for RSV infection, even during an outbreak setting.']\n",
      "235\n",
      "[133, 33, 123, 145, 108, 191, 42, 92, 107, 228]\n",
      "['These authors also confirmed the role of IL9 in the development and progression of EAE and implicated Il9 as a Th17-derived cytokine that contributes to inflammatory disease [94].Together, Th2 cells, Tr1 cells, and Tregs exert repressive effects on Th17 cells, and Th9 cells have a stimulatory effect on Th17 cells, suppressing EAE and MS.', 'In humans, nave CD4+ cells exposed to IL6, TGF, and IL21 can develop into Th17 cells, and the production of IL23 plays a role in maintaining these Th17 cells [40, 41].', 'They found that Mog-specific Th1, Th17, and Th9 cells, but not Th2 cells, induce EAE.', 'IFN-mediated IL27 production by innate immune cells has been shown to play a critical role in the immunoregulatory role of IFN in EAE by inhibiting Th17 cells in EAE mice and MS patients [91, 106, 107].', 'This suggests that STAT3 may be a therapeutic target for modulating CNS autoimmune diseases, and that Th1 cells can facilitate the entrance of Th17 cells into the CNS during EAE [85].An encephalitogenic Th1 cell line that induces the recruitment of host Th17 cells to the CNS during the initiation of EAE has been reported [49].', 'further demonstrated that the PPAR agonists ameliorate EAE by blocking IFN and IL17 production by Th1 and Th17 cells.', 'In humans, IL23 and IL1 also induce the development of Th17 cells expressing IL17A, IL17F, IL22, IL26, IFN, the chemokine CCL20, and the transcription factor ROR [5153], as illustrated in Figure 1 (adapted from Hirota et al.', 'The complex interactions of Th17 cells with different DCs, such as microglia, astrocytes, and peripheral DCs (including neutrophils and macrophages), all contribute to the immunopathogenesis of EAE and MS.IL1R KO mice have impaired Th17 cells and are protected from EAE [78], and IL1 increases the susceptibility to and progression of relapse onset in MS [79], implying a role for IL1 in the development of EAE and MS. EAE was abolished by a virus-expressing IL4 but not by a virus-expressing IL10 in chronic relapsing EAE.', 'STAT3 is required for the production of IL17 by Th17 cells, the generation of double positive T cells expressing IL17 and IFN, and T cell trafficking into CNS tissues.', 'Although the exact roles of Th1 and Th17 cells in the development of MS lesions are not well understood, it appears that both these effector T-cell populations can cause CNS inflammation and demyelinating lesions in MS and EAE [50, 178].Our increasing understanding of the immunopathogenic roles of Th1, Th2, and Th17 cells and Tregs in MS/EAE should facilitate the development of novel immunomodulatory therapeutic approaches to MS [179, 180].']\n",
      "106\n",
      "[17, 6, 49, 52, 51, 54, 18, 13, 59, 53]\n",
      "['Human myelin basic protein (MBP)-specific T cell clones with degenerate peptide recognition were found to cross-react with a number of microbial peptides whereas T cell clones that were more specific cross-reacted only with one or two microbial peptides (M Martin and K Wucherpfennig, unpublished data).', 'This review will discuss the structural requirements for the activation of autoreactive T cells by microbial peptides in the development of human autoimmune diseases.Specificity versus the degeneracy of T cell receptor recognition MHC molecule binding of peptides is highly degenerate; a given MHC molecule will bind peptides from the majority of antigens when a set of overlapping antigen-derived peptides is tested.', 'Notably, the T cell clones that cross-reacted with a diverse set of microbial peptide sequences were not stimulated by these random peptide libraries indicating that such a level of degeneracy in peptide recognition is not required for T cell cross-reactivity with microbial peptides (M Martin, K Wucherpfennig, unpublished data).Another interesting aspect of the MBP(85-99) peptide is the fact that it also represents the immunodominant antibody epitope of MBP [34] .', 'Due to the similarity between the antibody and T-cell epitopes, a human papillomavirus peptide was recognized both by MBP-specific antibodies and by a MBP(85-99)-specific T cell clone [35] .Taken together, the analysis of MBP-specific T cell clones from MS patients demonstrates that microbial peptides with limited sequence homology are effective activators of autoreactive T cells.', 'Important differences, however, in the antibody and T cell epitopes were: firstly, a longer peptide was required for optimal T cell stimulation than for antibody binding, and secondly, sequence identity was required at every peptide position in the core of the antibody epitope whereas the MHC molecule contact residues in the T cell epitope could be substituted by other amino acids.', 'Other cross-reactive peptides of the MBP(85-99) Table 1 Examples of experimentally determined T cell cross-reactivity between self and microbial peptides in human autoimmune diseases.Organism/pathogen Antigen Sequence alignment* and reference Multiple sclerosis [3] CD4 + T cell clones HLA-DR2b-or HLA-DQ1 restricted Cross-reactive T-cell epitopes have also been identified for autoantigens in other human autoimmune diseases (Table 1) .', 'Each TCR peptide-contact residue could be substituted by at least one structurally related amino acid for T cell clones with degenerate peptide recognition; clones that were more specific required amino acid identity at the primary TCR peptide-contact residues (M Martin and K Wucherpfennig, unpublished data).', 'The specificity of the adult TCR repertoire is a balance between two possible extremes: highly specific TCRs that require particular amino acids at many positions of the MHC molecule-bound peptide and highly degenerate TCRs that only require certain sequence features in the MHC molecule-bound peptide and therefore cross-react with many different microbial peptides.', 'The development of autoimmunity by microbial antigens has also been studied by immunization with microbial Activation of autoreactive T calls by pepUdes from human pathogens Hausmann and Wucherpfennig 835 Table 2 Examples of experimentally determined T cell cross-reactivity between self and microbial peptides in experimental animal models.Experimental model and reference Organism/pathogen Antigen Sequence alignment* Experimental autoimmune uveitis [39] Lewis rats immunized with foreign peptidesExperimental ovarian autoimmune disease [40] B6AF antigens/peptides that have sequence homology with immunodominant T-cell epitopes ( Table 2 ).', 'These results make it unlikely that a single microbial peptide is responsible for the activation of autoreactive T cells in human autoimmune diseases.']\n",
      "109\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[13, 50, 20, 34, 104, 56, 81, 43, 17, 46]\n",
      "['This study is the first report of the outbreak of acute respiratory infection caused by adenovirus, occurred on school in Korea.On May 19, 2017, the cluster of acute respiratory infections due to adenovirus in the swimming department of a physical education school (School J) was reported to Korea Centers for Disease Control and Prevention (KCDC).', 'There were 14 identified cases in Study 2, and all of them were students.', 'As all students with respiratory symptoms were identified as members of the departments using the swimming pool (swimming and modern sports) at the on-site investigation performed on May 22, a retrospective cohort investigation (Study 1) was conducted instantaneously on 59 students and teachers who had been using the swimming pool.', 'In Study 1, a total of 33 cases were identified, of which 12 were confirmed cases and 21 were suspected cases and the attack rate was 55.9% (33/59).', 'Therefore, to identify the cause and the transmission routes, it is necessary to perform systematic investigation at the initiation of the investigation, and to identify the characteristics of the epidemic via in-depth investigation on the initial cases.In conclusion, 18 confirmed adenovirus respiratory infection cases and 29 suspected cases were identified in one physical education school in Korea.', 'In Study 2, being a member of the shooting department (RR: 20.70; 95% CI: 4.90 - 87.47) and being a first grade student of high school (RR: 10.95; 95% CI: 2.90 - 41.33) were identified as risk factors for infections, according to the results of multivariable logistic regression (Table 3).Adenovirus was detected in throat swabs in 11 out of 12 confirmed cases in Study 1, and the duration from symptom onset to specimen collection was 1 to 8 days (median 5 days).', 'The interval between the peak in the epidemic curve was 2-9 days, which was similar to the incubation period of acute respiratory infection caused by adenovirus (2-14 days) [23].This epidemic was initiated in student of the modern sports department using the swimming pool, spread in the swimming department, and transmitted to other students in other departments who were not using the swimming pool (Fig.', '1).In Study 2, a total of 14 cases were identified, of which 6 were confirmed cases and 8 were suspected cases; the attack rate was 3.9% (14/362).', 'Cases from April 10 (14 days before the first identified case) to July 2 (14 days after the last identified case) are included, and cases who tested positive for virus other than adenovirus on PCR tests are excluded.The physical education school J is an integrated school specialized in athletics education consisting of 12 classes, 2 classes per grade, with a total of 6 grades including middle and high school.', 'The outbreak period was 56 days.There were 33 identified cases in Study 1, of which 32 were students and 1 was a swimming teacher.']\n",
      "87\n",
      "[54, 85, 30, 43, 79, 77, 75, 64, 81, 33]\n",
      "['CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint The measures introduced by the UK Government appear to have high levels of uptake among participants and have resulted in very large (73%) reductions in the total number of contacts.', 'The column Have been in shows the total number of people who reported having been in quarantine or isolation for at least one day in the seven days before the survey.. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .', 'We present the number and percentage or mean and standard deviation where appropriate (Table 3) .We calculated the average number of social contacts per person per day overall, and stratified by age category, sex, household size, location of contact, type of contact, and day of the week.We then compared the mean total number of daily contacts by age group to POLYMOD stratified by contact location.We calculated social contact matrices for the age-specific daily frequency of direct social contacts, adjusting for the age distribution in the study population and reciprocity of contacts, using the socialmixr package in R 15 .As children (<18 years) were not included as survey participants, we imputed contacts for younger age groups (child-child and child-adult contacts) using the POLYMOD UK data.', 'We assessed the sensitivity of our results to a potential reduction in contacts over time by taking a conservative reduction of 50% between 5-18 year olds in the POLYMOD study, and repeating our approach to estimate the reduction in R0.. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint Table 2 .', 'CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .', 'CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .', 'CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .', 'CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .', 'CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .', 'CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint .']\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "list_of_summaries=[]\n",
    "for (cluster_index,item) in dic_clusters_docs.items():\n",
    "    list_of_summaries.append((cluster_index,summarize(item)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc_s_added=\"Report 48 see https://www.who. int/docs/default-source/ coronaviruse/situationreports/20200308-sitrep-48covid-19.pdf?sfvrsn=16f7ccef_4The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China, in December, 2019, now affects the whole world. As of March 8, 2020, more than 105 000 laboratoryconfirmed cases and more than 3500 deaths in over 100 countries had been reported.Since SARS-CoV-2 RNA was first detected in a stool specimen of the first reported COVID-19 case in the USA, 1 much attention has been paid to the study and reporting of gastrointestinal tract infection of SARS-CoV-2. According to a study 2 including 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in China as of Jan 29, 2020, nausea or vomiting, or both, and diarrhoea were reported in 55 (56%) and 42 (38%) patients. Autopsy studies are crucial to help understand the involvement of COVID-19 in the digestive system; however, to date, there has been only one autopsy report 3 for a man aged 85 years with COVID-19, which showed segmental dilatation and stenosis in the small intestine. Whether this finding is secondary to COVID-19 or a preexisting gastrointestinal comorbidity is unknown.COVID-19 has implications for the management of patients with pre-existing digestive diseases. Indeed, the presence and number of comorbidities is associated with poorer clinical outcome in patients with COVID-19. In the study 2 of 1099 patients with laboratoryconfirmed COVID-19, 261 (237%) patients with COVID-19 reported having at least one comorbidity, with hypertension, diabetes, and coronary heart disease being the most common. In this study, 2 23 (21%) patients had hepatitis B infection. Severe cases were more likely to have hepatitis B infection (24% vs 06%) than non-severe cases. Abnormal liver function tests, including elevated aspartate aminotransferase, alanine aminotransferase, and total bilirubin were noted. 2 Liver abnormalities in patients with COVID-19 might be due to viral infection in liver cells but could also be due to other causes such as drug toxicity and systemic inflammation. 4 Data suggest that liver injury is more prevalent in severe cases than in mild cases of COVID-19. 4 However, data about other underlying chronic liver conditions such as non-alcoholic fatty liver disease, alcohol-related liver disease, and autoimmune hepatitis, and their effect on prognosis of COVID-19 needs to be further evaluated.Liver transplantation might involve a risk of transmission of viral infection from donor to recipient, as shown in the previous SARS outbreak, and therefore donor screening and testing is crucial. 5 Although many patients had comorbidities in the reported series, 2 none had been a transplant recipient. Transplant clinicians are encouraged to follow guidance issued by The Transplantation Society, 6 as well as local health department guidelines for isolating, quarantining, testing, and monitoring returned travellers from endemic areas.Patients with cancer in general are more susceptible to infection due to their immunocompromised status caused by the malignancy and anticancer treatments. However, whether patients with gastrointestinal cancers are more likely to be infected with SARS-CoV-2 than healthy individuals remains unknown. In a recent nationwide analysis from China, 7 18 (1%) of 1590 COVID-19 cases had a history of cancer. Among these 18 cases, three had a history of colorectal cancer (one colonic tubular adenocarcinoma, one rectal carcinoma, and one colorectal carcinoma). 7 Patients with COVID-19 and cancer were observed to have a higher risk of severe events; several strategies have been proposed, such as intentional postponing of adjuvant chemotherapy or elective surgery on a patient-bypatient basis, stronger personal protection provisions, and more intensive surveillance or treatment. 7 Given the use of biologics and immunosuppressive agents, whether patients with inflammatory bowel disease (IBD) are more susceptible to SARS-CoV-2 infection has raised great concern. Currently no patients with IBD have been reported to be infected with SARS-CoV-2 in the IBD Elite Union, which incorporates the seven largest IBD referral centres in China with more than 20 000 patients with IBD. 8 Furthermore, no patients with IBD with SARS-CoV-2 infection have been reported from the three largest tertiary IBD centres in Wuhan (Tongji Hospital, Union Hospital, and Zhongnan Hospital) at the time that this manuscript was prepared (March 8, 2020) .Several strategies have been implemented in China to minimise the potential risk of SARS-CoV-2 infection in patients with IBD since the outbreak of COVID-19. First, the Chinese IBD Society issued official guidelines for managing patients with IBD in early February 2020. 9 The guidelines include practical recommendations on the use of immunosuppressive agents and biologics, diet, and intentional post ponement of elective surgery and endoscopy, as well as personal protection provisions; these are outlined in the panel. Second, the China Crohn's & Colitis Foundation has organised a group of volunteer gastroenterologists that specialise in IBD to offer online consultancy to patients with IBD since Jan 29, 2020. Third, an online virtual IBD visit programme has been initiated in some IBD centres, which provides convenient and cost-effective care, and could potentially reduce the risk of SARS-CoV-2 infection by avoiding close contact with infected patients in public areas. With the increasing concern from patients with IBD globally, helpful online resources about COVID-19 have been provided by international non-profit organisations such as Crohn's Colitis of Foundation America and Crohn's & Colitis UK. 10, 11 Such guidance and advice should be delivered urgently to health-care workers as well as patients with IBD.The comorbidity spectrum of digestive conditions and its impact on treatment and outcome of COVID-19 remains largely unknown. Further data need to be analysed from the COVID-19 cohort established by the National Health Commission of the People's Republic of China, which would help to more precisely ascertain the risk of SARS-CoV-2 infection in patients with digestive comorbidities such as IBD. These data and experience with guidance on how to manage patients with underlining comorbidities in China could facilitate integrated care for patients globally.We declare no competing interests. We thank the members of Chinese IBD Elite Union, Chinese Society of IBD and Chinese IBD Quality Care Evaluation Center Committee (IBDQCC) for their collaboration. RM and JL contributed equally. In June 2015 the Healthcare Infection Society held a twoday Middle East Infection Prevention Summit with the aim of uniting colleagues across the globe in driving down infection rates and improving infection prevention and control practice. In many ways the Middle East is a microcosm for the challenges in infection prevention and control across the world. The economies range from underdeveloped countries such as Egypt, with a low per-capita gross domestic product, to the wealthy hydrocarbon-exporting, and increasingly diversified, economies of the Gulf Cooperation Council countries; of course these vast economic differences impact on the resources available for healthcare. Moreover, there are large ex-patriot populations in many Middle Eastern countries and international travel to and from the Middle East is frequent, meaning that infections emerging there can quickly have a global impact.Two of the themes of the conference that have particular international relevance are the huge challenges presented by multidrug-resistant Gram-negative bacteria in Middle Eastern hospitals, and local experience with Middle East respiratory syndrome coronavirus (MERS-CoV). Coverage of the latter was particularly opportune, given the outbreak of MERS-CoV in South Korea in May 2015 originating from a traveller returning from visiting several Middle Eastern countries.This special section of the journal includes three papers relating to the Summit. Drs Omrani and Shalhoub present a review of MERS-CoV, and Dr Jon Otter and Professor Nesrene Omar describe their British and Egyptian perspectives of the Summit. 1e3Respiratory syncytial virus (RSV) is well known as a virus causing lower respiratory tract infection (LRTI) in infants and immunocompromised adults (1-3). Bronchopneumonia patterns are common findings of RSV-induced LRTI (RSV-LRTI); however, RSV-LRTI often shows variable findings on chest imaging (4-11). Although some factors, such as the virulence of RSV and host immune status, might affect the chest computed tomography (CT) findings of RSV-LRTI (12, 13), the detailed mechanisms remain unknown.From this perspective, an RSV outbreak due to genetically identical RSV is an ideal setting for investigating the chest images of RSV-LRTI. Thus far, however, there has only been one report showing the chest images of RSV-LRTI in the outbreak setting (11). In addition, reports investigating the correlation between the clinical manifestations and abnormal findings on chest CT remain rare (14).In 2014, a genetically identical RSV outbreak occurred in the hemato-oncology ward of the University of the Ryukyus Hospital (15), and a subset of RSV-infected patients underwent both chest X-ray and CT during the outbreak. We herein report our analysis of the radiological findings and the clinical manifestations in the outbreak.During the 2014 outbreak, RSV infection was diagnosed by reverse transcriptase polymerase chain reaction using respiratory specimens, and genetic proximity was confirmed by a phylogenetical analysis (15). Eight RSV-infected patients underwent both chest X-ray and CT during the outbreak. The clinical information and chest X-ray findings were retrospectively reviewed from patient medical records within one week of the chest CT scan.The medical records and radiological images of the collected cases were retrospectively reviewed, with identifying information removed. This study was reviewed and approved by the Clinical Research Ethics Committee of University of the Ryukyus.The patients' background characteristics, clinical manifestations, laboratory data, and findings from chest imaging are shown in Table. Seven cases (88%) received various immunosuppressive treatment, and none had airway diseases, such as bronchial asthma. Five cases (63%) had newly appearing abnormal findings on chest CT; however, no abnormal findings were detected by chest X-ray in 3 of those 5 patients (60%). Most cases had upper respiratory symptoms, including rhinitis and sore throat. However, lower respiratory symptoms, such as wheeze, sputum, and hypoxemia, were only seen in patients with newly appearing findings on chest CT. Bacterial culture for respiratory specimens was performed in six cases, and bacteria were detected in three cases; however, no patient was diagnosed with bacterial pneumonia or treated with targeted antibiotics against these detected bacteria. In addition, no cases received antiviral therapy against RSV.Chest CT findings for the five patients are shown in Figs. 1-5. The most common finding among these patients was bronchial wall thickenings; seen in 4 of 5 patients (80%). In terms of the findings in the parenchymal lesion, the patterns and distributions were varied and inconsistent. Two cases showed ground-glass opacities (GGOs) along the bronchi; however, the distribution differed, as one was a localized GGO and the other a multilobar GGO. One case showed ground-glass nodules with a tree-in-bud pattern. The remaining case showed diffuse GGOs with centrilobular septal thickening, also known as the crazy-paving pattern. Three cases underwent two or more CT scans during the course of their disease, and the abnormal findings on chest CT disappeared (Fig. 1, 2, 5).Chest CT showed variable findings for RSV infection, even during an outbreak setting. In most cases, chest X-ray failed to detect abnormalities. In RSV-infected hematological malignancy patients receiving anticancer chemotherapy, lower respiratory symptoms may predict the existence of CT abnormalities due to RSV-LRTI.The authors state that they have no Conflict of Interest (COI).1 18Giulia Polverari, MD 1 , Vincenzo Arena, MD 1 , Francesco Ceci, MD, PhD 2 , Ettore Pelosi, MD, PhD 1 , Annarita Ianniello, MD 1 , Elana Poli, MD 3 , Alberto Sandri, MD 4 This is a case of 73-year-old male patient who underwent medium lobe resection for pT2aN0 non-small cells lung cancer (NSCLC) in April 2016, without administration of adjuvant therapies. During routine CT scan performed in February 2020 a centimetric nodule in left superior lobe suspected for malignancy was reported. Functional imaging with 18 F-FDG PET/CT was requested by tumor board to evaluate nodule metabolism. 18 F-FDG PET/CT was scheduled for March 18 th 2020, twenty-seven days after SARS-CoV-2 outbreak in Italy. During triage procedures required for COVID-19 prevention, body temperature resulted < 37.5 C and the patient did not present nor cough or wheezing, neither shortness of breath. Patient declared no suspected expositions to infected people and he was a non-smoker with no cardiovascular comorbidities. The nuclear medicine team interpreted the PET scan as active inflammatory processes with consensus, with a CT pattern highly suspicious for on-going COVID-19 pneumonia, as reported in literature (1, 2) . After consultation with COVID-19 task-force authorities, the patient has been tested with real-time reverse transcription polymerase chain reaction (RT-PCR), resulted positive, and he was subsequently quarantined. However, hospitalization in intensive care unit was necessary three days after PET/CT scan for rapid disease progression and severe respiratory distress syndrome.At present, more than 80.000 people are affected by COVID-19 in Italy leading to COVID-19 related death more than 7000 of patients. PET scans are still offered to oncological patients to guarantee the continuation of best clinical practice, even in the scenario of national 3 restrictive directives. Thus, the number of asymptomatic pathogen carrier in Nuclear Medicine facilities is not negligible. COVID-19 radiological pattern (Rx and CT) has become known, usually described as peripheral predominant GGOs or lung consolidation involving mainly the lower lobes (3) . However, discrepancy between radiological patterns and clinical symptoms is possible and several studies have reported this clinical-radiological dissociation (4, 5) . The few reports of 18 F-FDG PET/CT in patients with COVID-19 currently available, describe in all cases symptomatic patients with common COVID-19 manifestation including fever, cough, shortness of breath, myalgia and fatigue (1, 2) . To the best of our knowledge this is the first case report in asymptomatic patient, investigated with 18 F-FDG PET/CT. This case highlights the rapid disease progression in asymptomatic patient presenting FDG avid COVID-19 pneumonia. While far from giving definitive evidence, asymptomatic patients presenting typical radiological CT patterns and positive FDG uptake should be promptly tested and strictly monitored, since sudden worsening of patient clinical condition, might be possible.All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from all individual participants included in the study.The authors declare that they have no conflict of interest.Dear Editor,For decades, Ebola members (EBOV) of the Filoviridae family of highly pathogenic, filamentous single-stranded RNA viruses have been responsible for sporadic self-limiting clusters of Ebola virus disease (EVD) in Central Africa. The current outbreak of EVD in West Africa has risen to epidemic status and is considered by the World Health Organization to be a public health emergency of international concern. This level of concern by the World Health Organization and other health-care authorities and providers is based on the high lethality of EBOV-Zaire in humans (up to 90%), its high communicability though body fluids, the high incidence of infection in primary health-care workers and the total lack of proven efficacious drugs or vaccines. Although there are a variety of potential EBOV inhibitors in the drug development pipeline, none have sufficient human safety data, which complicates estimates of their efficacy in the current crisis situation in West Africa.1 One such experimental drug is the Zmapp monoclonal antibody cocktail (n=3), which was shown to be highly effective in reversing advanced EVD in non-human primates.2 However, the rapid acquisition of EBOV sequence variation recently demonstrated during genomic surveillance of the current EVD epidemic suggests that drug development dependent on viral non-variant protein sequences may be problematic.3 In this Letter, we briefly address the evidence-based potential of several Toll-like receptor 3 agonists in late-stage clinical development for reducing the morbidity and mortality of EVD.Death from EBOV infection is associated with markedly impaired coagulation and innate immunity cascades, increased production of pro-inflammatory cytokines, profound immune suppression resulting in peripheral T lymphocyte apoptosis and a lack of adaptive immunity.4 By contrast, survivors of infection by EBOV develop an effective immune response with the production of EBOV neutralizing antibodies. Early events in EBOV infection influence the patient's ability to develop an effective immune response. The success of EBOV replication is dependent on viral inhibition of initial innate immune responses to infection. Disarming innate immune responses is a common mechanism employed by highly pathogenic human viruses, including those of the influenza and coronavirus families.5 EBOV is one of the more successful of the emerging highly pathogenic viruses in evasion of innate immune interference. Viral protein (VP35), an essential component of the EBOV replication matrix, represents an evidence-based target for the potential reduction of the morbidity and mortality of EVD.Double-stranded RNA (dsRNA) is a common component of viral replication, which initiates systemic signaling cascades that normally activate interferon (IFN) regulatory factors leading to the production of IFN-/ (type I IFNs). The IFNs activate multiple IFN response pathways necessary to inhibit viral replication, including transitory expression of enzymes such as 25 adenylate synthetase and protein kinase R, which require dsRNA as a cofactor for activity. To circumvent viral recognition by human cells, highly virulent viruses (including Ebola) have evolved different strategies to block the biological activities associated with the induction of IFN-/ and the subsequent multiplicity of anti-viral responses and the initiation of adaptive immunity. VP35 is a multifunctional major virulence protein that is indispensable for EBOV replication as a component of the viral polymerase complex.4 This factor also counteracts the host innate immune response by blocking the cellular production of and responses to type I IFN transient gene activation. Key components of the innate immune response to viral infection include activation of Toll-like receptor 3 and the helicases melanoma differentiation-associated protein 5 and retinoic acid-inducible gene1 by viral dsRNA.5 However, viral inhibition of these dsRNA responsive elements effectively disarms essential components of the innate immune response. In particular, a positively charged C-terminal amino acid motif (Figure 1) of VP35 binds to sequence-independent dsRNA, resulting in the suppression of multiple steps in the IFN signaling cascade, which otherwise would lead to a broad antiviral state with strong activation of both the innate and adaptive arms of the immune response.8 Thus, VP35 provides an attractive evidence-based target for antiviral interruption of EBOV, potentially ameliorating the pathogenesis of EVD.Various forms of dsRNA have been studied as inducers of type I IFNs. Although the original dsRNA studied for efficacy in humans, Poly I:Poly C, was found to induce serious adverse events in humans that limited pharmaceutical development, several derivatives have survived the rigors of animal and clinical testing. Poly ICLC (Hiltonol) (Oncovir, Inc., Washington, DC, USA) consists of Poly I:Poly C with non-covalent adduct polymeric chains of poly-L-lysine and carboxymethylcellulose. These adducts increase the drug half-life by steric hindrance of the phosphodiester backbone from RNAse hydrolysis. Hiltonol has been studied in clinical trials as a cancer therapy and as an adjuvant for cancer vaccines.9 Poly I:Poly C12U (rintatolimod, Ampligen) (Hemispherx Biopharma, Inc., Philadelphia, PA, USA) was designed as an IFN inducer with a markedly reduced incidence of adverse advents compared to the parent compound Poly I:Poly C8 and is devoid of adducts. Both Hiltonol and Ampligen have demonstrated antiviral activity against a wide variety of DNA and RNA viruses in preclinical testing.In animal studies, rintatolimd was efficacious as an epitope-expanding adjuvant for highly pathogenic avian influenza virus vaccines,10 and this drug is now being evaluated as an adjuvant in a variety of cancer vaccine trials. Rintatolimod has demonstrated activity in two double-blind, placebo-controlled clinical trials of chronic fatigue syndrome8 and is currently in an advanced clinical trial as a treatment for this condition. Hiltonol and/or rintatolimod experimental pharmaceuticals are attractive evidence-based candidates for the treatment of EVD on the expanded basis recently approved by the World Health Organization. The use of experimental pharmaceuticals beyond phase I in Food and Drug Administration-sanctioned clinical trials helps ensure the availability of products with established safety profiles sufficient for open-label clinical testing and analysis of efficacy. The use of potential drugs in clinical trials also helps ensure a reliable supply of clinical-grade drugs, which removes the ethical dilemma of patient selection for treatment.1M. genavense infections occur only rarely in persons other than AIDS patients (as in the present case), but they always occur in immunocompromised persons (7,8). To date, only 1 case of disseminated infection has been reported in a solid-organ (kidney) transplant recipient; the diagnosis was made by molecular identifi cation in isolates from blood and marrow cultures. That patient died of complications from M. genavense infection (9). Because M. genavense is a fastidious organism, the infections it causes are diffi cult to diagnose and their frequency is probably underestimated, which may change with increased use of direct molecular biological methods.Optimal treatment of M. genavense infections has not been established (10). Experience with M. genavense infections in AIDS patients and with other nontuberculous mycobacteria infections in solid-organ transplant recipients suggests that at least 2 antimicrobial drugs should be used for a prolonged period; when possible, immunosuppressive drugs should be concurrently reduced (1,3,6,10). Outcome of nontuberculous mycobacteria infections in transplant patients is highly variable (1,5) but was satisfactory in the present patient, who was treated with quintuple antimicrobialdrug therapy and reduced immunosuppressive therapy.This case of a disseminated infection due to M. genavense in a heart transplant recipient was diagnosed early. Universal 16S rRNA gene sequencing after amplifi cation directly from intestinal biopsy specimens enabled fast diagnosis and appropriate management. To the Editor: Bats are thought to be one of the most important reservoirs for viruses such as Nipah virus, severe acute respiratory syndrome (SARS) coronavirus, and Ebola virus (1). These pathogens became known after extensive surveys of bats following outbreaks. As a fi rst step in investigating unidentifi ed pathogens in bats and to help forecast the potential threat of emerging infectious diseases, we tried to isolate and characterize viruses that persistently infect bats. In the process, we isolated a novel adenovirus from a fruit bat in Japan.Pteropus dasymallus yayeyamae, or Ryukyu fl ying fox, is a fruit bat of Japan. With the permission of the governor of Okinawa, we caught 1 adult male bat of this species and used its spleen and kidneys to establish primary cell cultures. On the 4th passage of the primary adherent cells derived from the spleen, a cytopathic effect (CPE) appeared without any visible microbe, indicating that the cell culture contained a virus. The virus, tentatively named Ryukyu virus 1 (RV1), caused apparent CPE on primary kidney cells derived from a Ryukyu fl ying fox and on our established bat kidney T1 (BKT1) cells, which were derived from the kidney of a horseshoe bat (Rhinolophus ferrumequinum) and transformed with expression plasmid DNA encoding the large T antigen of replication origin-defective simian virus 40.To identify the virus, RV1, we applied the rapid determination of viral RNA (RDV) system version 1.0 (2). However, no viral nucleic acid sequence was detected from an RNA sample in the RV1-infected BKT1 cells. For detection of viral DNA, we developed a system for rapid determination of viral DNA sequences (RDV-D) by minor modifi cation to the RDV system for RNA viruses (2) (3) (4) . The results indicated that 2 of the fragments were homologous to the gene encoding the precursor of terminal protein (pTP) of adenoviruses. Further RDV-D analysis showed that 6 fragments (139 bp, DDBJ/EMBL/GenBank accession no. AB302970) were homologous to the pTP gene and that another 6 fragments (316bp, DDBJ/EMBL/ GenBank accession no. AB302971) were homologous to the gene encoding the precursor of protein VI (pVI) of adenoviruses. These results indicated that RV1 must belong to the family Adenoviridae.To further confi rm that RV1 isolate was an adenovirus, we used PCR and sequencing. We performed the fi rst reaction with the outer primer pair (polFouter and polRouter) of a nested PCR method, targeting the viral DNA polymerase gene with highly degenerate consensus primers that have been described recently (5) . A fragment of 550 bp was amplifi ed from RV1 as well as from human adenoviruses-1, -3, -4, and -7 (data not shown). Sequence analysis of the amplifi ed product (DDBJ/EMBL/GenBank accession no. AB303301) showed that RV1 was homologous to tree shrew adenovirus 1 (70.0% amino acid sequence identity), porcine adenovirus 5 (69.2%), canine adenovirus 1 (68.9%), human adenoviruses-3, -16, -21 and -50 (68.9%), and other viruses (>64.8%) in genus Mastadenovirus, but less homologous (46.7%-57.8%) to viruses in other genuses, Siadenovi-rus, Aviadenovirus, and Atadenovirus. In addition, a phylogenic tree based on amino acid sequences indicated that RV1 belongs to family Adenoviridae, genus Mastadenovirus (Figure) .Electron microscopy of RV1-infected BKT1 cells indicated that RV1 accumulated in the nucleus and that the size of capsids was 60-70 nm (data not shown). Restriction endonuclease analysis of the RV1 genome indicated that the genome was 20-30 kbp (data not shown). These features are consistent with RV1 being an adenovirus.Until now, a number of RNA viruses have been isolated from bats, but isolation of DNA virus is rare (1) . The isolation of the novel adenovirus seems to be possible because of usage of the primary cells originated from the host; DNA viruses might have more restricted host range than RNA viruses and require host-originated cells for the growth. In addition, our success in DNA virus isolation might have resulted from usage of the adult animal latently and persistently infected with DNA viruses such as adenovirus and herpesvirus.In conclusion, we isolated a novel virus from a fruit bat. This virus was isolated from a healthy bat, which suggests that the virus may persistently infect fruit bats. Although its pathogenicity for humans is still unknown, knowledge of RV1 will be useful in epidemiologic studies of infectious diseases emerging from bats because persistently infecting viruses might be isolated together with primary pathogens. We are planning to establish cell lines from bats and isolate more viruses from persistently infected bats. To the Editor: Fluoroquinolones (FQs) that are active against streptococcal species (e.g., levofl oxacin and moxifl oxacin) have been recommended by numerous national health authorities and international organizations for treating acute exacerbations of chronic bronchitis and pneumonia in adults (1). However, use of these antimicrobial drugs for treating community-acquired infections has led to an increase in FQ-resistant strains in bacteria such as Streptococcus pneumoniae. Group B streptococci (GBS, e.g., S. agalactiae) are the leading cause of invasive infections (pneumonia, septicemia, and meningitis) in neonates. GBS are also associated with bacteremia, endocarditis, and arthritis, and are responsible for deaths and illness in nonpregnant women with underlying diseases and in elderly adults (2) . We describe, to our knowledge, the fi rst GBS clinical isolate in France resistant to FQ; the isolate was from a patient treated with levofl oxacin.GBS CNR0717 strain was isolated as the predominant bacterium in a culture (>10 7 CFU/mL) from 2 purulent sputum samples from an 80year-old man (leukocytes >25, epithelial cells <10) obtained 8 days apart. This patient was treated for 2 weeks with levofl oxacin, 750 mg/day, for acute exacerbation of chronic bronchitis. No other relevant respiratory bacterial pathogens were present in these samples. GBS CNR0717, a capsular serotype IV strain, was suspected to have reduced susceptibility to FQs because no inhibition zone was observed around disks containing norfl oxacin and pefl oxacin disks, and reduced diameters were observed around disks containing ciprofl oxacin and levofl oxacin. Antibiograms were performed according to recommendations of the Clinical and Laboratory Standards Institute (3) on Mueller Hinton agar (Bio-Rad, Marnes la Coquette, France) supplemented with 5% horse blood. This strain was susceptible to all other antimicrobial drugs usually active against GBS (penicillin, erythromycin, clindamycin, tetracycline, rifampicin, vancomycin) and showed low-level resistance against aminoglycosides. MICs for 6 FQs ( Table) indicate that GBS CNR0717 was highly resistant to pefl oxacin and norfl oxacin, with MICs >64 mg/L, and showed increased MICs for ciprofl oxacin, sparfl oxacin, levofl oxacin, and moxifl oxacin. No reduction of FQ MICs was observed with reserpine (10 mg/L), which indicated that resistance to FQ was not caused by an active effl ux pump system. Three major mutations have been reported for FQ resistance in streptococci at codon positions 81 in gyrA and 79 or 83 in parC (4) . DNA sequence analysis of these regions showed a mutation in parC (Ser 79  Tyr) but not in the wild-type susceptible strain (NEM316). No mutation was detected in the gyrA gene. FQ resistance in streptococci is acquired through a stepwise process and has been extensively studied in S. pneumoniae. First-step mutants conferring low-level resistance generally result from mutations in either gyrA or parC. There is also Letters commenting on recent articles as well as letters reporting cases, outbreaks, or original research are welcome. Letters commenting on articles should contain no more than 300 words and 5 references; they are more likely to be published if submitted within 4 weeks of the original article's publication. Letters reporting cases, outbreaks, or original research should contain no more than 800 words and 10 references. They may have one Figure or Table and should not be divided into sections. All letters should contain material not previously published and include a word count.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [],
   "source": [
    "sentences_with_grp =  parse_document(doc_s_added)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "155"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sentences_with_grp)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [],
   "source": [
    "li =[]\n",
    "for l in dic_clusters_docs[0]:\n",
    "    sentence_without= parse_document(l)\n",
    "    li.append(len(sentence_without))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [],
   "source": [
    "s = sum(li)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "158"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "s"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 224,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(0, None), (1, None), (2, None), (3, None), (4, None)]"
      ]
     },
     "execution_count": 224,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list_of_summaries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
